

**Harvard Medical School
Curriculum Vitae**

Date Prepared: February 14, 2023
Name: Toni K. Choueiri
Office Address: Dana-Farber Cancer Institute
450 Brookline Avenue, DA-0929
Boston, MA 02215
Home Address: 150 Porter Street, Westwood, MA 02090
Work Phone: 617-632-5456
Work Email: toni_choueiri@dfci.harvard.edu
Work Fax: 617-632-2165
Place of Birth: Beirut, Lebanon

Education:

2000	M.D.	Medicine	Université Saint Joseph Faculté de Médecine, Beirut, Lebanon
2000	M.S.	Biology	Université Saint Joseph Faculté de Médecine

Postdoctoral Training:

7/2000-6/2001	Intern	Medicine	Hotel-Dieu de France University Hospital, Beirut, Lebanon
7/2001-7/2002	Intern	Internal Medicine	Cleveland Clinic, Cleveland, OH
7/2002-7/2004	Resident	Internal Medicine	Cleveland Clinic
7/2004-7/2007	Fellow	Hematology/Oncology	Cleveland Clinic
7/2006-7/2007	Fellow	Genomics (Ram Ganapathi)	Cleveland Clinic

Faculty Academic Appointments:

8/2007-9/2009	Instructor	Medicine	Harvard Medical School (HMS), Boston, MA
10/2009-1/2013	Assistant Professor	Medicine	HMS
2/2013-5/2018	Associate Professor	Medicine	HMS
5/2018-	Jerome and Nancy Kohlberg Professor	Medicine	HMS

Appointments at Hospitals/Affiliated Institutions:

8/2007-1/2014	Staff Physician	Medical Oncology	Dana-Farber Cancer Institute (DFCI), Boston, MA
8/2007-	Associate Physician	Medicine	Brigham and Women's Hospital (BWH), Boston, MA
1/2014-	Senior Physician	Medical Oncology	DFCI
10/2017-	Associate Member	Cancer Program	Eli and Edythe L. Broad Institute (Broad Institute) of Massachusetts Institute of Technology (MIT) and Harvard University (HU), Cambridge, MA

Other Professional Positions:

2008-2018	Member, Advisory Board	Kidney Cancer Association (KCA), Chicago, IL	
2008-	Member, Advisory Board	Pfizer Pharmaceuticals, New York, NY	1 day / year
2008-	Member, Advisory Board	Novartis Oncology, East Hanover, NJ	1 day / year

2008-	Member, Advisory Board	GlaxoSmithKline, Philadelphia, PA	1 day / year
2008-	Member, Advisory Board	Bayer/Onyx Pharmaceuticals, Emeryville, CA	1 day / year
2010, 2015	Member, Advisory Board	Eisai Inc., Woodcliff Lake, NJ	
2010	Member, Renal Cell Cancer Executive Council	Aveo Pharmaceuticals, Cambridge, MA	
2011	Member, Advisory Board	Seattle Genetics, Bothell, WA	
2012-	Member, Advisory Board	Exelixis Inc., South San Francisco, CA	2 days / year
2015	Member, Advisory Board	Prometheus Laboratories Inc., San Diego, CA	
2015	Member, Advisory Board	Roche Holding AG, Basel, Switzerland	
2016	Member, Advisory Board	Cerulean Pharma, Inc., Cambridge, MA	
2016-2019	Member, Advisory Board	Peloton Therapeutics, Dallas, TX	
2016-	Member, Advisory Board	Bristol-Myers Squibb (BMS), New York, NY	2 days / year
2016-	Member, Advisory Board	Merck, Kenilworth, NJ	2 days / year
2016-	Member, Advisory Board	AstraZeneca, London, United Kingdom	1 day / year
2017-	Member, Advisory Board	Genentech, South San Francisco, CA	1 day / year

2020-	Member, Advisory Board	EMD Serono, Darmstadt, Germany	1 day / year
2022-2026	Member, Academic Board	Academic and Community Cancer Research United	2 days / year

Major Administrative Leadership Positions:

Local

2007-2014	Director, Seminar Series in Genitourinary (GU) Oncology	DFCI
2008-2009	Co-Director, Multidisciplinary Kidney Cancer Clinic	Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC), Boston, MA
2009-	Director, Kidney Cancer Center	DF/BWCC
2010-	Co-Director, Tissue Acquisition Pathology and Clinical Data (TAPCD) Core, Kidney Cancer Specialized Program of Research Excellence (SPORE)	Dana-Farber/Harvard Cancer Center (DF/HCC), Boston, MA
2010-	Kidney Cancer Program 2010- Co-Chair, Epidemiology Outcomes Subcommittee 2012- Chair, Clinical Research Subcommittee 2012- Co-Leader	DF/HCC
2014-2016	Clinical Director, The Lank Center for Center for Genitourinary Oncology	DFCI
2015-2018	Medical Staff President, Medical Staff Executive Committee (MSEC)	DFCI
2016-	Director, Genitourinary Oncology Disease Center and the Lank Center for Genitourinary Oncology	DFCI

2022-	Medical Director, International Strategic Initiatives	DFCI
-------	---	------

National

2019-	Co-Chair, Kidney Cancer Research Summit (KCRS) Steering Committee	KidneyCAN, Philadelphia, PA
-------	---	-----------------------------

Committee Service:

Local

2008-	Scientific Council	DF/HCC
2010, 2012	Oncology Specialty Panel	HMS
2010-2011	Scientific Review Committee	DF/HCC
2010-	Clinical Faculty Council	DFCI
2011	Thesis Review Committee	Boston University, Boston, MA
	2011	Supervisor and second reader of Master's Degree Candidate, Matthew Lawlor, Biomedical Sciences
2012-2013	Thesis Review Committee	Tufts University, Boston, MA
	2012-2013	Advisor and primary reader of Master's Degree candidate, Miranda Rogers, Biomedical Sciences
2013	<i>Ad hoc</i> Search Committee for Chief of Hematology/Oncology at St. Elizabeth's Medical Center	DFCI
2013-2014	Executive Committee for Clinical Research	DFCI
2015-	Lank Center for Genitourinary Oncology Faculty Search Committee (Thirteen searches as of 12/31/2020)	DFCI
	2015-	Chair

2016	Scientific Advisory Board, Center for Immuno-Oncology	DFCI
	2016	Member
2017	Clinical Education/CME Task Force	DFCI
	2017	Chair
2018	Melanoma Program	DF/HCC
	2018	External advisor
2021-	Inclusion, Diversity, & Equity (ID&E) Executive Council	DFCI
	2021-	Implementation Team Lead
2021	Search Advisory Committee, Search for Senior Vice President, Communications	DFCI
2021	Faculty Search Committee, Center for Cancer Therapeutic Innovation	DFCI/BWH
2022-	CCTI Faculty Search Committee	DFCI
2022-	Ad Hoc Search Committee for the Chair of the Department of Urology	BWH
National		
2008-	Cancer and Leukemia Group B/Alliance for Clinical Trials Genitourinary Committee	Alliance for Clinical Trials in Oncology, Chicago, IL
2008-	Kidney/Testicular Cancers Panel	National Comprehensive Cancer Network (NCCN)
	2016	Kidney Subsequent Therapy Committee, Leader
	2019-	Reviewer, Chemotherapy Order Templates, Kidney Cancer

2010	Scientific Program Planning Committee	Society of Urologic Oncology
2012-	Scientific Steering Committee	KCA
	2012-2014	Member
	2014-2015	Vice-Chairman
	2015-2018	Chairman
2014-2016	8th Edition Kidney/Urinary Tract Expert Panel	The American Joint Committee on Cancer (AJCC), Chicago, IL
2014-	Genitourinary Cancers Steering Committee	National Cancer Institute (NCI), Bethesda, MD
	2014-2020	Renal Task Force Member
	2020-	SPOREs Representative
2019-	Kure it Cancer Medical Advisory Board	Kure it Cancer Research, Irvine, CA

International

2012-2015	Global Steering Committee on Cabozantinib in Renal Cell Carcinoma (METEOR)	Exelixis, Inc
	2012-2015	Chairman
2012-2015	Scientific Program Planning Committee	International Kidney Cancer Symposium (IKCS)
	2015	Chairman
2015-	Global Steering Committee on Avelumab in Renal Cell Carcinoma (JAVELIN 101)	Pfizer Oncology
	2015-	Member
2017-	Global Steering Committee on pembrolizumab in high-risk Renal Cell Carcinoma (KEYNOTE-564)	Merck Oncology

	2017-	Chairman
2018-	Global Steering Committee on HIF-2 inhibitor PT2977 trial in Renal Cell Carcinoma	Peloton Therapeutics
	2018-	Chairman
2018-	Global Steering Committee on nivolumab+cabozantinib trial in Renal Cell Carcinoma (Checkmate-9ER)	Bristol-Myers Squibb
	2018-	Co-Chairman
2018-	Global Steering Committee on nivolumab+cabozantinib+ipilimumab trial in Renal Cell Carcinoma (COSMIC-313)	Exelixis, Inc
	2018-	Chairman
2020-2023	Scientific Committee - Genitourinary tumours, non-prostate	ESMO
	2022	Track Chair, ESMO Congress 2022
2020-	Global Steering Committee on cabozantinib+atezolizumab in Renal Cell Carcinoma (CONTACT-03)	Exelixis, Inc
	2020-	Co-Chairman
2020-	Steering Committee	Global Society of Rare GU Tumors
	2020-	Secretary
2021-2025	Scientific Council Member	Institut Gustave Roussy
2021-	Global Steering Committee on tivozanib+nivolumab in Renal Cell Carcinoma (TiNivo-2)	AVEO Oncology
	2021-	Chairman

2021	French American Innovation Days in Oncology	L'Institut Servier
	2021	Program Committee

Professional Societies:

2002-2005	American College of Physicians (ACP)	
2004-2007	American Society of Hematology (ASH)	
	2004-2007	Associate Member
2004-	American Medical Association (AMA)	
2005-	American Society of Clinical Oncology (ASCO)	
	2012-2014	Member, GU Cancer/Non-prostate Educational Track Committee (Chair 2014)
	2013	Member, GU Cancers Symposium Organizing Committee (Kidney Track)
	2017-2020	Member, GU Cancer/Non-prostate Scientific Track Committee (Chair 2020)
	2018	Member, Social Media Working Group
2006-	American Association of Cancer Research (AACR)	
	2006-	Member
2007-	Massachusetts Medical Society (MMS)	
	2007-	Member
2017-	Congressional Directed Medical Research Programs (CDMRP), Kidney Cancer Research Program	
	2017-	Member

	2022-2023	FY23 Programmatic Review panel
2022-	The American Society for Clinical Investigation (ASCI)	
	2022-	Member
	2023	Abstract review committee, AAP/ASCI/APSA Joint Meeting Poster Session
Grant Review Activities:		
2009	Kidney Cancer Grants Review Section	The Netherlands Cancer Institute, Amsterdam, The Netherlands
	2009	<i>Ad hoc</i> External Reviewer
2010	Clinical Trials Advisory and Awards Committee	Cancer Research Institute, London, England, United Kingdom (UK)
	2010	<i>Ad hoc</i> External Reviewer
2011	Bladder Cancer Clinical Studies Group Progress Review Panel	National Cancer Research Institute, London, England, UK
	2011	<i>Ad hoc</i> External Reviewer
2013-2016	Conquer Cancer Foundation Grants Selection Committee 2013-2015: Young Investigator Awards 2013-2016: Career Development Awards	ASCO, Alexandria, VA
	2013-2016	<i>Ad hoc</i> External Reviewer
2014	American University of Beirut Faculty of Medicine Research Grants in Oncology	American University of Beirut, Beirut, Lebanon
	2014	<i>Ad hoc</i> External Reviewer
2015	Health Research Board Awards	The Health Research Board, Dublin, Ireland
	2015	<i>Ad hoc</i> External Reviewer (Biomarkers)

2016	DF/HCC Prostate Cancer SPORE	
	2016	Internal Reviewer
2016	Kure It-AACR Research Grant for Immunotherapy in Kidney Cancer Scientific Review Committee	AACR
	2016	<i>Ad hoc</i> External Reviewer
2017	KCA Young Investigator Award	
	2017	Internal Reviewer
2018	2018 ORIEN NOVA Team Science Award	
	2018	External Reviewer
2018	Kidney SPORE Development Research Projects	
	2018	Internal Reviewer
2019-2020	Review Committee	DFCI Early Career Faculty Innovation Fund
2020-2022	NextGen Grants for Transformative Cancer Research	AACR
	2020-2022	Review Committee Member

Editorial Activities:

Ad hoc Reviewer

American Journal of Clinical Oncology

Annals of Oncology

British Journal of Cancer

British Journal of Urology

Cancer

Cancer Cell

Cancer Immunology Research

Cancer Management and Research

Cancer Research

Cancer Treatment Reviews

Clinical Cancer Research

Clinical Genitourinary Cancer

Current Clinical Pharmacology

European Journal of Cancer

European Urology

JAMA Oncology

JNCI Cancer Spectrum

Journal of American Medical Association (JAMA)

Journal of Clinical Investigation (JCI)

Journal of Clinical Oncology (JCO)

Journal of Immunotherapy

Journal of Urology

Lancet Oncology

Nature Clinical Practice Oncology

Nature Communications

Neoplasia

New England Journal of Medicine

Oncology

The Medical letter, Inc

The Oncologist

Urology

Other Editorial Roles

2009-	Member, Editorial Board	Therapeutic Advances in Medical Oncology
2011	Guest Editor, Editorial Board	Hematology/Oncology Clinics of North America, Renal Cell Carcinoma issue (vol. 25, issue 4, pp. 651-950)
2011-	Member, Editorial Board	Clinical Genitourinary Cancer
2011-	Member, Editorial Board	Frontiers in Genitourinary Oncology
2012-2014	Member, Editorial Board	PDQ Cancer Genetics
2014-	Member, Editorial Board	Journal of Clinical Oncology
2015-	Member, Editorial Board	Tumori
2018	Member, Editorial Board	European Urology Oncology
2020-2023	Co-editor, GU Section	The Oncologist

Honors and Prizes:

2006	Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Scholarship	University of California, San Francisco, CA	Clinical Research
2007	ASCO Annual Meeting MERIT Award	ASCO	Clinical Research
2007	Korea Urological Cancer Society Recognition Award	Korea Urological Cancer Society, Seoul, Korea	Clinical Research
2007	Prostate Cancer Symposium MERIT Award	ASCO	Clinical Research

2008	Friends of DFCI Award	DFCI	Clinical Research
2011-2012	The Brigham Leadership Program	Harvard Business School, Boston, MA	Leadership
2012	Compassionate Caregiver Award	The Schwartz Center for Compassionate Healthcare, Boston, MA	Compassionate Patient Care
2012	Dana-Farber Harvard Business School Leadership Retreat	Harvard Business School	Leadership
2013	The George P. Canellos Award for Excellence in Clinical Investigation and Patient Care	DFCI	Clinical Investigation and Patient Care
2016	Eugene P. Schonfeld Award	KCA	Significant Contributions to the Field of Kidney Cancer
2018	Aresty Scholar	Wharton School of Business at the University of Pennsylvania, Philadelphia, PA	Executive Leadership and Education
2018-2022	Highly Cited Researcher (Top 1%)	Thomson Reuters	Clinical Medicine
2021	Giants of Cancer Care	OncoLive/Pfizer	Genitourinary Cancer
2022	Lifetime Achievement Award in Global Oncology	Emirates Oncology Society	

Report of Funded and Unfunded Projects

Past

2006-2010	Phase II Study of the c-Met Receptor Tyrosine Kinase (RTK) Inhibitor XL880 in Subjects with Papillary Renal Cell Carcinoma (RCC) Exelixis, Inc./XL880-201		
-----------	--	--	--

- PI
The major goal of this study was to address the role of dual VEGF/Met inhibition in papillary RCC.
- 2006-2012 Randomized Trial of Docetaxel plus ZD6474 as Compared with Docetaxel plus Placebo in Placebo in Advanced Previously Treated Transitional Cell Carcinoma
Astra Zeneca/IRUSZACT0026
PI
The major goal of this study was to randomly test the utility of dual VEGF/EGFR blockade in bladder in addition to chemotherapy.
- 2008-2010 A Phase II Single Arm Study of IMC-1121B in Patients with Metastatic Renal Cell Carcinoma with Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy
ImClone Systems, Inc./CP-12-0605
PI
The major goal of this study was to investigate the use of novel VEGFR antibody in refractory RCC.
- 2008-2010 A Study of Pazopanib vs. Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma
GlaxoSmithKline/VEG108844
PI
The major goal of this study was to provide head to head comparison of 2 standards of care sunitinib and pazopanib. This was the largest study of targeted therapy in mRCC.
- 2008-2010 Analgesic Use and Kidney Cancer.
National Institutes of Health (NIH)/5 P50 CA101942-Ext; Kidney Cancer Association and DF/HCC Kidney Cancer (KC) SPORE Joint Developmental Project Award
Co-PI (Co-PI: Eunyong Cho)
The major goal of this study was to measure the impact of analgesics (aspirin, other nonsteroidal anti-inflammatory drugs [NSAIDs], and acetaminophen) on the risk of developing RCC.
- 2008-2010 Gene Polymorphisms in Kidney Cancer: Relation to Prognosis and Response to Therapy
Dunkin' Donuts Rising Star Program
PI
The major goal of this study was to establish single-nucleotide polymorphism

(SNPs) that can predict RCC outcome focused on the risk of recurrence and response to therapy.

- 2008-2012
Translational Studies Based on Tumor Suppressor Proteins
Doris Duke Charitable Foundation/2006086
Sub-PI (PI: William Kaelin)
The major goal of this study was to advance knowledge about tumor suppressor proteins.
- 2008-2012
Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) in Muscle-invasive Bladder Cancer with Clinical and Correlative Endpoints
Amgen Inc. and DFCI
PI
The major goal of this study was to investigate the role of a novel regimen (ddMVAC) as neoadjuvant chemotherapy in high-risk bladder cancer with correlatives.
- 2009-2011
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma
Astellas Pharma Inc.
PI
The major goal of this study was to investigate the role of an IGFR inhibitor in advanced adrenal cancer in a randomized setting.
- 2009-2014
Core 3: Tissue Acquisition, Pathology and Clinical Data (SPORE)
Co-PI (Co-PI: Atkins)
The major goals of this study were to maintain tissue repository for the various investigators participating in this SPORE, to maintain clinical database, to provide histology and molecular pathology services to SPORE investigators, and to collaborate with Biostatistics Core in data analysis and auditing.
- 2010-2013
A Phase I Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects with Solid Tumors
Exelixis, Inc./XL-184-008
PI
The major goal of this study was to investigate a novel VEGF/MET inhibitor in clear cell RCC and the results led to a large phase III trial.

- 2010-2013 Treatment of VHL-/- clear cell renal carcinoma with HIF2 α sarn DF/HCC Kidney Cancer SPORE Project 2
Co-PI (Co-PI: William Kaelin)
The major goal of this study was to test if HIF2 α was a major target in clear-cell RCC with application to an early clinical trial.
- 2010-2013 Genetic Polymorphisms and the Risk of Recurrence in Renal Cell Cancer (RCC)
ASCO Career Development Award.
PI
The major goal of this study was to test specific SNPs involved in RCC pathogenesis as predictors of recurrence in a cohort of RCC patients who underwent surgery.
- 2010-2013 A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects with Localized or Locally Advanced RCC Following Nephrectomy
GlaxoSmithKline/VEG113387
PI
The major goal of this study was to test the efficacy of pazopanib in high-risk RCC
- 2010-2014 Bevacizumab and BKM-120 in Patients with Metastatic Renal Cell Carcinoma
Novartis/10-405
PI
The major goal of this study was to test the maximal tolerated dose of the combination in RCC.
- 2011-2012 Molecular characterization of metanephric adenoma of the kidney
Dana-Farber/Harvard Cancer Center;; Kidney Cancer SPORE Director Choice Award
PI
The major goal of this study was to characterize and validate BRAF mutations in metanephric adenoma.
- 2012-2015 Alliance for Clinical Trials in Oncology/ Cancer and Leukemia Group B (CALGB) and Cancer Therapy Evaluation Program (CTEP): Randomized Phase II Study Comparing Cabozantinib with Commercially Supplied Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma
Cooperative-group and CTEP-funded
PI

The major goal of this study was to compare front-line VEGF TKI vs. VEGF/Met inhibitor in advanced RCC. This was the first trial to do so and it was CTEP-funded.

- 2012-2021 Dana-Farber/Harvard Cancer Center Support Grant
NIH; P30CA006516-47
Program Leader (\$12,040, salary support only) (PI: Laurie Glimcher)
The primary goal of the Kidney Cancer Center is to promote collaborative interactions that will lead to new approaches to cancer prevention, diagnosis and treatment. My specific role is the program co-leader, for which I receive salary support.
- 2013-2014 Developmental Research Project: Biomarkers of Temsirolimus Activity in advanced renal cell carcinoma: genomics, genetic polymorphisms and protein expression
NIH/ P50; CA101942-10
PI
The major goal of this study was to investigate the mTOR pathway in a systematic fashion at the level of the tumor and host genetics, using several types of experimental methods such as tumor sequencing.
- 2013-2014 Evaluating Functional Consequences of Epigenetic Mutations Derived from Kidney Tumor Sequencing.
Department of Medical Oncology at DFCI
Co-PI (Co-PI: Matthew Freedman)
The major goal of this study was to functionally annotate tumor sequencing findings in human tissue and provide a logical strategy for studying the downstream effects of somatically altered chromatin-modifying genes.
- 2013-2014 Characterizing the Genetic Underpinnings Predicting Progression in HGT1 Bladder Cancer.
Department of Medical Oncology at DFCI
Co-PI (Co-PI: Joaquim Bellmunt)
The major goal of this study was to explore the genetic changes of an exclusive cohort of high-grade T1 tumors of the bladder.
- 2013-2017 International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium: The Next Generation of Studies.
Kidney Cancer Association
PI
The major goal of this project is to create a biobank from metastatic RCC patients treated with targeted therapy at member institutions of consortium.

- 2014-2015 Investigating Mechanisms of Anti-Tumor Activity of Angiotensin System Inhibitors (ASIs) in Renal Cell Carcinoma
Department of Medical Oncology at DFCI
PI
The major goal of this study was to investigate the preclinical effects of ASIs in RCC cell lines and in relation to systemic agents.
- 2014-2019 A Phase II, Randomized Study of MPDL3280A Administered as Monotherapy or in Combination with Bevacizumab Versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma
Roche Holding AG
PI
The major goal of this study is to test front-line VEGF TKI (Standard) vs. novel immune checkpoint blocker vs. combination drugs that block both pathways.
- 2014-2020 A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients with Papillary Renal Cell Carcinoma (PRCC)
AstraZeneca
PI
The major goal of this study is to test a pure MET inhibitor (volitinib) in advanced papillary RCC. This is the first biomarker-based trial dedicated to this disease.
- 2014-2021 A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, A HIF-
2014-2018 2a Inhibitor, In Patients with Advanced Clear Cell Renal Cell Carcinoma
NCE Peloton Therapeutics, Inc.; PS5324101
2018-2021 PI (\$101,377)
The major goal of this study is to test a HIF-2 inhibitor in advanced RCC based on significant work from several laboratory collaborators; this is the first study of a HIF-2 inhibitor in clinic.
- 2015-2017 Genetic Predictors of Response to mTOR Inhibitors in Advanced Renal Cancer
NIH/NCI; Omnibus R21 CA191687
Co-PI (Co-PI: David Kwiatkowski)
The major goals of this proposal were 1) to identify genetic predictors of response to agents targeting the mTOR pathway in advanced RCC using targeted sequencing of candidate genes in the mTOR pathway; and 2) to identify acquired mutations that develop in tumors that initially respond to mTOR inhibitors and then progress.

- 2015-2017 2015 Kure It Research Grant
AACR
Co-Leader (PI: Eliezer Van Allen)
The major goals of this project were 1) to develop computational algorithms that characterize genomic mechanisms of response to PD-1/PD-L1 inhibition in mRCC; and 2) to evaluate predictive plasma biomarkers of response to PD-1/PD-L1 inhibitors in clinical cohorts. My role in this project is to provide clinical and translational guidance and to co-supervise the project.
- 2015-2017 Investigating mechanisms of anti-tumor activity of angiotensin system inhibitors
Pfizer, Inc., (Investigator Initiated Research)
PI
The major goal of this study was to understand the molecular mechanisms underlying the survival advantage demonstrated in patients with metastatic renal cell carcinoma (RCC) ASIs in addition to VEGF and mTOR targeted therapy by employing in vivo methods, employing RCC tumor xenograft models.
- 2015-2019 Exploratory Soluble Factors (sPD-L1 and kynurenine and metabolites) in Nivo-Treated Patients
Bristol-Myers Squibb
PI
The major goals of this study are to determine serum PD-L1 and serum kynurenine in patients with metastatic RCC and melanoma who received nivolumab, and to expand initial proof of concept year 1 trials into testing of serum/plasma obtained as part of other nivolumab monotherapy or combination studies.
- 2015-2020
Targeting mTOR
Dependent
Mechanism in
Clear Cell Renal
Carcinoma (Project
3) Targeting mTOR Dependent Mechanism in Clear Cell Renal Carcinoma (Project 3)
DF/HCC Kidney Cancer SPORE; P50 CA101942
Co-Lead of Project 3 (PI: David McDermott and William Kaelin)
The translational goals of this project are: 1) to identify genetically defined subsets of RCC patients that can be predicted to have a sustained clinical response to rapalog therapy, enabling a personalized medicine approach to treatment selection in RCC; 2) to perform a biomarker-based clinical trial of an mTOR kinase inhibitor (MLN0128) in RCC patients who progressed on prior rapalogs; 3) to use a novel CRISPR/Cas9-based screening system to identify synergistic therapeutic approaches to targeting mTOR in concert with rapalogs or mTOR kinase inhibitors.

2015-2021 2015- NCE 2016-2021	<p>Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (Msb0010718c) in Combination With Axitinib (Inlyta) Versus Sunitinib (Sutent) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma</p> <p>Pfizer, Inc., (Investigator Initiated Research); PS5285101 PI (\$957,087)</p> <p>The major goal of this study is to demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients (patient population prospectively defined as noted in Section 7.5.1) with aRCC.</p>
2016-2017	<p>Understanding PD-1 Function in RCC By Analyzing Extremes of Response – A Biomarker Study</p> <p>Bristol-Myers Squibb Investigator Initiated Research PI</p> <p>The aims of this study were: 1) to test the hypothesis that either pre-treatment cytokine levels or on-treatment changes in cytokine levels will correlate with response group; 2) to test the hypothesis that the baseline transcriptional signature from tumor biopsies will correlate with response group. It also tested the alternative hypothesis that on-treatment changes in transcripts correlate with response group.</p>
2016-2020	<p>Combining NeoVax, A Personalized Neoantigen Vaccine, with Ipilimumab to Treat Advanced Clear Cell Renal Carcinoma</p> <p>Gateway for Cancer Research; G-14-1000 PI (\$1,090,039)</p> <p>The major goals of this project are 1) determine the safety of NeoVax in combination with locally administered Ipilimumab; 2) estimate recurrence-free survival as an exploratory endpoint from this small patient population; and 3) evaluate the magnitude of the T cell response to each immunizing neoantigen and the phenotypic properties of the induced T cell populations.</p>
2016-2020	<p>Identifying Tissue-based Predictive Biomarkers for Cabozantinib in Renal Cell Carcinoma</p> <p>Exelixis, Inc PI (\$114,857)</p> <p>The purpose of the research is to interrogate potential cabozantinib targets (at protein, RNA and DNA level) in a large cohort (with an available control arm) to determine whether any of them correlate with clinical response.</p>
2017-2019	<p>Correlation of Mutation Findings in TSC1, TSC2 and MTOR with Response to Rapalog Therapy in Patients with Metastatic Renal Cell Carcinoma</p>

(mRCC)
Novartis; A10674 SRA
PI

The goals of this project were: 1) complete the mutation analysis of a full cohort of trial patients treated with rapalog therapy; and 2) empower te statistical analysis in order to determine the positive predictive value of a mutation in TSC1, TSC2, and MTOR for response to rapalog therapy.

2017-2019 T-cell Receptor Repertoire as a Predictive Biomarker of Response to PD-1 Inhibitors in Advanced Renal Cell Carcinoma
Dana-Farber Cancer Insitute; 2018 Medical Oncology Award
PI
The goals of this project are: 1) establish the TCR-seq experimental platform for cost-effective immune repertoire profiling; 2) test TCR- β diversity in mRCC patients treated with nivolumab; and 3) develop bioinformatics methods to predict response nivolumab in mRCC patients.

2017-2020 Epi Study
AstraZeneca; A10383 SRA
PI
The goal of this project is to conduct research activites as a contribution to AstraZeneca's retrospective observational study of outcomes and MET statues in PRCC.

2017-2021 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)
Bristol-Myers Squibb; PS5308201
PI (\$150,816)
Primary Objective: To assess the efficacy (ORR, DOR, and PFSR at 24 weeks) of each FRACTION-RCC study treatment combination (relative to nivolumab in combination with ipilimumab, when applicable) in participants with advanced RCC

2017-2021 Serum Metabolomics in RCC Patients Receiving Nivolumab or Everolimus as Part of the CheckMate025 Phase III Trial
Bristol-Myers Squibb; A11301SRA
PI (\$214,734)
The goals of this project are: 1) to test whether chemical compositions and associated changes of the serum metabolome could reveal distinct metabolic environments in patients treated with nivolumab; and assess the correlation

between serum metabolomic levels with clinical response to nivolumab and everolimus and to validate our findings in two external cohorts.

2018-2020

Differential Expression of c-Met and PD-L1 Expression/Other Immune Biomarkers on the CABOSUN Trial

Exelixis, Inc; A11730 SRA

PI

The goal of this project is to investigate the prognostic and/or predictive value of c-MET concurrently with other biomarkers of immune response on the CABOSUN trial (such as PD-L1) constituting 1) preliminary data for correlative studies of the planned PDIGREE study that is planned by the Alliance. 2) It will also provide a benchmark for cabozantinib activity in PD-L1 (+) vs. PD-L1 (-) populations.

2018-2020

Identification of Genomic Drivers of Brain Metastases in Renal Cell Carcinoma

NIH/NCI; R21 CA220253

Co-PI (Co-PI: Priscilla Brastianos)

The goals of this project are: 1) To test the hypothesis that brain metastases have unique molecular drivers, we will perform whole exome sequencing and epigenetic profiling of matched intracranial and extracranial sites. Using genomic characterization of matched primary renal cell tumors, brain metastases, and extracranial distant metastatic sites, and comparing to TCGA data, we aim to identify genetic alterations that are significantly enriched in brain metastases; and 2) to test the hypothesis that recurrent brain metastases harbor specific genomic alterations driving their clinical behavior including resistance to therapy, we propose to analyze CSF samples, plasma samples and brain metastases before, during therapy and after progression on targeted therapy and PD-1 inhibitors.

2018-2020

Phase II Broad Institute Cancer Model and Development Center
Broad Institute (Boehm/Ligon)/NCI/Leidos Biomedical Research, Inc.

Co-Investigator (PI: David Hoffmann)

The Broad CMDC has three goals: 1) Achieve industry scale: Produce 100 patient-derived models per year with a focus on cancer types currently lacking precision therapies (Gastroesophageal, Pancreas, Glioblastoma and Pediatric Solid Tumors); 2) Innovate to maximize efficiency: Iteratively optimize and refine workflows to improve success rates, maximize efficiencies and reduce costs; 3) Succeed for rare cancers: Demonstrate proof-of-concept for how to overcome key bottlenecks in rare and underrepresented cancers.

- 2018-2020 Developing tissue-based predictors of response and intrinsic resistance to immune checkpoint therapy with nivolumab in metastatic renal cell carcinoma via whole exome/transcriptome and immunohistochemistry (IHC)/immunofluorescence (IF) analyses of pre-treatment clinical tumor samples
 Bristol-Myers Squibb; A11441
 Co-PI (\$1,868,444)
 The goal of this proposal is to 1) develop and apply computational biology algorithms that systematically interrogate hypothesized genomic *response* effectors, 2) determine the landscape of intrinsic and genomic *resistance* mechanisms to nivolumab in mRCC, and 3) to assess the predictive value of immune checkpoint protein expression in tumor cells and tumor-infiltrating immune cells through IHC/IF analyses.
- 2018-2021 AXL and c-MET cross-talk in regulating immune escape of renal cancer cells
 Exelexis, Inc.; EXEL#231097
 Co-PI (Co-PI: Soumitro Pal, \$49,131)
 In this study we will explore the mechanism(s) by which the AXL-c-MET cross-talk can regulate PD-L1 expression in renal cancer cells, and modulate immune-mediated killing. Further, we will study how the inhibition of AXL-c-MET cross-talk can prevent PD-L1-mediated renal tumor growth *in vivo*.
- 2018-2021 Predictive biomarkers for nivolumab treatment in metastatic renal cell carcinoma
 DOD/KCRP TRPA; KC170161
 PI (\$600,000)
 The goals of this project will focus on the validation of blood-based biomarkers of response to nivolumab in metastatic ccRCC: 1) validate the impact of nivolumab therapy on kynurenine, and to examine whether changes in kynurenine levels correlate with nivolumab benefit; 2) validate the negative predictive value of serum adenosine in patients treated with nivolumab. Furthermore, we will also focus on the validation of tissue-based biomarkers of response to nivolumab in metastatic ccRCC: a) validate the predictive value of biomarkers expression by immunostaining assays in patients treated with nivolumab; 2) validate the predictive value of tumor genetic alterations in patients treated with nivolumab; 3) investigate the predictive value of T-effector- and myeloid-associated gene signatures in patients treated with nivolumab.
- 2019-2020 Mapping the Genomic Landscape and Molecular Vulnerabilities of Translocation Renal Cell Carcinoma
 DFCI; Claudia Barr Award

Mentor (PI: Viswanathan)
(\$260,000)

This grant seeks to considerably advance our molecular understanding of TFE3-TRCC by performing comprehensive genomic, transcriptomic, small molecule, and functional genetic profiling of this rare but devastating disease.

Aim 1) To perform linked-read whole genome sequencing (Aim 1.1) and transcriptome sequencing (Aim 1.2) on a cohort of tumor-normal pairs from patients with TFE3-TRCC.

Aim 2) To uncover novel therapeutic vulnerabilities of TFE3-TRCC via genome-scale functional genetic CRISPR/Cas9 screening (Aim 2.1) and large-scale small molecule screening (Aim 2.2).

2019-2021, 2019-2021

Histopathological review of tumor tissue slides from the CheckMate 214 trial

Bristol-Myers Squibb
PI (\$111,124)

The goals of this project are: 1) Assessment of sarcomatoid and rhabdoid features in H&E slides from patients enrolled in the CheckMate 214 trial; 2) Assessment of PD-L1 expression in the subset of cases with sarcomatoid and rhabdoid.

2019-2021

Host Immune Signatures as Therapy Response Biomarkers in Metastatic Renal Cell Carcinoma

DOD / KCRP IDA; KC180129
PI (\$400,000)

The goals of this study are: 1) To identify immune response factors by characterizing the tumor immune microenvironment from pre-treatment mRCC tumor RNA-seq data; 2) Evaluate whether observing an expansion of tumor-infiltrating immune repertoire in post treatment blood is associated with patient response to VEGF-TT, ICB and ICB+VEGF-TT; 3) Validate the results using other mRCC cohorts with VEGF-TT, ICB and ICB+VEGF-TT treatment.

2019-2022

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

Exelixis, Inc.; PS5355401
PI (\$98,282)

Aims: The objective of this study is to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and ipilimumab versus

nivolumab and ipilimumab in previously untreated subjects with intermediate- and poor-risk advanced or metastatic RCC.

2019-2022 Functionally Characterizing the Enhancer Cistrome in Advanced Human Kidney Cancer
DOD / KCRP IDA; W81XWH-18-KCRP-IDA
Co-Investigator (PI: Mark Pomerantz)
(\$400,000)
The major goals for this project are: 1) To characterize the genome-wide landscape of open chromatin and active regulatory elements and their connections to target genes in the progression from localized to metastatic ccRCC. Aim 2) To perform epigenome-wide CRISPR-based screens across the epigenome to identify the functional relevance of regulatory elements associated with ccRCC in model systems.

2019-2022 Development and testing of circulating-free methylated DNA as a prognostic biomarker for recurrent kidney cancer
DOD / KCRP TDA; KC180206
PI (\$454,701)
The major goals for this study are: 1) To evaluate the relationship between cfmeDNA and recurrence in patients with early-stage RCC treated with placebo; 2) To evaluate the relationship between cfmeDNA and recurrence in patients with early-stage RCC treated with pazopanib.

Current

2019-2023 Developing a Transition Pipeline for VHL Mutant Malignancies
BIDMC / NIH; U01 U01CA236489
Site PI
The aims of this project are: 1) To Evaluate the Efficacy of HIF2 α inhibitor based Combination Strategies in Translational Clinical Trials in ccRCC; 2) To Exploit Therapeutic Targets that are Synthetic Lethal with VHL; 3) To Develop a ccRCC Syngeneic Preclinical Model to Test the Combination of HIF2 α Antagonists and Novel Immunotherapies

2020-2024 Understanding CD8⁺ T-Cell Specificity and Function in Renal Cell Carcinoma
DOD; KC190128
Mentor (PI: Braun)
(\$1,290,500)
Goals: Systematically identify the classes of tumor antigens in ccRCC, Link the T cell clonality of TILs in ccRCC with antigen specificity, and connect

specific ccRCC target antigens and TIL clonotypes with response or resistance to anti-PD-1-based treatments.

2020- Small Molecule HIF2 α Inhibitors for Treatment of Renal Cell (Project 1) DF/HCC Kidney Cancer SPORE; P50 CA101942
Co-Investigator and Lead of Clinical Trial of Project 1(\$162,380) (PI: David McDermott and William Kaelin)
The major goal of this project is to identify new diagnostic tools and therapeutic targets in kidney cancer based on small molecule HIF2 α inhibitors for treatment of renal cell carcinoma.

2020- Tissue Acquisition, Pathology and Clinical Data (Core 2) DF/HCC Kidney Cancer SPORE; P50 CA101942
Co-Leader of Core 2 (\$35,600) (PI: David McDermott and William Kaelin)
The major goal of this project is to provide collaborating investigators multiple pathology services to support the five SPORE Research Projects as well as all current and future Career Development Program (CDP) and Development Research Projects (DRP) awardees: to provide a specimen bank for SPORE investigators, to maintain a database of key clinical variables, and to provide pathology services to SPORE investigators.

2020- DF/HCC Clinical Trials Site Application for Kidney Cancer Research Consortium Award Mechanism
DOD/BIDMC; KC190162
Site PI
(\$137,340 DFCI only)
The major goal between our institutions is to design and efficiently execute mechanistically driven clinical studies testing novel agents, combinations, and schedules in centers of excellence with a strong translational and basic research backgrounds. These trials will accelerate discovery, and will enable the development of therapies and tumor assessment.

Training Grants and Mentored Trainee Grants

2013-2015 Identification of Biomarkers of Response to MET inhibitors in papillary RCC.
Foundation de France and UNICANCER
Mentor (PI: Laurence Albiges)
The major goal of this grant was to provide training abroad in kidney cancer clinical research and investigation.

Unfunded Current Projects

2008- Patterns of Care, Racial Disparities, Cost Effectiveness and Resources Utilization in the Care of Patients with Genitourinary Malignancies
PI
This ongoing health outcomes research project is in collaboration with the BWH Division of Urology (Quoc-Dien Trinh, MD) and Department of Radiation Oncology (Paul Nguyen, MD).

Report of Local Teaching and Training

Teaching of Students in Courses:

HMS Courses

2021-	Cancer Biology AISC 600.0 3rd/4th year medical students	HMS 8 hours / year
-------	--	-----------------------

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs):

2008-	Genitourinary Clinical Case Management Medical Oncology Fellows Internal Medicine Residents Pathology Residents Junior Attendings	DFCI 12 hours / year
2010-	Renal Cell Carcinoma Trial Designs: Bench to Bedside Medical Oncology Fellows	DFCI 2 hours / year
2022	Investigator Series: How to Develop a Major Clinical Trial Fellows	DFCI 1 hour / year

Clinical Supervisory and Training Responsibilities:

2007-	Clinic Preceptor Rotating GU Medical Oncology Fellows	DFCI Two sessions per week
2007-	Clinic Preceptor Rotating International Medical Oncology Fellows	DFCI One session per month

2007-	Clinical Supervisor Rotating Medical Oncology Residents and Physician Assistants	BWH Twenty sessions per year
2010-	Primary Clinical Supervisor Medical Oncology Physician Assistant	BWH One session every six months
2012-	Primary Continuity Clinic Preceptor GU Medical Oncology Fellow	DFCI One session per week

Laboratory and Other Research Supervisory and Training Responsibilities:

2007-	Supervision and mentorship in preparing clinical protocols, conducting research, experimental design, and trials interpretation. Active role in career development and choosing future specialty college students, clinical research coordinators, and medical students	DFCI Varies: daily to weekly, lasting a few weeks to one year
2010-	Supervision and mentorship in preparing grant applications, manuscripts, and PowerPoint presentations genitourinary oncology research fellows	DFCI Varies: daily to weekly, lasting a few weeks to one year
2014-2015	Co-supervision research associate in the Matthew Freedman Laboratory	DFCI Bi-weekly research meeting, plus one hour 1:1 meeting per week
2014-	Supervision in my translational laboratory post-doctoral fellow	DFCI Bi-weekly research meeting, plus one hour 1:1 meeting per week

Formally Mentored Harvard Medical, Dental and Graduate Students:

2010-2012	Christopher Richards, M.D. (HMS Class of 2011), Fellow, Pulmonary and Critical Care Medicine Program at Massachusetts General Hospital (MGH) and Beth Israel Deaconess Medical Center (BIDMC), Boston, MA Career stage: medical student and resident. Mentoring role: research advisor/Mentor for 2 projects regarding tyrosine-kinase inhibitor (TKI)
-----------	--

increased cardiac toxicity and treatment-related deaths; one poster, published two papers in *JCO*.

2015-2016 Claire Wagner, HMS Class of 2019
Clinic preceptor and career development.

2019-2020 Jeffrey Graham, HSPH Class of 2020
Career stage: Assistant Professor, University of Manitoba, Canada
Mentoring role: Main advisor for final project, titled “Effectiveness of immune checkpoint inhibitors in advanced non-clear cell renal cell carcinoma”, for MPH in Epidemiology

Other Mentored Trainees and Faculty:

2007-2008 Kevin Courtney, M.D., Ph.D./ Assistant Professor of Medicine, University of Texas Southwestern Medical Center, Dallas, TX
Career stage: Hem/Onc fellow. Mentoring role: research advisor.
Accomplishments: advised on projects regarding RCC overview; published two articles.

2007-2009 James Cleary, M.D., Ph.D./ Instructor in Medicine, HMS, Physician, DFCI
Career stage: Hem/Onc fellow. Mentoring role: research advisor.
Accomplishments: advised on projects regarding the role of sunitinib re-challenge in metastatic RCC; published one paper.

2009-2010 Aymen Elfiky, M.D., M.A., M.P.H./ Division Director, Hematology/Oncology, The Brooklyn Hospital Center, Brooklyn, NY
Career stage: Hem/Onc fellow. Mentoring role: research advisor.
Accomplishments: advised on projects regarding the role of targeted therapy washout in metastatic RCC; published 2 papers.

2009-2012 Fabio Schutz, M.D./ Research Associate, DFCI, and Attending Physician, Hospital San Jose, Sao Paulo, Brazil
Career stage: fellow. Mentoring role: research advisor.
Accomplishments: advising on projects regarding SNP polymorphisms in RCC recurrence and vascular endothelial growth factor (VEGF) TKI toxicity; published six papers, including two in *JCO* and one in *Lancet Oncology*; three posters and one oral presentation at ASCO meeting; two ASCO Foundation MERIT Awards.

2009- Daniel Heng, M.D., M.P.H./ Staff Medical Oncologist, Tom Baker Cancer Centre; Clinical Associate Professor, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Career stage: junior attending. Mentoring role: Advisor.

Accomplishments: mentor on several outcomes research papers about prognostication in metastatic RCC patients treated with targeted agents, published > 30 papers in journals such as *JCO* and *Lancet Oncology*.

2010 Denis Jardim, M.D./ Attending Physician, Hospital Sirio Libanes, São Paulo, Brazil

Career stage: fellow. Mentoring role: research advisor.

Accomplishments: advised on projects regarding the effect of bevacizumab and hematologic effects; published one paper.

2010 Donnette Dabydeen, M.D./ Interventional Radiologist, Rochester General Hospital, Rochester, NY

Career stage: fellow. Mentoring role: research advisor.

Accomplishments: advised on a project regarding mammalian target of rapamycin (mTOR) inhibitors' toxicity and radiologic changes; published one paper.

2010 Georges Azzi, M.D./ Co-Director, Department of Hematology/Oncology, Holy Cross Medical Group, Fort Lauderdale, FL

Career stage: resident. Mentoring role: research advisor.

Accomplishments: advised on projects regarding bevacizumab cardiovascular effect; published two papers, including one in *JCO*.

2010- Katherine Krajewski, M.D./ Assistant Professor of Radiology, HMS, Cancer Imaging Program Fellowship Associate Director and Physician, DFCI

Career stage: fellow/junior fellow. Mentoring role: research advisor.

Accomplishments: advising on several projects regarding new radiologic criteria predicting outcome in RCC and bladder cancer therapies; published more than five papers.

2012 Lauren Harshman, M.D./ Assistant Professor of Medicine, HMS, Physician, DFCI

Career stage: attending. Mentoring role: research advisor.

Accomplishments: advised on 2 projects regarding conditional survival and mTOR inhibitor use in advanced RCC patients treated with targeted therapy; published several papers, including one paper in *Lancet Oncology*.

2012-2013 Yüksel Ürün, M.D./ Associate Professor of Medicine, Ankara University School of Medicine, Ankara, Turkey

Career stage: fellow. Mentoring role: research advisor.

Accomplishments: advised on projects regarding genitourinary malignancies; published two papers.

- 2012-2015 Andre Fay, M.D./ Professor of Medicine, Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil
Career stage: fellow. Mentoring role: research advisor.
Accomplishments: advised on projects regarding renal cell carcinoma and biomarkers; published more than 10 papers; several ASCO Foundation MERIT Awards; oral presentation at the 2014 International Kidney Cancer Symposium.
- 2012-2016 Marina Kaymakcalan, Pharm.D./ Clinical Pharmacist, DFCI
Career stage: fellow. Mentoring role: research advisor.
Accomplishments: advising on projects regarding renal cell carcinoma, clinical and translational; published more than 10 papers, including one in the *British Journal of Cancer*.
- 2012-2016 Rana McKay, M.D./ Assistant Professor of Medicine, UC San Diego Health Moores Cancer Center, San Diego, CA
Career stage: fellow, attending. Mentoring role: research advisor.
Accomplishments: advising on projects regarding renal cell carcinoma and prostate cancer; published more than 10 papers; oral presentation at the 2015 Genitourinary Cancers Symposium.
- 2013-2014 Ole-Petter Hamnvik, M.B.B.Ch., B.A.O., M.M./ Assistant Professor of Medicine, HMS Associate Program Director, Endocrinology Fellowship, Assistant Program Director, Internal Medicine (IM) Residency, BWH
Career stage: fellow. Mentoring role: research advisor.
Accomplishments: mentor on Master's thesis for the Scholars in Clinical Science Program (Harvard School of Public Health); published 1 paper.
- 2013-2015 Laurence Albiges, M.D./ Assistant Professor of Medicine and Chief of Genitourinary Oncology, Gustave Roussy Institute of Oncology, Villejuif, France
Career stage: attending. Mentoring role: research advisor.
Accomplishments: advised on projects regarding renal cell carcinoma; ASCO Foundation MERIT award; oral presentation at the 2015 Genitourinary Cancer Symposium; published more than 10 papers.
- 2013-2016 Thai H. Ho, M.D., Ph.D./ Assistant Professor of Medicine, Mayo Clinic Arizona, Scottsdale, AZ
Career stage: fellow, attending. Mentoring role: research advisor.

Accomplishments: advising on projects regarding renal cell carcinoma related to biomarkers; published two papers.

- 2013- Sumanta K. Pal, M.D./ Associate Clinical Professor and Co-Director of the Kidney Cancer Program, City of Hope Comprehensive Cancer Center, Duarte, CA
Career stage: attending. Mentoring role: research advisor.
Accomplishments: advising on projects regarding renal cell carcinoma related to prognostic models, biomarkers, genomics, and clinical trials; published more than ten papers, including several in *Annals of Oncology* and *European Urology*.
- 2014-2015 Pooja Ghatalia, M.D./ Medical Oncology Fellow, Fox Chase Cancer Center, Philadelphia, PA
Career stage: resident. Mentoring role: research advisor.
Accomplishments: advising on projects regarding meta-analysis of targeted therapies side effects; published 6 papers, including one in *British Journal of Cancer*.
- 2015-2016 Guillermo de Velasco, M.D., Ph.D./ Attending Physician, University Hospital 12 de Octubre, Madrid, Spain
Career stage: attending. Mentoring role: research advisor.
Accomplishments advising on projects regarding renal cell carcinoma (clinical and translational); published several abstracts and papers.
- 2015-2016 Raphael Brandão Moreira, M.D./ Chief Fellow, Beneficencia Portuguesa Hospital - Sao Paulo, Brazil
Career stage: fellow. Mentoring role: research advisor
Accomplishments: advising on projects regarding renal cell carcinoma (clinical and translational); published more than 5 papers.
- 2015-2017 Aly-Khan Lalani, M.D., F.R.C.P.C./ Assistant Professor, McMaster University and Physician, Hamilton Health Science, Ontario, Canada
Career stage: fellow. Mentoring role: research advisor.
Accomplishments: mentor on a project related to outcomes in mRCC patients; published more than 10 papers.
- 2015-2017 Nawar Hanna, M.D./ Urologic Oncology Fellow, Brigham and Women's Hospital, Boston, MA
Career stage: fellow. Mentoring role: research advisor.
Accomplishments: advising on outcomes-based research projects regarding renal cell carcinoma (clinical); published more than 5 papers.

- 2015- David Braun, M.D., Ph.D. / Instructor in Medical Oncology, DFCI, HMS
 Career stage: fellow, instructor. Mentoring Role: co-mentor.
 Accomplishments: advising on projects related to immunotherapy in renal cell carcinoma (clinical and translational); published more than 12 papers in journals such as Nat Med, JAMA Oncol, and J Clin Oncol.
- 2015- Dominick Bossé M.D., M.Sc. F.R.C.P.C./ Assistant Professor, University of Ottawa, The Ottawa Hospital Cancer Centre, Ottawa, Canada
 Career stage: fellow. Mentoring role: research advisor.
 Accomplishments: advising on projects regarding renal cell carcinoma (clinical and translational); published more than 10 papers.
- 2016-2017 Thomas Seisen, M.D./ Urologic Oncology Research Fellow, Brigham and Women's Hospital, Boston, MA
 Career stage: fellow. Mentoring role: research advisor.
 Accomplishments: advising on outcomes-based research projects regarding renal cell carcinoma (clinical); published more than 5 papers.
- 2016- Pier Nuzzo, M.D., Ph.D. / Fellow in Medical Oncology, DFCI, HMS
 Career stage: fellow. Mentoring Role: co-mentor.
 Accomplishments: advising on projects related to cell-free methylated DNA assays in renal cell carcinoma and bladder cancer; published more than 10 papers, including Nat Med.
- 2017- Amin Hassan Nassar, M.D. / Clinical Fellow in Medicine, BWH, HMS
 Career stage: fellow. Mentoring Role: co-mentor.
 Accomplishments: advising on projects related to genomic biomarkers in kidney and bladder cancers; published more than 12 papers.
- 2017- Jacob Berchuck, M.D. / Instructor in Medical Oncology, DFCI, HMS
 Career stage: fellow, instructor. Mentoring Role: co-mentor.
 Accomplishments: advising on projects related to renal cell carcinoma and cell-free methylated DNA assays in genitourinary tumors; published more than 15 papers, including Nat Med.
- 2017- Ronan Flippot, M.D., M.Sc. / Fellow in Medical Oncology, DFCI, HMS
 Career stage: fellow. Mentoring Role: primary mentor.
 Accomplishments: advising on projects related to biomarkers in renal cell carcinoma (clinical and translational); published 9 papers.
- 2018- Marios Giannakis, M.D., Ph.D. / Assistant Professor of Medicine, HMS, Physician, DFCI
 Career Stage: attending. Mentoring Role: primary mentor.

Accomplishments: Mentor on an ASCO Career Development Award; published 4 papers, one in Science and one Nat Commun.

- 2018- Sarah Abou Alaiwi, M.D. / Resident in Medicine, BWH, HMS
Career stage: fellow. Mentoring Role: co-mentor.
Accomplishments: advising on projects related to epigenetics in genitourinary tumors; published more than 10 papers.
- 2018- Shveta Motwani, M.D./Instructor of Medicine, HMS, Nephrologist, BWH
Career stage: attending. Mentoring Role: secondary mentor.
Accomplishments: advising on projects related to nephrotoxicity from systemic therapy in solid cancers, including kidney cancer (clinical).
- 2018- Ziad Bakouny, M.D., M.Sc. / Research Fellow in Medical Oncology, DFCI, HMS
Career stage: fellow. Mentoring Role: primary mentor.
Accomplishments: advising on projects related to renal cell carcinoma (clinical and translational); published more than 20 papers.
- 2019-2020 Laure Hirsch, M.D.
Career stage: fellow. Mentoring Role: mentor.
Accomplishments: advising on projects related to RCC; published one paper on COVID-19 and cancer care disparities in Cancer Cell.
- 2019- Praful Ravi, M.B., B.Ch.
Career stage: fellow, instructor. Mentoring Role: primary mentor.
Accomplishments: advising on clinical and translational projects related to genitourinary tumors; published more than 5 papers.
- 2020- Chris Labaki, M.D.
Career stage: fellow. Mentoring Role: mentor.
Accomplishments: advising on clinical and translational projects related to genitourinary tumors.
- 2021- Muhieddine Labban, M.D.
Career stage: fellow. Mentoring Role: co-mentor.
Accomplishments: advising on projects related to health service.

Formal Teaching of Peers (e.g., CME and other continuing education courses):

No presentations below were sponsored by 3rd parties/outside entities

2008, 2010, 2012, 2014, 2016, 2018, 2021	Treatment of Advanced Renal Cell Carcinoma Biennial Urologic Cancer Course, DF/BWCC and HMS	Single presentation every other year Boston, MA
2008-	Advances and Updates in the Treatment of Renal Cell Carcinoma Lank Center for Genitourinary Oncology CME Course, DFCI	Single presentation per year Boston, MA
2011, 2014	Choosing Systemic Therapy for Patients with Renal Cell Cancer Advances in Genitourinary Cancers Course, DFCI and HMS	Single presentation per year Boston, MA

Local Invited Presentations:

No presentations below were sponsored by 3rd parties/outside entities

2007	Clinical Factors Associated with Outcome in RCC Patients/ Lecture Department of Medicine, BIDMC	
2007	Role of Combination VEGF Agents in Metastatic RCC/ Lecture Department of Medicine, BIDMC	
2008	Novel Agents in Renal Cell Carcinoma/ Lecture VA Boston Healthcare System Outpatient Clinic, Jamaica Plain Campus, Boston, MA	
2009-	ASCO and Genitourinary Cancers Symposium: Update on RCC/ Lecture Department of Medicine, BIDMC DF/HCC	
2010, 2012	Updates in Renal and Bladder Cancers for the Urologist/ Countway Urology Rounds Department of Urology, BWH	
2011	Current Update on Medical Oncology: Approach to Common Malignancies: Renal Cancer and Bone Metastases / Invited Lecture Arbeitsgemeinschaft für Osteosynthesefragen (AO) North America Spine Tumor Symposium, Boston, MA	

- 2012 The Role of cMET as a Target in RCC: Preclinical and Current Clinical Data/ Lecture
DF/HCC Kidney Cancer Program
- 2013 Kidney Cancer: From Epidemiology to Therapy/ DFCI Network Grand Rounds
Department of Medical Oncology, DFCI
- 2013 Renal Cell Carcinoma: An Update in Diagnosis, Targets and Therapies/ Renal Grand Rounds
Department of Nephrology, BWH, MGH
- 2013-2014 Kidney and Bladder Cancers/ Lecture
HMS Cancer Medicine and Hematology Conference, Boston, MA
- 2013- Renal Cell Carcinoma: What the Radiologist May Want to Know/ Lecture
Cancer Imaging Program Fellowship Conference, Department of Medical Oncology, DFCI
- 2014 Immuno-Oncology: Future Perspectives in Renal Cell Carcinoma/ Lecture
Center of Immuno-Oncology Seminars, Department of Medicine, DFCI
- 2014 Renal Cell Carcinoma: The Latest Updates/ Physician Assistants Grand Rounds
Department of Medical Oncology, DFCI
- 2015 Cabozantinib vs. Everolimus Phase 3 Trial/ Lecture
Department of Medicine, BIDMC and DF/HCC
- 2015 Overview of Immunotherapy in Kidney Cancer/ Lecture
Cancer Immunology GU Retreat, Department of Medicine, DF/HCC
- 2018 Best of ASCO in RCC/ Lecture
DF/HCC Kidney Cancer Program
- 2019 Kidney cancer Treatments Emerging from Studies of the VHL Tumor Suppressor Gene/ Medical Oncology Grand Rounds
Department of Medical Oncology, DFCI
- 2020 Clinically Challenging Cases in Cancer/ Invited lecture
HMS High Impact Cancer Research Program

- 2021 55 year old man with metastatic renal cell carcinoma (Presented by Dr. Christine Ryan)/ Discussant
New Patient Conference, Medical Oncology, DFCI (Virtual)
- 2021 Advanced Disease: VEGF and IO Combinations / Invited Lecture
20th Biennial Course in Urologic Oncology, DF/HCC
- 2021 Adjuvant Immunotherapy in RCC: Keynote 564 and Beyond/ Invited lecture
Kidney Cancer Program Monthly Speakers, DF/HCC
- 2021 Latest Treatment Options, Clinical Trial Research, Side Effect Management, Nutritional Support, Educational Resources and Patient Advocacy/ Panelist
13th Annual Dana-Farber/Harvard Cancer Center Kidney Cancer Symposium, DF/HCC
- 2022 Adjuvant strategies in RCC
21st Biennial Course in Urologic Oncology, DF/HCC
- 2022 Renal Cell Carcinoma Meets Immuno-Oncology / Invited Lecture
Center for Immuno-Oncology Lecture Series, DFCI

Report of Regional, National and International Invited Teaching and Presentations

Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

Regional

- 2008 Genitourinary Cancers Case Presentation/ Lecture
Department of Medicine, Emerson Hospital, Concord, MA
- 2008 Second-line Therapy for Advanced Bladder Cancer/ Lecture
Department of Medicine, Fall River Hospital, Fall River, MA
- 2009 GU Cancer Tumor Board/ Lecture
Department of Medicine, Saint Anne's Hospital, Fall River, MA
- 2009 Kidney Cancer Issues/ Grand Rounds
Department of Medicine, Melrose-Wakefield Hospital, Melrose, MA
- 2009 Kidney Cancer Tumor Board/ Lecture
Department of Medicine, Middlesex Hospital, Middlesex, CT

- 2009 Updates in RCC and Novel Agents/ Lecture
International Oncology Symposium ONCOLEAD Program, Boston, MA
(Turkish Oncology Society)
- 2010 Kidney and Bladder Cancer in 2010: Bridging the Gap between Medical
Oncology and Urology/ Urology Grand Rounds/ Visiting Professorship
Department of Medicine, University of Connecticut Health Center,
Farmington, CT
- 2013 Kidney Cancer: An Updated Overview of the Essentials/ Grand Rounds
Tufts Cancer Center, Tufts University School of Medicine, Boston, MA
- 2014 “The Doctor Is In” Seminar: MITers: Let Us Think Together About Renal
Cell Cancer/ Lecture
Koch Institute, MIT, Cambridge, MA
- 2016 Novel Drugs in Renal Cancer and Biomarkers/ Grand Rounds
Boston Medical Center, Boston University, Boston, MA
- 2021 Charting New Territories in Renal Cell Cancer / Invited Lecture
Brown Cancer Center Invited Research Seminar, Providence, RI, Virtual

National

- 2007 Papillary Carcinoma - TKI Data/ Lecture
International Kidney Cancer Symposium (IKCS), Chicago, IL
- 2007 Relation of Prognosis and Therapy Response to von Hippel-Lindau syndrome
(VHL) Genotype/ Lecture
Kidney and Bladder Congress, Chicago, IL
- 2008 Novel agents in Papillary Renal Cell Carcinoma/ Lecture
International Kidney Cancer Symposium, Chicago, IL
- 2009 Doc Talk: Emerging Therapies in RCC/ Lecture
Imedex, an E-learning Center, Cleveland, OH
- 2009 Dosing Patterns in Advanced Renal Cell Carcinoma/ Lecture
International Kidney Cancer Symposium, Chicago, IL
- 2009 The Role of VEGF-targeted Therapy in Sarcomatoid Renal Cell Carcinoma/
Lecture
Kidney Cancer Association, Chicago, IL

- 2010 Community Oncology: Urology Clinical Debates/ Lecture
Department of Medicine, University of Kansas Medical Center, Kansas City, KS
- 2010 RCC: A Model Disease for VEGF-targeted Therapy/ Lecture
12th Annual Angiogenesis Meeting, Boston, MA
- 2010 Renal Cell Carcinoma/ Grand Rounds
Department of Medicine, Jersey City Medical Center, Jersey City, NJ
- 2010 Sequencing TKIs and mTOR Inhibitors in Renal Cell Carcinoma/ Lecture
Chemotherapy Foundation Symposium XXVIII, New York, NY
- 2011 Care Delivery for Cancer Patients/ Panel Member
NCCN Academy for Excellence & Leadership in Oncology, School of
Pharmaceutical & Biotech Business, Philadelphia, PA
- 2012 A Phase II and Biomarker Study (MET111644) of the Dual Met/VEGFR-2
Inhibitor Foretinib in Patients with Sporadic and Hereditary Papillary Renal
Cell Carcinoma: Final Efficacy, Safety, and PD Results/ Lecture
Genitourinary Cancers Symposium, San Francisco, CA
- 2012 Activity of Cabozantinib (XL184) in Patients with Metastatic, Refractory
Renal Cell Carcinoma (RCC)/ Lecture
ASCO Annual Meeting, Chicago, IL
- 2012 Biomarkers in Kidney Cancer/ Grand Rounds
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY
- 2012 Clinical Practice Decisions in Advanced Renal Cell Carcinoma/ Lecture
NCCN 17th Annual Conference, Hollywood, FL
- 2012 Renal Cell Carcinoma: Current and Emerging Paradigms/ Grand Rounds
Department of Medicine, Columbia University Medical Center, New York,
NY
- 2012 Targeted Therapy in Unresectable and Recurrent Renal Cell Cancer/ Lecture
NCCN 2012 Congress: Genitourinary Cancers, Nashville, TN
- 2013 Care of Patients with Renal Cell Cancer/ Lecture
NCCN 18th Annual Conference, Hollywood, FL

- 2013 Moving Forward on Treatment of Metastatic RCC/ Lecture
ASCO Annual Meeting, Chicago, IL
- 2013 Phase III Trial of Cabozantinib vs. Everolimus in Metastatic RCC Patients
Treated with Prior VEGF-Targeted Agents (Trials in Progress)/ Lecture
IKCS, Chicago, IL
- 2013 Update on Trials and Targets in Renal Cell Cancer/ Lecture
US Oncology Research Forum, Dallas, TX
- 2014 Biomarkers in RCC and Clinical Trials Design / Lecture
NCCN Designing Clinical Trials in the Era of Multiple Biomarkers and
Targeted Therapies Working Group Meeting, Philadelphia, PA
- 2014 Novel Targets in the Treatment of Metastatic Renal Cell Carcinoma/ Lecture
EPIC (Emerging Paradigms in Care) GU Malignancies in 2014 and Beyond,
Washington, DC
- 2015 Best of ASCO Kidney Cancer Update/ Lecture
Best of ASCO Annual Meeting, Florida Hospital Cancer Institute, Orlando,
FL
- 2015 Genitourinary Cancers Maintenance of Certification Course/ Speaker
ASCO Annual Meeting, Chicago, IL
- 2015 Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell
Carcinoma (mRCC): Association of Biomarkers with Clinical Outcomes/
Lecture
ASCO Annual Meeting, Chicago, IL
- 2015 Novel Targets in the Treatment of Metastatic RCC Outside Immuno-
Oncology/ Lecture
EPIC (Emerging Paradigms in Care) GU Malignancies in 2015 and Beyond:
An Expert Panel Discussion, Washington, DC
- 2015 Phase 1b Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-
Naive Patients with Advanced Renal Cell Carcinoma/ Lecture
International Kidney Cancer Symposium, Miami, FL
- 2015 Renal Cell Cancer: Year in Review/ Keynote Lecture
Genitourinary Cancers Symposium, Orlando, FL

- 2016 General Session 9: Clear and Non-Clear Cell Renal Cancer/ Session Chair
Genitourinary Cancers Symposium, San Francisco, CA
- 2016 Genomic Medicine in Genitourinary Cancers/ Lecture
Foundation Medicine Panel Discussion, San Francisco, CA
- 2016 Impacting Signaling Pathways to Treat Renal Cell Carcinoma/ New York GU:
9th Annual Interdisciplinary Prostate Cancer Congress and other
Genitourinary Malignancies
Physicians Education Resource (PER) CME Conference, New York, NY
- 2016 Overall Survival in Metastatic RCC Phase 3 Study Evaluating Cabozantinib
versus Everolimus (METEOR), a Randomized Phase 3 Trial of Cabozantinib
versus Everolimus in Patients with Advanced Renal Cell Carcinoma/Abstract
ASCO Annual Meeting, Chicago, IL
- 2016 Renal Cell Carcinoma: Recent Advances and New Questions
Physicians Education Resource (PER) CME Conference, San Francisco, CA
- 2016 Shifting Paradigms in Treating Advanced Renal Cancer/ Grand Rounds
Moffitt Cancer Center, Tampa, FL
- 2016 Surgical Approaches and Systemic Therapies in the Management of Kidney
Cancer/ Lecture
NCCN Oncology Fellows Program: New Horizons in Quality Cancer Care,
Hollywood, FL
- 2017 New Drug in Oncology and Their Incorporation into the Clinic: Cabozantinib
for Renal Cell Carcinoma/ Speaker
ASCO Annual Meeting, Chicago, IL
- 2017 Taking the Leap into a New Era of Anti-Tumor Efficacy in Advanced RCC:
How to Organize Selection and Sequencing of Therapies Throughout the
Disease Continuum/ Session Chair
PVI-MLI Symposium, Orlando, FL
- 2018 Metabolomic Characterization of Immune-Checkpoint Blockade in RCC/
Speaker
II-ON Annual Symposium, Philadelphia, PA
- 2019 ASCO Update for Kidney/ Invited presentation
ASCO Direct Highlights, Orlando, FL

- 2019 How I Think, How I Treat: Understanding & Implementing a New Wave of Immunotherapeutic and Targeted Treatment Models in the Management of Advanced RCC/ Physician Education
Medical Learning Institute CME Conference, Miami, FL (Medical Learning Institute Inc.)
- 2019 Moving Forward in Kidney Cancer Management/ Grand Rounds
Winship Cancer Institute, Emory University, Atlanta, GA
- 2019 Overview of the Harvard SPORE/ Lecture
International Kidney Cancer Symposium, Miami, FL
- 2019 Reflections on Cabozantinib in the Clinic/ Lecture
Exelixis, San Francisco, CA (Exelixis)
- 2019 SPORE Projects DF/HCC/ Lecture
Kidney Cancer Research Summit, Philadelphia, PA
- 2020 How the Biology of RCC Informs and Drives Therapeutic Strategies/ Lecture
Genitourinary Cancers Symposium, San Francisco, CA
- 2020 Newly Diagnosed mRCC (KEYNOTE-426, JAVELIN Renal 101, Checkmate214, CheckMate-9ER, CABOSUN) / Invited Lecture
Institutional Perspectives in Cancer: Genitourinary Cancers (OncLive), Virtual
- 2020 The Next Frontier in Kidney Cancer Clinical and Translational Research/
Grand Rounds
David H. Koch Center Seminar Series, MD Anderson Cancer Center, Houston, TX
- 2020 What's on the Horizon for Clear Cell RCC?/ Lecture
Genitourinary Cancers Symposium, San Francisco, CA
- 2020 Best of 2020: Including ESMO Updates / Invited Lecture
Kidney Cancer Research Summit 2020, Philadelphia, PA, Virtual
- 2020 New developments in renal cancer / Grand Rounds
Mt. Sinai Hematology/Medical Oncology Fellows Conference & Grand Rounds, New York, NY, Virtual
- 2020 Emerging biology and Therapeutics in Clear cell Renal Cell Carcinoma /
Grand Rounds

- New York Presbyterian Hospital - Weill Cornell Medicine Heme/Onc Grand Rounds, New York, NY, Virtual
- 2021 Novel concepts in Kidney cancer management
Miami Cancer Institute Multispecialty Grand Rounds, Miami, FL, Virtual
- 2021 Personalizing first line management of advanced RCC / Invited Lecture
Binaytara Foundation Renal Cell Carcinoma Conference, Issaquah, WA, Virtual
- 2021 Recent Updates in Renal Cell Cancer
Lehigh Valley Cancer Institute Kidney Cancer Survivor Event, Salisbury Township, PA, Virtual
- 2021 Updates on the Biology and Novel Approaches in Renal Cell Cancer / Grand Rounds
Columbia University Hematology Oncology Grand Rounds, New York, NY, Virtual
- 2021 Renal Cell Carcinoma: recent clinical and translational updates / Invited Lecture
Fred Hutch/UW Medical Oncology and Clinical Research Division Seminar Series, Seattle, WA, Virtual
- 2021 Updates in the Management of Kidney Cancer / Grand Rounds
Baylor University Medical Center Dallas Internal Medicine Grand Rounds, Houston, TX, Virtual
- 2021 ESMO Recap: KEYNOTE-564 / Invited Lecture
Society for Urologic Oncology Live Webinar, Virtual
- 2021 Future of Adjuvant Therapy in RCC / Invited Lecture
International Kidney Cancer Symposium, Session: The State of Adjuvant Therapy and How to Move Forward, Austin, TX, Virtual
- 2021 Engaging in Collaborative Research Relationships with Basic and Translational Scientists / Invited Lecture
Conquer Cancer 2021 Virtual Scientific and Career Development Retreat, Alexandria, VA, Virtual
- 2021 International Conversation / Panelist
Journal of Clinical Oncology (JCO), Virtual

- 2022 Renal Cell Carcinoma as a Model Disease to Rethink Strategies and Opportunities for Clinical Trials / Invited Lecture
Oncology Center of Excellence Research Rounds, Virtual
- 2022 Adjuvant Therapy for RCC; Clinical Trials Pearls & Pitfalls / Grand Rounds
Moffitt Grand Rounds, Tampa, Florida, Virtual
- 2022 KEYNOTE-564, 30-month Follow-Up / Invited Lecture
UroToday ASCO GU 2022 Discussion
- 2022 HIF-2a inhibitor clinical trials / Invited Lecture
CUNY Advanced Science Research Center - Brooklyn College Cancer Center
joint symposium on Cancer Therapeutics, Brooklyn, NY
- 2022 Leidy Urologic Oncology Visiting Professor / Workshop
Fox-Chase Cancer Center, Philadelphia, PA
- 2022 Changing the Treatment Paradigm in High-risk Kidney Cancer / Invited
Lecture
Pittsburgh Annual Oncology Symposium, Pittsburgh, PA
- 2022 Exelixis Renal Cell Carcinoma (RCC) National Advisory Board / Moderator
Virtual (Exelixis)
- 2022 ASCO Update for Kidney / Invited Lecture
AdventHealth Cancer Institute, Orlando, FL
- 2022 A Paradigm Shift in High-Risk Kidney Cancer/ Invited Lecture
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (Virtual)

National Abstract Oral Presentations

- 2011 A double-blind randomized trial of docetaxel plus vandetanib versus
docetaxel plus placebo in platinum-pretreated advanced urothelial cancer/
Poster
Genitourinary Cancer Symposium, Orlando, FL
- 2012 A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2
inhibitor foretinib in patients with sporadic and hereditary papillary renal cell
carcinoma: Final efficacy, safety, and PD results/ Poster
Genitourinary Cancer Symposium, San Francisco, CA

- 2012 Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)/ Poster
ASCO Annual Meeting, Chicago, IL
- 2013 Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors/ Poster
Genitourinary Cancer Symposium, Orlando, FL
- 2014 Immunomodulatory Activity of Nivolumab in Previously Treated and Untreated Metastatic Renal Cell Carcinoma (mRCC): Biomarker-Based Results from a Randomized Clinical Trial/ Poster
ASCO Annual Meeting, Chicago, IL
- 2015 Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (mRCC): Association of biomarkers with clinical outcomes/ Poster
ASCO Annual Meeting, Chicago, IL
- 2016 Overall survival in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma/ Poster
ASCO Annual Meeting, Chicago, IL
- 2017 Avelumab Plus Axitinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma: Phase 3 Study (JAVELIN Renal 101)/ Poster
ASCO Annual Meeting, Chicago, IL
- 2017 First-line Avelumab + Axitinib Therapy in Patients (pts) with Advanced Renal Cell Carcinoma (aRCC): Results from a Phase Ib Trial / Abstract Oral Presentation
ASCO Annual Meeting, Chicago, IL
- 2018 A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER)/ Poster
ASCO Annual Meeting, Chicago, IL
- 2018 KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma/ Poster
ASCO Annual Meeting, Chicago, IL
- 2018 Optimizing Systemic Therapy in Advanced Renal Cell Carcinoma/Oral
ASCO Annual Meeting, Chicago, IL

- 2019 Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)/ Poster
Genitourinary Cancers Symposium, San Francisco, CA
- 2020 Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)/ Poster
Genitourinary Cancers Symposium, San Francisco, CA
- 2022 Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564 / Abstract Oral Presentation
Genitourinary Cancers Symposium, San Francisco, CA

International

- 2008 Updates in Metastatic Renal Cell Carcinoma: The Role of the Medical Oncologist and the Urologist / Invited Lecture
V Maratona Urológica do Rio de Janeiro, Rio de Janeiro, Brazil (The National Cancer Institute of Brazil)
- 2008-2011, Best of ASCO Genitourinary Cancer Update (Middle-East) / Invited Lecture
2015 Lebanese Society of Medical Oncology, Beirut, Lebanon
- 2009 Prognostic Factors in RCC / Invited Lecture
Second Pavia International Symposium of Advanced Kidney Cancer Perugia- Pavia post-ASCO Kidney Cancer Meeting, Pavia, Italy
- 2009 Saudi Renal Cell Carcinoma Expert Meeting / Invited Lecture
Dubai, United Arab Emirates (Saudi Medical Society)
- 2009 VEGF and mTOR-targeted agents in RCC / Invited Lecture
Saudi Renal Cell Carcinoma Expert Meeting, Dubai, United Arab Emirates (Saudi Medical Society)
- 2011 Biomarkers in Advanced RCC, New Therapies for Advanced Prostate Cancer and Management of Rising Prostate-Specific Antigen (PSA) after Therapy for Prostate Cancer / Invited Lecture
VIII Maratona Urológica do Rio de Janeiro, Rio de Janeiro, Brazil (The National Cancer Institute of Brazil)

- 2011 Optimizing Treatment Sequence in RCC / Invited Lecture
Novartis Oncology, Beirut, Lebanon
- 2011 Predictive Factors in RCC and Current Practice / Invited Lecture
Spanish Society of Medical Oncology, Malaga, Spain
- 2011 The Potential for Biomarkers in RCC / Invited Lecture
Turkish Oncology Forum, Izmir, Turkey
- 2012 Exploring the Role of Salvage Treatments After Failure of VEGF TKI / Invited
Lecture
3rd International Brazilian Societies of Urology and Medical Oncology
Conference in Uro-Oncology, São Paulo, Brazil
- 2012 Novel Targets and Clinical Trials in Renal Cell Cancer / Invited Lecture
International Expert Joint Meeting in mRCC, Barcelona, Spain (Spanish Oncology
Genitourinary Group)
- 2014 State of the Art Kidney, Bladder, and Prostate Cancers Management and What the
Next 5 Years Will Hold / Invited Lecture
Congress Oncologia d'Or. Rio de Janeiro, Brazil
- 2014 Update on Renal Cancer Drugs and Targets / Invited Lecture
102th Japanese Urological Association, Kobe, Japan
- 2015 Biomarkers of Immunotherapy Response / Invited Lecture
The 10th Annual GUMOC Meeting, Ottawa, Ontario, Canada
- 2015 Câncer do Trato Urinário Coordenador (Urinary Cancers Coordinator) / Invited
Lecture
1 Simpósio Internacional de Imuno-Oncologia (1st International Immuno-
Oncology Symposium), Sao Paulo, Brazil
- 2015 Hormone - Resistant Prostate Cancer: Beyond “Super Hormones”:
Immunotherapy, Radiopharmaceuticals and Others / Invited Lecture
Lebanese Society of Medical Oncology Annual Meeting, Beirut, Lebanon
- 2015 Immuno-Oncology: Future Perspectives for Metastatic Renal Cell Carcinoma /
Invited Lecture
Renal Horizons Summit, Athens, Greece
- 2015 Médecine personnalisée et nouvelles drogues dans le cancer du rein. Mirage ou
réalité (Personalized Medicine and New Drugs in Kidney Cancer. Mirage or

- Reality) / Invited Lecture
6th Congress de l'Association pour la Recherche sur les Tumeurs du Rein (6th Congress of the Association of Kidney Cancer Research), Chantilly, France
- 2015 Novel Targets and Trials in Metastatic Bladder Cancer / Invited Lecture
Lebanese Society of Medical Oncology Annual Meeting, Beirut, Lebanon
- 2015 Perspectives on Immuno-Oncology in Renal Cell Carcinoma / Invited Lecture
The 10th Annual GU Medical Oncologists of Canada (GUMOC) Meeting, Ottawa, Ontario, Canada
- 2015 RCC: What Did 2014 Bring Us? / Invited Lecture
Lebanese Society of Medical Oncology Annual Meeting, Beirut, Lebanon
- 2017 Mechanism of Disease: Role of VEGF, MET, AXL, and Immune Pathways in RCC / Invited Lecture
European Society of Medical Oncology, Madrid, Spain
- 2017 Updates in Metastatic RCC Management / Invited Lecture
American University of Beirut, Beirut, Lebanon
- 2017- Best of ASCO 2017 Non-Prostate Abstracts / Invited Lecture
Lebanese Society of Medical Oncology, Beirut, Lebanon
- 2018 Emerging Biomarkers in Immune Checkpoint Markers in RCC / Invited Lecture
9th Annual Canadian Kindey Cancer Forum, Ontario, Canada
- 2018 Immune Checkpoint Blockades in the Clinic: Unanswered Questions, Optimizing Use and Patterns of Response / Invited Lecture
9th Annual Canadian Kindey Cancer Forum, Ontario, Canada
- 2018 Kidney Cancer: Journey in Targets, Trial, and Biomarkers / Invited Lecture
Le Printemps de la FM, Beirut, Lebanon
- 2018 Metastatic Bladder Cancer: State of the Art / Invited Lecture
Le Printemps de la FM, Beirut, Lebanon
- 2018 Real World Data from the IMDC Group / Invited Lecture
Kidney Cancer International Expert Exchange Meeting, Barcelona, Spain
- 2018 Recent Breakthroughs in Therapeutics in 1L / Invited Lecture
Kidney Cancer International Expert Exchange Meeting, Barcelona, Spain

- 2019 Frontline in mRCC: Ready to select treatment? / Workshop
European Society for Medical Oncology Congress 2019, Barcelona, Spain
- 2019 Re-difiniendo el tratamiento del cáncer: Impacto de la IO en el tratamiento del cancer. La cura es posible? / Invited Lecture
RCC Forum, Buenos Aires, Argentina
- 2020 How I Treat mRCC at Each Line of Therapy / Symposium
Israeli Society for GU Oncology Virtual Education Event, Tel Aviv, Israel
- 2020 ESMO GU Highlights / Invited Lecture
LATAM2020 ESMO Highlights Webinar, Sao Paolo, Brazil, Virtual
- 2020 The Future of Systemic Treatment of Metastatic Renal Cell / Invited Lecture
UroTarget 2020, Buenos Aires, Argentina, Virtual
- 2020 VHL/HIF (and VEGF) inhibitors in Cancer: The Example of Clear-Cell Renal Cell Carcinoma
32nd European Organisation for Research and Treatment of Cancer-NCI-AACR symposium, Brussels, Belgium, Virtual
- 2020 Cancer du rein métastatique: comment optimiser la séquence thérapeutique en 2020? / Invited Lecture
Association Chifae pour la prévention et la recherche sur le cancer 3ème Congrès International d'Oncologie Genito-Urinaira, Morocco, Virtual
- 2020 GU Non-Prostaet: Results of COSMIC-021 & CheckMate 9ER Trials / Invited Lecture
Best of ESMO UAE 2020, Dubai, Virtual
- 2021 Masterclass in Uro-Oncology focusing on Kidney Cancer / Invited Lecture
Association Chifae Masterclass sur le cancer du rein 3eme edition, Casablanca, Morocco, Virtual
- 2021 Recent Advances in the Management of advanced Renal Cell Carcinoma- A Focus on First Line Immuno-oncology Regimens / Invited Lecture
MSD Japan-China-Asia/Pacific Virtual Meeting, Singapore, Virtual
- 2021 Update in the management of advanced RCC / Invited Lecture
Canadian Urological Association Visiting Virtual Professor Program, Virtual

- 2021 Circulating Biomarkers for Potential Clinical Adoption in Renal Cancer / Invited Lecture
European International Kidney Cancer Symposium, Virtual
- 2021 Novel Therapies for RCC: HIF-alpha / Invited Lecture
Société Internationale d'Urologie Bench to Bedside Uro-Oncology GU Cancer Triad, Quebec, Canada, Virtual
- 2021 Renal Cell Cancer in 2021: from Biology to Clinic / Grand Rounds
Centre Hospitalier Universitaire Vaudois Oncology Grand Rounds, Lausanne, Switzerland, Virtual
- 2021 Is there an optimal first-line combination approach for metastatic mRCC? / Invited Lecture
ESMO Annual Congress, Session: Realising potential combination and personalised therapy, Virtual
- 2021 Kidney Cancer: First-Line treatment in RCC / Invited Lecture
Sociedad Mexicana de Oncologia 39th National Congress in Oncology, Monterrey, Mexico, Virtual
- 2021 Masterclass – Adyuvancia en RCC / Invited Lecture
Urotarget 2021, Buenos Aires, Argentina, Virtual
- 2021 Adjuvant Therapy for RCC: ASCO 2021-Now / Invited Lecture
Best of ASCO 2021, Sri Lanka, Virtual
- 2022 Updates In Systemic Therapy For Advanced Renal Cell Carcinoma / Invited Lecture
CMC Oncology Forum, Dubai, UAE, Virtual
- 2022 Adjuvant treatment in RCC and new molecules / Invited Lecture
9th Belgian Multidisciplinary meeting on Urological Cancers, La Hulpe, Belgium
- 2022 New horizons of mRCC Treatment / Invited Lecture
MSD Brazil Latin America Cancer Connection Webinar
- 2022 Update adjuvant therapie: KN 564 recente updates / Invited Lecture
Dutch Renal Cancer Group 11th National RCC Multidisciplinary Symposium, Bennekomseweg, The Netherlands
- 2022 Kidney Cancer Journal Roundtable / Invited Lecture
Virtual (AVEO)

- 2022 New Strategies for the treatment of advanced RCC: Cabozantinib + Nivolumab as a new standard of care / Invited Lecture
Brazil Checkmate 9ER launch: New Perspectives for the Treatment of Advanced RCC (BIO-Brazilian Information Oncology)
- 2022 Quantum leap of adjuvant therapy in renal cell carcinoma / Invited Lecture
MSD Taiwan Launch Symposium-Adjuvant Therapy in RCC (Merck)
- 2022 Best of ASCO 2022, Genitourinary Cancer - Kidney and Bladder
Beirut, Lebanon
- 2022 Exploring adjuvant immunotherapy in Renal Cell Carcinoma / Invited Lecture
MSD Singapore Urofair Virtual Symposium
- 2022 Providing context: SAVOIR, CALYPSO, and SAMETA / Invited Lecture
AstraZeneca Virtual Advisory Board
- 2022 Recent Update in Adjuvant Kidney Cancer / Invited Lecture
Emirates Oncology Society 3rd Annual Conference, Intercontinental Dubai
Festival City, United Arab Emirates
- 2022 Systemic treatment in kidney cancer: new algorithms in 2022 / Invited Lecture
5th Edition of Onco-Urology Congress, Marrakesh, Morocco
- 2022 Challenges and Perspectives for Cancer Immunotherapy
Brazilian Society of Clinical Oncology (SBOC) Congress
- 2022 How does current evidence affect the future design of clinical trials in kidney cancer? / Invited Lecture
XIII Simposio Científico SOGUG, Madrid, Spain
Keynote lecture
- 2022 RCC: Beyond first line / Invited Lecture
2nd International Genitourinary Cancer Conference, Jeddah, Saudi Arabia
- 2022 Therapeutic decision in the treatment of first-line renal cell carcinoma - "Pick the winner"? / Invited Lecture
Portuguese Society of Oncology 19th National Congress of Oncology, Porto, Portugal
- 2023 Update in the treatment of KIDNEY CANCER (early RCC disease) / Invited Lecture

International Abstract Oral Presentations

- 2015 Late-Breaking Abstract: Cabozantinib versus Everolimus in Patients with
Advanced Renal Cell Carcinoma: Results of the Randomized Phase 3 Trial/
Presidential Session Lecture
European Cancer Congress, Vienna, Austria
- 2016 Late-Breaking Abstract: CABOzantinib versus SUNitinib (CABOSUN) as initial
targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor
and intermediate risk groups: Results from ALLIANCEA031203 trial/ Presidential
Session Lecture
ESMO Congress 2016, Copenhagen, Denmark
- 2020 Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced
renal cell carcinoma: first results from the randomized phase 3 CheckMate 9ER
trial/ Presidential Session Lecture
ESMO Congress 2020, Virtual
- 2021 Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with
renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564/
Proffered Paper session – Genitourinary tumours, non-prostate 2
ESMO Congress 2021, Virtual
- 2022 Phase 3 study of cabozantinib (C) in combination with nivolumab (N) and
ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of
IMDC intermediate or poor risk (COSMIC-313)./Presidential Symposium III
ESMO Congress 2022, Paris, France

Report of Clinical Activities and Innovations

Current Licensure and Certification:

- 2004-2007 Ohio Medical License
- 2004-2014 Certification, American Board of Internal Medicine
- 2007- Certification, American Board of Internal Medicine-Medical Oncology
- 2007- Massachusetts Medical License

Practice Activities:

2007-2014	Inpatient Care	Medical Oncology, BWH	One month per year
2007-2015	Ambulatory Care	Medical Oncology, DFCI	Four sessions per week
2014-	Inpatient Care	Medical Oncology, BWH	1-2 weeks per year
2015-2018	Ambulatory Care	Medical Oncology, DFCI	Three sessions per week
2018-	Ambulatory Care	Medical Oncology, DFCI	Two sessions per week

Clinical Innovations:

Developing a standard of care of patients with cancer and COVID-19

I led the COVID-19 restructuring and recovery efforts in my division at DFCI, coordinating with multiple stakeholders and institutional leadership. I was the first DFCI faculty member to be at the frontline of the COVID pandemic, serving on our Special Pathogens Team (SPT) in March providing weekend coverage at the Brigham and Women’s Hospital.

I am a founding Steering Committee member of the COVID-19 and Cancer Consortium (CCC19) where I co-chair the Funding and Data Use and Publication committees. I am co-first author of the first major publication in Lancet from CCC19 that described risk factors for 30-day mortality in nearly 1000 patients with COVID19 and cancer. We expanded our research into COVID-19 reporting into disruption of care during the pandemic both in oncology patients and in cancer screening.

Development of models of care delivery for kidney cancer at the national and international levels

Based on my work in genitourinary tumors and my clinical expertise, I am part of the Kidney Cancer Panel of the NCCN, an alliance of several of the world's leading cancer centers. The NCCN Guidelines are considered a worldwide authoritative source and the arbiter of high quality cancer care. Through my work at DFCI and BWH, I was able to take this expertise to serve and contribute to these prestigious guidelines. Moreover, the panel chair and I serve on the writing committee of the panel for the kidney cancer guidelines.

From 2015-2018, I was the chairman of the Medical & Scientific Steering Committee of the KCA. The KCA is an international organization made up of patients, family members, physicians, researchers, and other health professionals globally, in more than 100 countries. We aim to shape the direction of kidney cancer clinical care in the world by funding, promoting, establishing guidelines and collaborating with the NCI, ASCO, and other institutions on clinical projects. We have 2 recurring international

meetings/year (one in the US and one in Europe) with more than 300 participants aimed at improving the care of kidney cancer patients.

Electronic medical record (EMR) computerization including clinical trials reporting templates and chemotherapy at DFCI

I was part of the EMR modification, which has improved practice in the area of order entries related to clinical trials reporting, chemotherapy orders, and toxicity reporting for experimental agents. These outcomes have been reported at DFCI-wide meetings among all disease centers.

The BWH Quality Education and Safety Training (QUEST) Academy

After one year of regular meetings and didactic lectures at the Harvard Business School, I was appointed as the team leader of a six-person effort to design a two-day training and education conference. We created a conference led by experts at BWH and provided important and practical information on approaches to providing high quality healthcare delivery and patient safety. The long-term goal is to cultivate a new generation of health care providers who have the ability to successfully problem solve in order to deliver excellence in the most cost effective and efficient ways. We were invited to present our work at a large meeting at BWH with leadership attendance including the CEO of the hospital.

The use of growth factors in cabazitaxel-treated metastatic prostate cancer patients

For the first time, we have identified risk factors for febrile neutropenia when getting cabazitaxel chemotherapy and we have identified good clinical practice guidelines at DFCI, which has led to the judicious use of growth factor support and significant costs savings nationally. We have presented our work at an international meeting (the 2014 Genitourinary Cancer Symposium).

Report of Technological and Other Scientific Innovations

PBRM1 biomarkers predictive of anti-immune checkpoint response (2018)

US11377696B2 // WO2018132287A1

The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies, which is being developed clinically for potential use in segmenting patients for therapy selection.

Biomarkers of clinical response and benefit to immune

WO2019089740A1

The present invention relates, in part, to methods for stratifying patients and predicting response of a cancer in a subject to immune checkpoint therapy

checkpoint inhibitor therapy (2018) based upon a determination and analysis of amounts of such biomarkers, compared to a control.

Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy (2021) WO2022086852A2
 The present invention is based on the identification of novel metabolite biomarkers predictive of development of immune-related adverse events when receiving anti-immune checkpoint therapies.

Report of Education of Patients and Service to the Community

No presentations below were sponsored by 3rd parties/outside entities

Educational Material for Patients and the Lay Community:

Books, monographs, articles and presentations in other media

2011	Quoted in "Conditional Survival' Important in Kidney Cancer" by Yael Waknine	News Article	Medscape Oncology (September 11, 2011), available at http://www.medscape.com/viewarticle/770691
2011	Quoted in "No Clear Link between Statins and Kidney Cancer" by Genevra Pittman	News Article	July 28, 2011, available at http://www.reuters.com/article/2011/07/28/us-statins-kidney-cancer-idUSTRE76R7LS20110728
2012	Quoted in "Fatal Adverse Events with Pazopanib, Sorafenib, Sunitinib" by Zosia Chustecka	News Article	Medscape Oncology (February 9, 2012), available at http://www.medscape.com/viewarticle/758349
2014	Clinical Trials in non-clear cell RCC: ESPN, ASPEN and beyond	Video	October 28, 2014, available at https://www.oncologytube.com/video/clinical-trials-in-

non-clear-cell-rcc-espn-
aspen-and-beyond/1033983

2014	Dr. Choueiri discusses a new Phase 2 clinical trial on volitinib in patients with papillary renal cell carcinoma (pRCC)	Video	November 26, 2014, available at http://www.oncologytube.com/v/1034111/dr-toni-choueiri-discusses-a-new-phase-2-clinical-trial-on-volitinib-in-patients-with-papillary-renal-cell-carcinoma-(prcc)
2014	Risk Factors and a Model to Predict Toxicity-related Treatment Discontinuation in Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated with Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy: Results from the International Metastatic RCC Database Consortium (IMDC)	Video	November 13, 2014, available at https://www.oncologytube.com/video/risk-factors-and-a-model-to-predict-toxicity-related-treatment-discontinuation-in-patients-with-metastatic-renal-cell-carcinoma-mrcc-treated-with-vascular-endothelial-growth-factor-vegf-targeted-therapy-results-from-the-international-metastatic/1034023
2015	Cabozantinib improves advanced kidney cancer survival: METEOR trial results	Video	September 27, 2015, available at http://ecancer.org/conference/665-ecc-2015/video/4036/cabozantinib-improves-advanced-kidney-cancer-survival--meteor-trial-results.php
2015	Dr. Toni Choueiri on Cabozantinib Versus	Video	September 26, 2015, available at

	Everolimus in Renal Cell Carcinoma		https://www.onclive.com/conference-coverage/ecc-2015/dr-toni-choueiri-on-cabozantinib-versus-everolimus-in-renal-cell-carcinoma
2015	Dr. Toni Choueiri on Cabozantinib and Nivolumab Combination in Kidney Cancer	Video	November 3, 2015, available at https://www.onclive.com/onclive-tv/dr-toni-choueiri-on-cabozantinib-and-nivolumab-combination-in-kidney-cancer
2015	ECC 2015: METEOR, a phase 3 trial, showed cabozantinib improved survival in advanced kidney cancer	Video	September 29, 2015, available at https://www.oncologytube.com/video/ecc-2015-meteor-a-phase-3-trial-showed-cabozantinib-improved-survival-in-advanced-kidney-cancer/1036019
2015	ECC 2015: Press programme with updates on METEOR, CheckMate 025, and EURO CARE-5	Video	September 30, 2015, available at https://www.oncologytube.com/v/1036029/video/promising-therapeutic-developments-for-hodgkin-lymphoma/10005269
2015	Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?	Video	September 1, 2015, available at https://www.oncologytube.com/video/immunotherapy-for-kidney-cancer-patients-in-the-front-line-setting-coming-soon/1035698
2015	Immunotherapy for Metastatic Kidney	Video	August 27, 2015, available at

	Cancer Shows Increased Survival		https://www.oncologytube.com/video/immunotherapy-for-metastatic-kidney-cancer-shows-increased-survival/1035647
2015	Phase Ib Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naïve Patients With Advanced Renal Cell Carcinoma	Video	November 18, 2015, available at https://www.oncologytube.com/video/phase-ib-dose-finding-study-of-axitinib-plus-pembrolizumab-in-treatment-na-ve-patientswith-advanced-renal-cell-carcinoma/1036439
2015	Toni K. Choueiri, MD, on Cabozantinib vs Everolimus in Patients With Advanced Renal Cell Carcinoma	Video	September 2015, available at https://ascopost.com/archive/meetings/2015-european-cancer-congress/toni-k-choueiri-md-on-cabozantinib-vs-everolimus-in-patients-with-advanced-renal-cell-carcinoma/
2015	Welcome to the 14th International Kidney Cancer Symposium 2015	Video	November 18, 2015, available at https://www.oncologytube.com/video/welcome-to-the-14th-international-kidney-cancer-symposium-2015/1036441
2016	ASCO 2016 Update: Kidney, Bladder and Prostate Cancers	Video	June 2016, available at https://www.youtube.com/watch?v=INWF3Uy1F8c
2016	ASCO GU 2016: Highlights	Video	January 8, 2016, available at https://ecancer.org/video/45

39/asco-gu-2016--
highlights.php

2016	Annual Meeting GU 2016 Update on Clear Cell and non-Clear Cell Renal Carcinomas	Video	January 9, 2016, available at https://www.oncologytube.com/v/1037007/annual-meeting-gu-2016-update-on-clear-cell-and-non-clear-cell-renal-carcinomas
2016	Biomarkers of response and resistance in kidney cancer	Video	October 18, 2016, available at https://www.oncologytube.com/video/biomarkers-of-response-and-resistance-in-kidney-cancer/10000075
2016	Cabozantinib improves PFS in metastatic renal cell carcinoma	Video	October 10, 2016, available at https://ecancer.org/video/5247/cabozantinib-improves-pfs-in-metastatic-renal-cell-carcinoma.php
2016	Cabozantinib over sunitinib for metastatic renal cell carcinoma	Video	October 10, 2016, available at https://ecancer.org/video/5276/cabozantinib-over-sunitinib-for-metastatic-renal-cell-carcinoma.php
2016	CheckMate 025 phase III trial	Video	March 9, 2016, available at https://www.oncologytube.com/video/checkmate-025-phase-iii-trial/1037717
2016	David F. McDermott, MD, and Toni K. Choueiri, MD, on Advanced RCC: Nivolumab in	Video	June, 2016, available at https://ascopost.com/archive/meetings/2016-asco-annual-meeting/toni-k-choueiri-md-and-david-f-mcdermott-md-on-

	Previously Treated Patients		advanced-rcc-nivolumab-in-previously-treated-patients/
2016	Dr. Choueiri on CABOSUN Trial Results for RCC	Video	October 12, 2016, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-cabosun-trial-results-for-rcc
2016	Dr. Choueiri on FDA Approval of Cabozantinib for RCC	Video	April 25, 2016, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-fda-approval-of-cabozantinib-for-rcc
2016	Dr. Choueiri on FDA Approval of Lenvatinib Plus Everolimus in RCC	Video	May 13, 2016, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-fda-approval-of-lenvatinib-everolimus-in-rcc
2016	Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC	Video	October 20, 2016, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-ongoing-trials-of-immunotherapy-in-rcc
2016	Dr. Choueiri on Significance of CheckMate-025 Study for RCC	Video	January 8, 2016, available at https://www.onclive.com/conference-coverage/gu-2016/dr-choueiri-on-significance-of-checkmate-025-study-for-rcc
2016	Dr. Choueiri on Using Immunotherapy to Treat RCC	Video	April 10, 2016, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-using-immunotherapy-to-treat-rcc

2016	ESMO 2016: Press Brief on results of CABOSUN trial cabozantinib compared to sunitinib in RCC	Video	October 18, 2016, available at https://www.oncologytube.com/video/esmo-2016-press-brief-on-results-of-cabosun-trial-cabozantinib-compared-to-sunitinib-in-rcc/10000085
2016	Jonathan E. Rosenberg, MD, and Toni K. Choueiri, MD, on Bladder Cancer: Mutation Burden and Atezolizumab	Video	June, 2016, available at https://ascopost.com/archives/meetings/2016-asco-annual-meeting/jonathan-e-rosenberg-md-and-toni-k-choueiri-md-on-bladder-cancer-mutation-burden-and-atezolizumab/
2016	Kidney Cancer Highlights from Annual Meeting GU 2016 Genitourinary Symposium	Video	January 9, 2016, available at https://www.oncologytube.com/v/1037008/kidney-cancer-highlights-from-asco-gu-2016-genitourinary-symposium
2016	Link between non-aspirin NSAID use and risk of developing renal cell cancer	Video	January 7, 2016, available at https://ecancer.org/video/4535/link-between-non-aspirin-nsaid-use-and-risk-of-developing-renal-cell-cancer.php
2016	METEOR trial: cabozantinib vs everolimus in advanced renal cell carcinoma	Video	June 5, 2016, available at https://ecancer.org/video/4809/meteor-trial--cabozantinib-vs-everolimus-in-advanced-renal-cell-carcinoma.php
2016	Nivolumab, Cabozantinib Offer	Interview	February 15, 2016, available at

	New Second-Line Options in RCC		https://www.onclive.com/web-exclusives/nivolumab-cabozantinib-offer-new-second-line-options-in-rcc
2016	Novel Targeted Agents in Development, But Will Compete With Immunotherapy in RCC	Interview	November 4, 2016, available at https://www.onclive.com/conference-coverage/kidney-2016/novel-targeted-agents-in-development-but-will-compete-with-immunotherapy-in-rcc
2016	Subgroup analyses of METEOR	Video	January 7, 2016, available at https://www.oncologytube.com/video/subgroup-analyses-of-meteor/1036972
2016	Sumanta K. Pal, MD, and Toni K. Choueiri, MD, on Urothelial Carcinoma: Efficacy of an FGFR Inhibitor	Video	June, 2016, available at https://ascopost.com/archive/meetings/2016-asco-annual-meeting/sumanta-k-pal-md-and-toni-k-choueiri-md-on-urothelial-carcinoma-efficacy-of-an-fgfr-inhibitor/
2016	Toni Choueiri, MD: Renal Cancer Update	Video	January 2016, available at http://video.ascopost.com/conferences/2016-genitourinary-cancers-symposium/toni-choueiri-md-renal-cancer-update/
2016	Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert	Video	June, 2016, available at https://ascopost.com/archive/meetings/2016-asco-annual-meeting/toni-k-choueiri-md-and-paul-l-nguyen-md-on-prostate-

	Perspectives on Four Studies		cancer-expert-perspectives-on-four-studies/
2016	Toni K. Choueiri, MD, on Metastatic RCC: Results From the ALLIANCE A031203 Trial	Video	October, 2016, available at https://ascopost.com/archives/meetings/2016-esmo-congress/toni-k-choueiri-md-on-metastatic-rcc-results-from-the-alliance-a031203-trial/
2017	CABOSUN Trial of Upfront Cabozantinib in Metastatic RCC	Video	April 18, 2017, available at https://www.onclive.com/peer-exchange-archive/advanced-kidney-cancer/cabosun-trial-of-upfront-cabozantinib-in-metastatic-rcc
2017	Choosing Frontline Therapy for Metastatic Kidney Cancer	Video	March 27, 2017, available at https://www.onclive.com/peer-exchange-archive/advanced-kidney-cancer/choosing-frontline-therapy-for-metastatic-kidney-cancer
2017	Choosing Post-Progression Therapy for Metastatic RCC	Video	April 3, 2017, available at https://www.onclive.com/peer-exchange-archive/advanced-kidney-cancer/choosing-postprogression-therapy-for-metastatic-rcc
2017	Choueiri Covers CABOSUN Excitement and Beyond in RCC	Interview	September 27, 2017, available at https://www.onclive.com/web-exclusives/choueiri-covers-cabosun-excitement-and-beyond-in-rcc

2017	Choueiri Discusses Avelumab Axitinib, Other Novel RCC Combos	Interview	August 3, 2017, available at https://www.onclive.com/web-exclusives/choueiri-discusses-avelumabaxitinib-other-novel-rcc-combos
2017, 2017	Choueiri Discusses Papillary RCC, Other Developments in Kidney Cancer	Interview	March 7, 2017, available at https://www.onclive.com/web-exclusives/choueiri-discusses-papillary-rcc-other-developments-in-kidney-cancer
2017	Clinical Trials of Post-Progression Therapy for mRCC	Video	April 10, 2017, available at https://www.onclive.com/peer-exchange-archive/advanced-kidney-cancer/clinical-trials-of-postprogression-therapy-for-mrcc
2017	Dr. Choueiri on Avelumab Plus Axitinib in mRCC	Video	June 8, 2017, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-avelumab-plus-axitinib-in-mrcc
2017	Dr. Choueiri on Existing Therapies for Kidney Cancer	Video	April 25, 2017, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-existing-therapies-for-kidney-cancer
2017	Dr. Choueiri on Impact of CABOSUN Results in Renal Cell Carcinoma	Video	September 10, 2017, available at https://www.onclive.com/conference-coverage/esmo-2017/dr-choueiri-on-impact-of-cabosun-results-in-renal-cell-carcinoma

2017	Dr. Choueiri on Overall Findings of the CABOSUN Trial for RCC	Video	February 3, 2017, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-overall-findings-of-the-cabosun-trial-for-rcc
2017	Dr. Choueiri on Overall Findings of the CABOSUN Trial for RCC	Video	February 3, 2017, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-overall-findings-of-the-cabosun-trial-for-rcc
2017	Dr. Choueiri on Savolitinib in Papillary Renal Cell Cancer	Video	April 13, 2017, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-savolitinib-in-papillary-renal-cell-cancer
2017	Dr. Choueiri on Synergy Between Immunotherapy and VEGF Inhibitors in RCC	Video	July 25, 2017, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-synergy-between-immunotherapy-and-vegf-inhibitors-in-rcc
2017	Dr. Choueiri on Trials Investigating Combination Regimens for RCC	Video	August 7, 2017, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-trials-investigating-combination-regimens-for-rcc
2017	Dr. Choueiri on the Biology of the CABOSUN Trial for RCC	Video	August 21, 2017, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-the-biology-of-the-cabosun-trial-for-rcc

2017	Dr. Choueiri on the Research with Immunotherapy in RCC	Video	October 13, 2017 available at
2017	Dr. Choueiri on the Role of Cabozantinib in RCC	Video	October 10, 2017, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-the-role-of-cabozantinib-in-rcc
2017, 2017	Dr. Choueiri on the Role of Traditional Agents in Kidney Cancer	Video	February 27, 2017, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-the-role-of-traditional-agents-in-kidney-cancer
2017	Immuno-Oncology: Changing the Treatment Landscape in RCC	Video	April 26, 2017, available at https://www.oncologytube.com/video/immuno-oncology-changing-the-treatment-landscape-in-rcc/10001344
2017	Rapidly Evolving Paradigms for Treating Advanced RCC	Video	March 20, 2017, available at https://www.onclive.com/peer-exchange-archive/advanced-kidney-cancer/rapidly-evolving-paradigms-for-treating-advanced-rcc
2017	Robert J. Motzer, MD, and Toni Choueiri, MD: Results of the PROTECT Trial	Video	July 17, 2017, available at http://jnccn360.org/kidney/videos/results-of-the-protect-trial/

2017	Thoughts on Metastatic Kidney Cancer	Video	May 2, 2017, available at https://www.onclive.com/peer-exchange-archive/advanced-kidney-cancer/thoughts-on-metastatic-kidney-cancer
2017	Toni Choueiri, MD and Laurence Albiges, MD, PhD, on Urothelial, RCC, and Other GU Malignancies: Two Key Trials	Video	September 12, 2017, available at
2017	Toni Choueiri, MD, on Newer Agents in the Treatment of Renal Cell Carcinoma	Video	July 11, 2017, available at http://jnccn360.org/kidney/videos/newer-agents-in-the-treatment-of-renal-cell-carcinoma/
2017	Toni K. Choueiri, MD, and Bernard J. Escudier, MD, on RCC: Trial Results on Sunitinib	Video	June 14, 2017, available at http://jnccn360.org/kidney/videos/rcc-trial-results-on-sunitinib/
2017	Toni K. Choueiri, MD, and Michael D. Staehler, MD, PhD, on RCC: Results From the SWITCH-II and SURTIME Trials	Video	October 4, 2017, available at https://jnccn360.org/kidney/videos/rcc-results-from-the-switch-ii-and-surtime-trials/
2017	Toni K. Choueiri, MD, and Sumanta K. Pal, MD, on Top Kidney Cancer Abstracts: Expert Perspectives	Video	June, 2017, available at https://ascopost.com/videos/2017-asco-annual-meeting/toni-k-choueiri-md-and-sumanta-k-pal-md-on-top-kidney-cancer-abstracts-expert-perspectives/

2017	Toni K. Choueiri, MD, on Papillary RCC: Phase II Trial Results	Video	February, 2017, available at https://ascopost.com/videos/2017-genitourinary-cancers-symposium/toni-k-choueiri-md-on-papillary-rcc-phase-ii-trial-results/
2017	Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial	Video	October, 2017, available at
2017, 2017	Toni K. Choueiri, MD, on Untreated RCC: Phase II Trial Results	Video	February, 2017, available at https://ascopost.com/videos/2017-genitourinary-cancers-symposium/toni-k-choueiri-md-on-untreated-rcc-phase-ii-trial-results/
2017	Toni K. Choueiri, MD, on Urothelial Cancer: Trial Results From Borealis-2	Video	February, 2017, available at https://ascopost.com/videos/2017-genitourinary-cancers-symposium/toni-k-choueiri-md-on-urothelial-cancer-trial-results-from-borealis-2/
2017	VEGF TKI Therapy in the Adjuvant Setting of RCC	Video	April 26, 2017, available at https://www.onclive.com/peer-exchange-archive/advanced-kidney-cancer/vegf-tki-therapy-in-the-adjuvant-setting-of-rcc
2017	What Change in First Line for 2018 in Kidney Cancer	Video	April 25, 2017, available at https://www.oncologytube.com/video/what-change-in-first-line-for-2018-in-kidney-cancer/10001331
2018	ASCO 2018: Top Oncologists Select	Interview	May 30, 2018, available at https://www.onclive.com/conference-coverage/asco-2018/asco-2018-top-

	Key, Practice- Changing Abstracts		oncologists-select-key- practice-changing-abstracts
2018	Advances and Next Steps in RCC	Interview	December 18, 2018, available at https://www.onclive.com/web-exclusives/choueiri-highlights-advances-and-next-steps-in-rcc
2018	Biomarkers in RCC	Video	November 13, 2018, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-biomarkers-in-rcc
2018	Bladder Cancer Roundup	Video	June 2018, available at http://ascopost.com/videos/2018-asco-annual-meeting/toni-choueiri-and-jonathan-rosenberg-bladder-cancer-roundup/
2018	CANTATA Trial in RCC	Video	October 4, 2018, available at https://www.onclive.com/onclive-tv/dr-choueiri-discusses-the-cantata-trial-in-rcc
2018	Checkpoint Inhibitor TKI Combinations in RCC	Video	November 21, 2018, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-checkpoint-inhibitortki-combinations-in-rcc
2018	Checkpoint Inhibitors in RCC	Video	July 3, 2018, available at https://www.onclive.com/onclive-tv/dr-choueiri-discusses-checkpoint-inhibitors-in-rcc

2018	Considerations for Using Adjuvant Therapy in mRCC	Video	August 16, 2018, available at https://www.onclive.com/peer-exchange/rcc-treatment-paradigm/considerations-for-using-adjuvant-therapy-in-mrcc
2018	Current State of RCC Treatment	Video	May 17, 2018, available at https://www.onclive.com/onclive-tv/dr-choueiri-discusses-the-current-state-of-rcc-treatment
2018	Deferred Therapy for Favorable-Risk mRCC Patients	Video	August 3, 2018, available at https://www.onclive.com/peer-exchange/rcc-treatment-paradigm/deferred-therapy-for-favorable-risk-mrcc-patients
2018	Disease Progression in Patients with Metastatic RCC	Video	August 13, 2018, available at https://www.onclive.com/peer-exchange/rcc-treatment-paradigm/disease-progression-in-patients-with-metastatic-rcc
2018	Evolving Treatment Landscape of Renal Cell Carcinoma	Video	August 22, 2018, available at https://www.onclive.com/peer-exchange/rcc-treatment-paradigm/evolving-treatment-landscape-of-renal-cell-carcinoma
2018	Frontline Trials of Immunotherapy in RCC	Video	December 3, 2018, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-

			frontline-trials-of-immunotherapy-in-rcc
2018	Impact of the JAVELIN Renal 101 Findings in RCC	Video	October 24, 2018, available at https://www.onclive.com/conference-coverage/esmo-2018/dr-choueiri-on-the-impact-of-the-javelin-renal-101-findings-in-rcc
2018	Latest in Genitourinary Cancer Research	Video	April 11, 2018, available at https://www.onclive.com/onclive-tv/dr-choueiri-highlights-the-latest-in-genitourinary-cancer-research
2018	Metastatic RCC: Perspectives on the Carmena Trial	Video	June, 2018, available at http://ascopost.com/videos/2018-asco-annual-meeting/laurence-albiges-and-toni-choueiri-on-metastatic-rcc-perspectives-on-the-carmena-trial/
2018	Neovax: From Translation to Bedside	Video	November 5, 2018, available at https://www.oncologytube.com/v/10005484/neovax-from-translation-to-bedside
2018	Newly Diagnosed Metastatic Renal Cell Carcinoma	Video	July 11, 2018, available at https://www.onclive.com/peer-exchange/rcc-treatment-paradigm/newly-diagnosed-metastatic-renal-cell-carcinoma
2018	Next Steps for Treatment in RCC	Video	December 12, 2018, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-

			next-steps-for-treatment-in-rcc
2018	Promising Avelumab/Axitinib Data in RCC	Interview	November 20, 2018, available at https://www.onclive.com/web-exclusives/choueiri-highlights-promising-avelumabaxitinib-data-in-rcc
2018	RCC: Novel Combinations for Advanced Disease	Video	June, 2018, available at http://ascopost.com/videos/2018-asco-annual-meeting/laurence-albiges-and-toni-choueiri-on-novel-combinations-for-advanced-rcc/
2018	RCC: Novel Combinations for Advanced Disease	Video	June 11, 2018, available at https://jnccn360.org/kidney/videos/novel-combinations-for-advanced-disease/
2018	RCC: Perspectives on KEYNOTE-427 and IMmotion151	Video	June 2018, available at http://ascopost.com/videos/2018-asco-annual-meeting/toni-choueiri-and-elizabeth-plimack-on-keynote-427-and-immotion151/
2018	RCC: Results from the PROSPER Trial	Video	June, 2018, available at http://ascopost.com/videos/2018-asco-annual-meeting/toni-choueiri-and-lauren-harshman-on-the-prosper-trial/
2018	Recent RCC Advances	Interview	July 26, 2018, available at https://www.onclive.com/web-exclusives/choueiri-

			reflects-on-recent-rcc-advances
2018	Selecting Immunotherapy versus VEGF TKI for mRCC	Video	July 30, 2018, available at https://www.onclive.com/peer-exchange/rcc-treatment-paradigm/selecting-immunotherapy-versus-vegf-tki-for-mrcc
2018	Sequencing Approaches in Metastatic Renal Cell Carcinoma	Video	August 15, 2018, available at https://www.onclive.com/peer-exchange/rcc-treatment-paradigm/sequencing-approaches-in-metastatic-renal-cell-carcinoma
2018	Standard of Care Continues to Shift in RCC	Interview	May 11, 2018, available at https://www.onclive.com/web-exclusives/standard-of-care-continues-to-shift-in-rcc
2018	Sunitinib 42 vs 21 Schedule for Patients with mRCC	Video	August 7, 2018, available at https://www.onclive.com/peer-exchange/rcc-treatment-paradigm/sunitinib-4-2-vs-2-1-schedule-for-patients-with-mrcc
2018	Trial updates in mRCC from ASCO: KEYNOTE-427, RESORT, E2810 & IMmotion151	Video	July 27, 2018, available at https://www.oncologytube.com/video/trial-updates-in-mrcc-from-asco-keynote-427-resort-e2810-amp-immotion151/10004754
2018	VEGF TKI + Immunotherapy Combinations for mRCC	Video	August 7, 2018, available at https://www.onclive.com/peer-exchange/rcc-treatment-paradigm/vegf-tki-plus-

			immunotherapy-combinations-for-mrcc
2018	mRCC: Cytoreductive Nephrectomy in the Modern Era	Video	July 25, 2018, available at https://www.onclive.com/peer-exchange/rcc-treatment-paradigm/mrcc-cytoreductive-nephrectomy-in-the-modern-era
2019	A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC	Video	March 31, 2019, available at https://www.oncologytube.com/video/a-first-in-human-phase-1-2-trial-of-the-oral-hif-2a-inhibitor-pt2977-in-patients-with-advanced-rcc/10006144
2019	ASCO GU 2019 renal highlights	Video	February 14, 2019, available at https://ecancer.org/video/7688/asco-gu-2019-renal-highlights.php
2019	Atezolizumab Plus Bevacizumab in Non-Clear Cell RCC	Video	April 11, 2019, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-atezolizumab-plus-bevacizumab-in-nonclear-cell-rcc/
2019	Avelumab Axitinib Data in RCC	Video	February 16, 2019, available at https://www.onclive.com/conference-coverage/gu-2019/dr-choueiri-discusses-avelumabaxitinib-data-in-rcc
2019	Avelumab/Axitinib Combo Biomarker	Interview	June 11, 2019, available at https://www.onclive.com/w

	Analysis May Lend Insight to Complex RCC Landscape		eb-exclusives/avelumab-axitinib-combo-biomarker-analysis-may-lend-insight-to-complex-rcc-landscape
2019	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)	Video	June 6, 2019, available at https://www.oncologytube.com/video/biomarker-analyses-from-javelin-renal-101-avelumab-axitinib-a-ax-versus-sunitinib-s-in-advanced-renal-cell-carcinoma-arcc/10006447
2019	Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC	Video	June 1, 2019, available at https://ecancer.org/video/7909/biomarker-analysis-from-javelin-renal-101--avelumab-plus-axitinib-versus-sunitinib-in-arcc.php
2019	Checkpoint Inhibitors: Overall Survival and Polybromo-Associated Mutations	Video	June, 2019, available at https://ascopost.com/videos/2019-asco-annual-meeting/sarah-abou-alaiwi-and-toni-choueiri-on-checkpoint-inhibitors-and-polybromo-associated-mutations/
2019	Immunotherapy in RCC	Video	January 22, 2019, available at https://www.onclive.com/onclive-tv/dr-choueiri-discusses-immunotherapy-in-rcc
2019	NO OS Signal in Axitinib + Avelumab Combination Therapy	Video	April 17, 2019, available at https://www.oncologytube.com/video/treating-brain-metastases-from-rcc-with-nivolumab/video/elaboratin

			g-on-frontline-therapies/10006219
2019	Novel Oral HIF-2 Alpha Inhibitor PT2977	Video	April 17, 2019, available at https://www.oncologytube.com/video/novel-oral-hif-2-alpha-inhibitor-pt2977/10006221
2019	Randomised phase 2 study of sapanisertib (TAK-228/MLN0128) +/- TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma	Video	April 1, 2019, available at https://www.oncologytube.com/video/randomised-phase-2-study-of-sapanisertib-tak-228-mln0128-tak-117-versus-everolimus-in-patients-with-vegf-targeted-therapy-refractory-metastatic-clear-cell-renal-cell-carcinoma/10006146
2019	Renal Cell Carcinoma: Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid/Rhabdoid Disease	Video	June, 2019, available at https://ascopost.com/videos/2019-asco-annual-meeting/ziad-bakouny-and-toni-choueiri-on-genomic-characterization-of-sarcomatoidrhabdoid-rcc/
2019	Renal Cell Carcinoma: Next-Generation Immuno-oncology Therapies	Video	March, 2019, available at https://ascopost.com/videos/2019-asco-sitc-clinical-immuno-oncology-symposium/toni-choueiri-and-ziad-bakouny-on-next-generation-immuno-oncology-therapies-in-rcc/
2019	Renal Cell Carcinoma: Trial Results on Avelumab Plus Axitinib vs Sunitinib	Video	February, 2019, available at https://ascopost.com/videos/2019-genitourinary-cancers-symposium/toni-

			choueiri-on-avelumab-plus-axitinib-vs-sunitinib/
2019	Subgroup Analysis of the JAVELIN Renal 101 Trial in RCC	Video	June 10, 2019, available at https://www.onclive.com/onclive-tv/dr-choueiri-on-the-subgroup-analysis-of-the-javelin-renal-101-trial-in-rcc/
2019	The Combination of Avelumab + Axitinib (Ave/Axi) in Advanced RCC: a legitimate 1st line contender	Video	April 2, 2019, available at https://www.oncologytube.com/video/the-combination-of-avelumab-axitinib-ave-axi-in-advanced-rcc-a-legitimate-1st-line-contender/10006171
2019	mTOR & PI3 Kinase Inhibitor Study	Video	April 17, 2019, available at https://www.oncologytube.com/video/mtor-pi3-kinase-inhibitor-study/10006220
2020	Impact the coronavirus disease 2019 pandemic has had on diagnosing and treating patients with renal cell carcinoma	Video	August 7, 2020, available at https://www.onclive.com/view/dr-choueiri-on-the-impact-of-the-covid-19-pandemic-on-treatment-in-rcc
2020	Significance of the COVID-19 and Cancer Consortium during the coronavirus disease 2019 pandemic	Video	August 15, 2020, available at https://www.onclive.com/view/dr-choueiri-on-the-significance-of-the-ccc19-during-the-covid-19-crisis
2022	Oncology Today with Dr. Neil Love: Management of Renal	Podcast	November 29, 2022, available at https://podcasts.apple.com/gb/podcast/management-of-renal-cell-carcinoma-with-

Report of Scholarship

ORCID: 0000-0002-9201-3217

* Co-author, ** Mentee

Peer-Reviewed Scholarship in print or other media:

Research Investigations:

1. Deitcher SR, **Choueiri T**, Srkalovic G, Hussein MA. Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. *Br J Haematol*. 2003 Dec;123(5):959. PMID: 14632794
2. **Choueiri TK**, Mekhail T, Hutson TE, Ganapathi R, Kelly GE, Bukowski RM. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. *Ann Oncol*. 2006 May;17(5):860-865. PMID: 16524966
3. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, **Choueiri TK**, Dawson AE, Budd GT, Tubbs RR, Casey G, Weil RJ. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cyokeratin CK5/6, and overexpress HER2 or EGFR. *Am J Surg Pathol*. 2006 Sep;30(9):1097-1104. PMID: 16931954
4. Abou-Jawde RM, Baz R, Walker E, **Choueiri TK**, Karam MA, Reed J, Faiman B, Hussein M. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. *Haematologica*. 2006 Oct;91(10):1410-1413. PMID: 16963396
5. Hicks DG, Yoder BJ, Short S, Tarr S, Prescott N, Crowe JP, Dawson AE, Budd GT, Sizemore S, Cicek M, **Choueiri TK**, Tubbs RR, Gaile D, Nowak N, Accavitti-Loper MA, Frost AR, Welch DR, Casey G. Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. *Clin Cancer Res*. 2006 Nov 15;12(22):6702-6708. PMID: 17121889, PMCID: PMC1661839
6. Baz R, Walker E, Karam MA, **Choueiri TK**, Jawde RA, Bruening K, Reed J, Faiman B, Ellis Y, Brand C, Srkalovic G, Andresen S, Knight R, Zeldis J, Hussein MA. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. *Ann Oncol*. 2006 Dec;17(12):1766-1771. PMID: 16980599

7. **Choueiri TK**, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. *Cancer*. 2006 Dec 1;107(11):2609-2616. PMID: 17075879
8. Baz R, Walker E, **Choueiri TK**, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. *Acta Haematol*. 2007;117(3):162-167. PMID: 17148935
9. Short SM, Yoder BJ, Tarr SM, Prescott NL, Laniauskas S, Coleman KA, Downs-Kelly E, Pettay JD, **Choueiri TK**, Crowe JP, Tubbs RR, Budd TG, Hicks DG. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. *Breast J*. 2007;13(2):130-139. PMID: 17319853
10. **Choueiri TK**, Rini B, Garcia JA, Baz RC, Abou-Jawde RM, Thakkar SG, Elson P, Mekhail TM, Zhou M, Bukowski RM. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. *Ann Oncol*. 2007 Feb;18(2):249-255. PMID: 17060490
11. **Choueiri TK**, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. *Cancer*. 2007 Aug 1;110(3):543-50. PMID: 17577222
12. Tamaskar I, **Choueiri TK***, Sercia L, Rini B, Bukowski R, Zhou M. Differential expression of caveolin-1 in renal neoplasms. *Cancer*. 2007 Aug 15;110(4):776-782. PMID: 17594718
13. Escudier B, **Choueiri TK**, Oudard S, Szczylik C, Négrier S, Ravaud A, Chevreau C, Venner P, Champagne P, Croteau D, Dupont E, Hariton C, Bukowski RM. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. *J Urol*. 2007 Nov;178(5):1901-1905. PMID: 17868728
14. **Choueiri TK**, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. *J Clin Oncol*. 2008 Jan 1;26(1):127-131. PMID: 18165647

15. **Choueiri TK**, Baz RC, McFadden CM, Khasawneh M, Karam MA, Kelly M, Hussein MA. An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. *BJU Int.* 2008 Mar;101(6):712-715. PMID: 17970789
16. **Choueiri TK**, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. *J Urol.* 2008 Mar;179(3):906-10; discussion 910. PMID: 18207194
17. Rini BI, **Choueiri TK**, Elson P, Khasawneh MK, Cotta C, Unnithan J, Wood L, Mekhail T, Garcia J, Dreicer R, Bukowski RM. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. *Cancer.* 2008 Sep 15;113(6):1309-1314. PMID: 18618496
18. **Choueiri TK**, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. *J Urol.* 2008 Sep;180(3):860-5; discussion 865. PMID: 18635227
19. Hu JC, Hevelone ND, Ferreira MD, Lipsitz SR, **Choueiri TK**, Sanda MG, Earle CC. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. *J Urol.* 2008 Nov;180(5):1969-1974. PMID: 18801512
20. **Choueiri TK**, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. *Cancer.* 2009 Mar 1;115(5):981-987. PMID: 19152438, PMCID: PMC2931827
21. Medioni J, **Choueiri TK**, Zinzindohoué F, Cho D, Fournier L, Oudard S. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. *J Urol.* 2009 Jun;181(6):2470-5; discussion 2475. PMID: 19371877
22. Duh MS, Dial E, **Choueiri TK**, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. *Curr Med Res Opin.* 2009 Aug;25(8):2081-2090. PMID: 19586325
23. Wiklund F, Tretli S, **Choueiri TK**, Signoretti S, Fall K, Adami HO. Risk of bilateral renal cell cancer. *J Clin Oncol.* 2009 Aug 10;27(23):3737-3741. PMID: 19597028

24. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, **Choueiri TK**. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol*. 2009 Dec 1;27(34):5794-5799. PMID: 19826129
25. Nguyen PL, Chen MH, Beard CJ, Suh WW, **Choueiri TK**, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. *Cancer*. 2010 Feb 1;116(3):610-615. PMID: 19957321
26. **Choueiri TK**, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. *Cancer*. 2010 Apr 15;116(8):1887-1892. PMID: 20162710
27. Bellmunt J, **Choueiri TK**, Fougeray R, Schutz FA, Salhi Y, Winkvist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. *J Clin Oncol*. 2010 Apr 10;28(11):1850-1855. PMID: 20231682
28. **Choueiri TK**, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. *BJU Int*. 2010 May;105(9):1247-1254. PMID: 19863525
29. Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, **Choueiri TK**. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. *Urol Oncol*. 2011;29(6):756-763. PMID: 20451414
30. Vickers MM, **Choueiri TK**, Rogers M, Percy A, Finch D, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. *Urology*. 2010 Aug;76(2):430-434. PMID: 20223508
31. **Choueiri TK**, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma

- receiving vascular endothelial growth factor-targeted therapy. *BJU Int.* 2010 Sep;106(6):772-8. PMID: 20230385, <https://doi.org/10.1111/j.1464-410X.2010.09218.x>
32. Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, **Choueiri TK**, D'Amico AV. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. *BJU Int.* 2010 Oct;106(7):979-985. PMID: 20230380
33. **Choueiri TK**, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. *Cancer.* 2010 Nov 15;116(22):5219-5225. PMID: 20665500, PMCID: PMC4667556
34. Aho DA, Hoffman KE, Hu JC, **Choueiri TK**, D'Amico AV, Nguyen PL. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. *Urology.* 2010 Nov;76(5):1201-1205. PMID: 20709376
35. Robinson ES, Khankin EV, **Choueiri TK**, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. *Hypertension.* 2010 Dec;56(6):1131-1136. PMID: 20956731, PMCID: PMC3078049
36. Zama IN, Hutson TE, Elson P, Cleary JM, **Choueiri TK**, Heng DY, Ramaiya N, Michaelson MD, Garcia JA, Knox JJ, Escudier B, Rini BI. Sunitinib rechallenge in metastatic renal cell carcinoma patients. *Cancer.* 2010 Dec 1;116(23):5400-5406. PMID: 21105118
37. Hoffman KE, Nguyen PL, Chen MH, Chen RC, **Choueiri TK**, Hu JC, Kuban DA, D'Amico AV. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. *J Urol.* 2011 Jan;185(1):116-120. PMID: 21074194
38. **Choueiri TK**, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. *J Urol.* 2011 Jan;185(1):60-66. PMID: 21074201
39. Hu JC, Prasad SM, Gu X, Williams SB, Lipsitz SR, Nguyen PL, **Choueiri TK**, Choi WW, D'Amico AV. Determinants of performing radical prostatectomy pelvic lymph

node dissection and the number of lymph nodes removed in elderly men. *Urology*. 2011 Feb;77(2):402-406. PMID: 20719365

40. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, **Choueiri TK**, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. *J Urol*. 2011 Feb;185(2):439-444. PMID: 21167518, PMCID: PMC4668716
41. **Choueiri TK**, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. *J Clin Oncol*. 2011 Feb 20;29(6):632-638. PMID: 21205755
42. Flavin R, Finn SP, **Choueiri TK**, Ingoldsby H, Ring M, Barrett C, Rogers M, Smyth P, O'Regan E, Gaffney E, O'Leary JJ, Loda M, Signoretti S, Sheils O. RET protein expression in papillary renal cell carcinoma. *Urol Oncol*. 2012;30(6):900-905. PMID: 21396847, PMCID: PMC8445588
43. Nguyen PL, Chen MH, **Choueiri TK**, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV. Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. *Int J Radiat Oncol Biol Phys*. 2011 Apr 1;79(5):1318-1322. PMID: 20605366
44. Nguyen PL, Gu X, Lipsitz SR, **Choueiri TK**, Choi WW, Lei Y, Hoffman KE, Hu JC. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. *J Clin Oncol*. 2011 Apr 20;29(12):1517-1524. PMID: 21402604, PMCID: PMC3082972
45. Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, **Choueiri TK**. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. *Eur Urol*. 2011 May;59(5):856-862. PMID: 21306819
46. Schutz FA, Jardim DL, Je Y, **Choueiri TK**. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. *Eur J Cancer*. 2011 May;47(8):1161-1174. PMID: 21470847
47. Schutz FAB, Je Y, Azzi GR, Nguyen PL, **Choueiri TK**. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. *Ann Oncol*. 2011 Jun;22(6):1404-1412. PMID: 21115602

48. Heng DY, Xie W, Bjarnason GA, Vaishampayan U, Tan MH, Knox J, Donskov F, Wood L, Kollmannsberger C, Rini BI, **Choueiri TK**. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. *Cancer*. 2011 Jun 15;117(12):2637-2642. PMID: 21656741, PMCID: PMC3856357
49. **Choueiri TK**, Schutz FA, Hevelone ND, Nguyen PL, Lipsitz SR, Williams SB, Silverman SG, Hu JC. Thermal ablation vs surgery for localized kidney cancer: a surveillance, epidemiology, and end results (SEER) database analysis. *Urology*. 2011 Jul;78(1):93-98. PMID: 21550636
50. Huang SP, Bao BY, Wu MT, **Choueiri TK**, Goggins WB, Huang CY, Pu YS, Yu CC, Huang CH. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. *Prostate*. 2011 Aug 1;71(11):1189-1197. PMID: 21656829
51. Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Négrier S, Escudier B, Eisen T, Dutcher J, Atkins M, Heng DY, **Choueiri TK**, Motzer R, Bukowski R, International Kidney Cancer Working Group. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. *Clin Cancer Res*. 2011 Aug 15;17(16):5443-5450. PMID: 21828239, PMCID: PMC3387987
52. Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, **Choueiri TK**. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. *J Clin Oncol*. 2011 Sep 1;29(25):3450-3456. PMID: 21810682
53. Cho E, Curhan G, Hankinson SE, Kantoff P, Atkins MB, Stampfer M, **Choueiri TK**. Prospective evaluation of analgesic use and risk of renal cell cancer. *Arch Intern Med*. 2011 Sep 12;171(16):1487-1493. PMID: 21911634, PMCID: PMC3691864
54. Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF, Powles T, Chowdhury P, Karapetis C, Harper PG, **Choueiri TK**, Chowdhury S. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. *BJU Int*. 2011 Oct;108(8):1279-1283. PMID: 21244613
55. Schutz FA, Je Y, **Choueiri TK**. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials. *Crit Rev Oncol Hematol*. 2011 Nov;80(2):291-300. PMID: 21339073

56. Williams SB, Gu X, Lipsitz SR, Nguyen PL, **Choueiri TK**, Hu JC. Utilization and expense of adjuvant cancer therapies following radical prostatectomy. *Cancer*. 2011 Nov 1;117(21):4846-4854. PMID: 21365630
57. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, **Choueiri TK**, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. *Eur J Cancer*. 2011 Dec;47(18):2706-2714. PMID: 22078932, PMCID: PMC4167844
58. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, **Choueiri TK**. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. *JAMA*. 2011 Dec 7;306(21):2359-2366. PMID: 22147380
59. Macfarlane R, Heng DY, Xie W, Knox JJ, McDermott DF, Rini BI, Kollmannsberger C, **Choueiri TK**. The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. *Cancer*. 2012 Jan 15;118(2):365-370. PMID: 21717427
60. Liu W, **Choueiri TK**, Cho E. Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. *Cancer*. 2012 Feb 1;118(3):797-803. PMID: 21751202, PMCID: PMC3193897
61. **Choueiri TK**, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bublely GJ, Taplin ME, Rosenberg JE, Kantoff PW. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. *J Clin Oncol*. 2012 Feb 10;30(5):507-512. PMID: 22184381, PMCID: PMC4104290
62. Huang SP, Bao BY, Wu MT, **Choueiri TK**, Goggins WB, Liu CC, Huang CY, Pu YS, Yu CC, Wu TT, Huang CN, Huang CH, Wu WJ. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. *Aging Male*. 2012 Mar;15(1):34-41. PMID: 21615239
63. Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, **Choueiri TK**, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D'Amico AV, Ennis RD. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure

or myocardial infarction. *Int J Radiat Oncol Biol Phys*. 2012 Mar 15;82(4):1411-1416. PMID: 21708431

64. Schutz FA, Je Y, Richards CJ, **Choueiri TK**. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. *J Clin Oncol*. 2012 Mar 10;30(8):871-877. PMID: 22312105
65. Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S, Donskov F, Rini BI, **Choueiri TK**. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. *Ann Oncol*. 2012 Jun;23(6):1549-1555. PMID: 22056973, PMCID: PMC3858023
66. Yu HY, Hevelone ND, Lipsitz SR, Kowalczyk KJ, Nguyen PL, **Choueiri TK**, Kibel AS, Hu JC. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. *Eur Urol*. 2012 Jun;61(6):1239-1244. PMID: 22482778
67. Tseng YD, Chen MH, Beard CJ, Martin NE, Orio PF, Loffredo M, Renshaw AA, **Choueiri TK**, Hu JC, Kantoff PW, D'Amico AV, Nguyen PL. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. *J Urol*. 2012 Jun;187(6):2068-2073. PMID: 22498212
68. Krajewski KM, Fougeray R, Bellmunt J, Pons F, Schutz FA, Rosenberg JE, Salhi Y, **Choueiri TK**. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. *Eur J Cancer*. 2012 Jul;48(10):1495-1502. PMID: 22176867
69. Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, Pedrosa I, **Choueiri TK**. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome. *Eur J Cancer*. 2012 Jul;48(10):1519-1524. PMID: 22483544
70. Ulmer WD, Prasad SM, Kowalczyk KJ, Gu X, Dodgion C, Lipsitz S, Palapattu GS, **Choueiri TK**, Hu JC. Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. *J Urol*. 2012 Sep;188(3):775-780. PMID: 22818134
71. Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, **Choueiri TK**. Conditional survival of patients with

metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. *Lancet Oncol.* 2012 Sep;13(9):927-935. PMID: 22877847, PMCID: PMC3856362

72. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, **Choueiri TK**, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. *Cancer.* 2012 Oct 1;118(19):4777-4784. PMID: 22282219, PMCID: PMC3791849

73. **Choueiri TK**, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, McKenney JK, Brown V, Lampron ME, Zhou M, Hirsch MS, Signoretti S. BRAF Mutations in Metanephric Adenoma of the Kidney. *Eur Urol.* 2012 Nov;62(5):917-922. PMID: 22727996, PMCID: PMC4516083

74. Joh HK, Cho E, **Choueiri TK**. ABO blood group and risk of renal cell cancer. *Cancer Epidemiol.* 2012 Dec;36(6):528-532. PMID: 22841339, PMCID: PMC3717382

75. **Choueiri TK**, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. *J Clin Oncol.* 2013 Jan 10;31(2):181-186. PMID: 23213094, PMCID: PMC3532390

76. Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, **Choueiri TK**. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. *Lancet Oncol.* 2013 Jan;14(1):81-87. PMID: 23219378, PMCID: PMC3769687

77. Parekh A, Chen MH, Hoffman KE, **Choueiri TK**, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, Graham PL, D'Amico AV, Nguyen PL. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. *Urology.* 2013 Jan;81(1):130-134. PMID: 23273077, PMCID: PMC5105593

78. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, **Choueiri TK**. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model:

a population-based study. *Lancet Oncol.* 2013 Feb;14(2):141-148. PMID: 23312463, PMCID: PMC4144042

79. Sonpavde G, Pond GR, Fougeray R, **Choueiri TK**, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. *Eur Urol.* 2013 Apr;63(4):717-723. PMID: 23206856, PMCID: PMC4127896
80. Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, **Choueiri TK**, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. *Brachytherapy.* 2013;12(5):415-421. PMID: 23651926
81. Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, Culine S, **Choueiri TK**. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. *Ann Oncol.* 2013 Jun;24(6):1466-1472. PMID: 23419284
82. Kowalczyk KJ, **Choueiri TK**, Hevelone ND, Trinh QD, Lipsitz SR, Nguyen PL, Lynch JH, Hu JC. Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. *BJU Int.* 2013 Aug;112(4):E273-E280. PMID: 23452093
83. Kapadia S, Hapani S, **Choueiri TK**, Wu S. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. *Acta Oncol.* 2013 Aug;52(6):1202-1212. PMID: 23594201
84. **Choueiri TK**, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. *Ann Oncol.* 2013 Aug;24(8):2092-2097. PMID: 23658373
85. Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, **Choueiri TK**, Heng DY. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium

criteria. *Cancer*. 2013 Aug 15;119(16):2999-3006. PMID: 23696129, PMCID: PMC3934562

86. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, **Choueiri TK**. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *N Engl J Med*. 2013 Aug 22;369(8):722-731. PMID: 23964934
87. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, MacKenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, **Choueiri TK**, Heng DY, International mRCC Database Consortium. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. *Target Oncol*. 2013 Sep;8(3):203-209. PMID: 23300029, PMCID: PMC4144038
88. Vickers MM, Al-Harbi H, **Choueiri TK**, Kollmannsberger C, North S, MacKenzie M, Knox JJ, Rini BI, Heng DY. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. *Clin Genitourin Cancer*. 2013 Sep;11(3):311-315. PMID: 23684422
89. Galsky MD, Xie W, Nakabayashi M, Ross RW, Fennessy FM, Tempany CM, **Choueiri TK**, Khine K, Kantoff PW, Taplin ME, Oh WK. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. *Prostate Cancer Prostatic Dis*. 2013 Sep;16(3):266-270. PMID: 23712318, PMCID: PMC4026061
90. **Choueiri TK**, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. *Clin Cancer Res*. 2013 Sep 15;19(18):5218-5226. PMID: 23881929, PMCID: PMC4522695
91. **Choueiri TK**, Cheng S, Qu AQ, Pastorek J, Atkins MB, Signoretti S. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). *Urol Oncol*. 2013 Nov;31(8):1788-1793. PMID: 23141780, PMCID: PMC4522691

92. Kowalczyk KJ, Harbin AC, **Choueiri TK**, Hevelone ND, Lipsitz SR, Trinh QD, Tina Shih YC, Hu JC. Use of surveillance imaging following treatment of small renal masses. *J Urol*. 2013 Nov;190(5):1680-1685. PMID: 23764074
93. Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, **Choueiri TK**, Hoffman KE, Martin NE, Hu JC, Nguyen PL. Marital status and survival in patients with cancer. *J Clin Oncol*. 2013 Nov 1;31(31):3869-3876. PMID: 24062405, PMCID: PMC4878087
94. Motzer RJ, Johnson T, **Choueiri TK**, Deen KC, Xue Z, Pandite LN, Carpenter C, Xu CF. Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. *Ann Oncol*. 2013 Nov;24(11):2927-2928. PMID: 24107802, PMCID: PMC6394110
95. Harshman LC, Fougeray R, **Choueiri TK**, Schutz FA, Salhi Y, Rosenberg JE, Bellmunt J. The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. *Br J Cancer*. 2013 Nov 12;109(10):2548-2553. PMID: 24129239, PMCID: PMC3833211
96. Pond GR, Bellmunt J, Fougeray R, **Choueiri TK**, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. *Clin Genitourin Cancer*. 2013 Dec;11(4):495-500. PMID: 23800847
97. **Choueiri TK**, Je Y, Cho E. Analgesic use and the risk of kidney cancer: A meta-analysis of epidemiologic studies. *Int J Cancer*. 2014 Jan 15;134(2):384-396. PMID: 23400756, PMCID: PMC3815746
98. Heng DY, **Choueiri TK**, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. *Ann Oncol*. 2014 Jan;25(1):149-154. PMID: 24356626, PMCID: PMC4155479
99. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, **Choueiri T**, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. *Invest New Drugs*. 2014 Feb;32(1):178-187. PMID: 24242861, PMCID: PMC4560460
100. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI,

Heng DY, **Choueiri TK**. Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. *Eur Urol*. 2014 Mar;65(3):577-584. PMID: 23962746, PMCID: PMC4123121

101. Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, **Choueiri TK**. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: Implications for alternative response criteria. *Cancer*. 2014 Mar 1;120(5):711-721. PMID: 24264883, PMCID: PMC4031652
102. Wang Y, **Choueiri TK**, Lee JL, Tan MH, Rha SY, North SA, Kollmannsberger CK, McDermott DF, Heng DY. Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. *Br J Cancer*. 2014 Mar 18;110(6):1433-1437. PMID: 24548864, PMCID: PMC3960609
103. Sun M, Karakiewicz PI, Sammon JD, Sukumar S, Gervais MK, Nguyen PL, **Choueiri TK**, Menon M, Trinh QD. Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. *BMJ Open*. 2014 Mar 23;4(3):e003921. PMID: 24657917, PMCID: PMC3963094
104. Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, **Choueiri TK**. The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. *Eur Urol*. 2014 Apr;65(4):723-730. PMID: 24184025, PMCID: PMC4142674
105. Agarwal N, Bellmunt J, Maughan BL, Boucher KM, **Choueiri TK**, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. *Clin Genitourin Cancer*. 2014 Apr;12(2):130-137. PMID: 24220220, PMCID: PMC4142680
106. Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, **Choueiri TK**, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.

Clin Cancer Res. 2014 Apr 1;20(7):1873-1883. PMID: 24486590, PMCID: PMC3975677

107. Ko JJ, **Choueiri TK**, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. *Br J Cancer*. 2014 Apr 15;110(8):1917-1922. PMID: 24691425, PMCID: PMC3992507
108. Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, **Choueiri TK**. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). *BJU Int*. 2014 May;113(5b):E67-E74. PMID: 24053727, PMCID: PMC4117702
109. Pond GR, Agarwal N, Bellmunt J, **Choueiri TK**, Qu A, Fougerey R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. *BJU Int*. 2014 May;113(5b):E137-E143. PMID: 24219029
110. Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, **Choueiri TK**, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. *Cancer Discov*. 2014 May;4(5):546-553. PMID: 24625776, PMCID: PMC4122326
111. Gandaglia G, Sammon JD, Chang SL, **Choueiri TK**, Hu JC, Karakiewicz PI, Kibel AS, Kim SP, Konijeti R, Montorsi F, Nguyen PL, Sukumar S, Menon M, Sun M, Trinh QD. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. *J Clin Oncol*. 2014 May 10;32(14):1419-1426. PMID: 24733797
112. Krajewski KM, Franchetti Y, Nishino M, Fay AP, Ramaiya N, Van den Abbeele AD, **Choueiri TK**. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. *Oncologist*. 2014 May;19(5):507-514. PMID: 24755461, PMCID: PMC4012965
113. Motzer RJ, Hutson TE, McCann L, Deen K, **Choueiri TK**. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. *N Engl J Med*. 2014 May 1;370(18):1769-1770. PMID: 24785224

114. Aizer AA, Wilhite TJ, Chen MH, Graham PL, **Choueiri TK**, Hoffman KE, Martin NE, Trinh QD, Hu JC, Nguyen PL. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. *Cancer*. 2014 May 15;120(10):1532-1539. PMID: 24863392
115. Kroeger N, **Choueiri TK**, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY. Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. *Eur Urol*. 2014 Jun;65(6):1086-1092. PMID: 23916693
116. Garcia JA, Hudes GR, **Choueiri TK**, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y, Schwartz JD, Thompson JA. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. *Cancer*. 2014 Jun 1;120(11):1647-1655. PMID: 24577874
117. Seible DM, Gu X, Hyatt AS, Beard CJ, **Choueiri TK**, Efstathiou JA, Miyamoto DT, Mitin T, Martin NE, Sweeney CJ, Trinh QD, Beckman JA, Basaria S, Nguyen PL. Weight gain on androgen deprivation therapy: which patients are at highest risk?. *Urology*. 2014 Jun;83(6):1316-1321. PMID: 24726149
118. **Choueiri TK**, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bublely GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. *J Clin Oncol*. 2014 Jun 20;32(18):1889-1894. PMID: 24821883, PMCID: PMC7057274
119. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, **Choueiri TK**, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. *Eur Urol*. 2014 Jul;66(1):77-84. PMID: 24613583, PMCID: PMC4058355
120. Aizer AA, Chen MH, Parekh A, **Choueiri TK**, Hoffman KE, Kim SP, Martin NE, Hu JC, Trinh QD, Nguyen PL. Refusal of curative radiation therapy and surgery among patients with cancer. *Int J Radiat Oncol Biol Phys*. 2014 Jul 15;89(4):756-764. PMID: 24803037
121. Aizer AA, Falit B, Mendu ML, Chen MH, **Choueiri TK**, Hoffman KE, Hu JC, Martin NE, Trinh QD, Alexander BM, Nguyen PL. Cancer-specific outcomes among young

adults without health insurance. *J Clin Oncol*. 2014 Jul 1;32(19):2025-2030. PMID: 24888800, PMCID: PMC4879691

122. Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, **Choueiri TK**, Heng DY. A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2014 Aug;12(4):e127-e131. PMID: 24485801
123. Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, **Choueiri TK**. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. *Clin Genitourin Cancer*. 2014 Aug;12(4):262-269. PMID: 24795159
124. **Choueiri TK**, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, Kaelin WG, Dutcher JP. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. *Ann Oncol*. 2014 Aug;25(8):1603-1608. PMID: 24827131, PMCID: PMC6279111
125. Guancial EA, Werner L, Bellmunt J, Bamias A, **Choueiri TK**, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. *Cancer Med*. 2014 Aug;3(4):835-844. PMID: 24846059, PMCID: PMC4303151
126. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, **Choueiri TK**, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. *Urology*. 2014 Aug;84(2):386-392. PMID: 24975710
127. Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, **Choueiri TK**, Rosenberg JE. Identification of ALK gene alterations in urothelial carcinoma. *PLOS One*. 2014;9(8):e103325. PMID: 25083769, PMCID: PMC4118868
128. McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, **Choueiri TK**. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. *Eur Urol*. 2014 Sep;66(3):502-509. PMID: 24613250, PMCID: PMC4145043

129. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Lago-Hernandez C, Chen YW, **Choueiri TK**, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Trinh QD, Nguyen PL. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. *Prostate Cancer Prostatic Dis.* 2014 Sep;17(3):273-279. PMID: 24980272
130. Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaiparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, **Choueiri TK**, Hakimi AA, TheCancer Genome Atlas Research Network, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ. The somatic genomic landscape of chromophobe renal cell carcinoma. *Cancer Cell.* 2014 Sep 8;26(3):319-330. PMID: 25155756, PMCID: PMC4160352
131. Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, **Choueiri TK**. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. *Clin Genitourin Cancer.* 2014 Oct;12(5):335-340. PMID: 24787966, PMCID: PMC4164603
132. Khambati HK, **Choueiri TK**, Kollmannsberger CK, North S, Bjarnason GA, Vaishampayan UN, Wood L, Knox JJ, Tan MH, MacKenzie MJ, Donskov F, Rini BI, Heng DY, International mRCC Database Consortium. Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. *Clin Genitourin Cancer.* 2014 Oct;12(5):354-358. PMID: 24819320, PMCID: PMC4156559
133. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, **Choueiri TK**, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. *Clin Genitourin Cancer.* 2014 Oct;12(5):e189-e195. PMID: 24861952
134. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, **Choueiri TK**, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL. Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. *J Geriatr Oncol.* 2014 Oct 1;5(4):352-358. PMID: 24862107
135. Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, **Choueiri TK**. Cytoreductive

nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur Urol.* 2014 Oct;66(4):704-710. PMID: 24931622

136. Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, **Choueiri TK**, Bajorin DF, Solit DB, Gabriel S, D'Andrea A, Garraway LA, Rosenberg JE. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. *Cancer Discov.* 2014 Oct;4(10):1140-1153. PMID: 25096233, PMCID: PMC4238969
137. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Sammon JD, Schmid M, **Choueiri TK**, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Lathan C, Kim SP, Trinh QD, Nguyen PL. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. *Urol Oncol.* 2014 Nov;32(8):1285-1291. PMID: 24846344
138. Ravi P, Karakiewicz PI, Roghmann F, Gandaglia G, **Choueiri TK**, Menon M, McKay RR, Nguyen PL, Sammon JD, Sukumar S, Varda B, Chang SL, Kibel AS, Sun M, Trinh QD. Mental health outcomes in elderly men with prostate cancer. *Urol Oncol.* 2014 Nov;32(8):1333-1340. PMID: 25153773
139. **Choueiri TK**, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S. PD-L1 expression in nonclear-cell renal cell carcinoma. *Ann Oncol.* 2014 Nov;25(11):2178-2184. PMID: 25193987, PMCID: PMC4288138
140. Gandaglia G, Sun M, Hu JC, Novara G, **Choueiri TK**, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. *Eur Urol.* 2014 Dec;66(6):1125-1132. PMID: 24495466
141. Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, **Choueiri TK**, Hakimi AA, Hsieh JJ. Genomic investigation of etiologic heterogeneity: methodologic challenges. *BMC Med Res Methodol.* 2014 Dec 22;14:138. PMID: 25532962.
142. Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, **Choueiri TK**, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, Rathmell WK. Expression of ror2 mediates invasive

phenotypes in renal cell carcinoma. PLOS One. 2014;9(12):e116101. PMID: 25542006, PMCID: PMC4277431

143. Pal SK, He M, Tong T, Wu H, Liu X, Lau C, Wang JH, Warden C, Wu X, Signoretti S, **Choueiri TK**, Karam JA, Jones JO. RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res. 2015 Jan;13(1):130-137. PMID: 25183163, PMCID: PMC4608366
144. Hamnvik OP, **Choueiri TK**, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD, Williams JS. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015 Jan 15;121(2):311-319. PMID: 25236375, PMCID: PMC4293233
145. Ziehr DR, Mahal BA, Aizer AA, Hyatt AS, Beard CJ, D'Amico AV, **Choueiri TK**, Elfiky A, Lathan CS, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan;33(1):18.e7-18.e13. PMID: 25306287
146. Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, **Choueiri TK**. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015 Jan 20;112(2):296-305. PMID: 25349964, PMCID: PMC4453446
147. Roghmann F, Antczak C, McKay RR, **Choueiri T**, Hu JC, Kibel AS, Kim SP, Kowalczyk KJ, Menon M, Nguyen PL, Saad F, Sammon JD, Schmid M, Sukumar S, Sun M, Noldus J, Trinh QD. The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urol Oncol. 2015 Jan;33(1):17.e9-17.e18. PMID: 25443265
148. Aizer AA, Gu X, Chen MH, **Choueiri TK**, Martin NE, Efstathiou JA, Hyatt AS, Graham PL, Trinh QD, Hu JC, Nguyen PL. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw. 2015 Jan;13(1):61-68. PMID: 25583770
149. Pond GR, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, **Choueiri TK**, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougerey R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G. Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design. Clin Genitourin Cancer. 2015 Feb;13(1):71-79. PMID: 24993933
150. Mahal BA, Inverso G, Aizer AA, Ziehr DR, Hyatt AS, **Choueiri TK**, Hoffman KE, Hu JC, Beard CJ, D'Amico AV, Martin NE, Orzio PF 3rd, Trinh QD, Nguyen PL. Incidence

and Determinants of 1-Month Mortality after Cancer-Directed Surgery. *Ann Oncol*. 2015 Feb;26(2):399-406. PMID: 25430935

151. Sammon JD, McKay RR, Kim SP, Sood A, Sukumar S, Hayn MH, Hu JC, Kibel AS, Nguyen PL, Peabody JO, Saad F, Sun M, Varda B, Menon M, **Choueiri TK**, Trinh QD. Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. *Urology*. 2015 Feb;85(2):343-349. PMID: 25623683
152. Fay AP, Signoretti S, Callea M, Teló GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, **Choueiri TK**. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. *J Immunother Cancer*. 2015;3:3. PMID: 25767716, PMCID: PMC4357210
153. **Choueiri TK**, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C, Benson P, Ho TH, Pandite L, de Souza P, Powles T, Motzer RJ. Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. *Clin Cancer Res*. 2015 Mar 1;21(5):1071-1077. PMID: 25538263
154. Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, **Choueiri TK**, Freeman G, Pal S. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. *J Biol Chem*. 2015 Mar 27;290(13):8110-8120. PMID: 25645920, PMCID: PMC4375468
155. Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, **Choueiri TK**, Heng DY. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. *Lancet Oncol*. 2015 Mar;16(3):293-300. PMID: 25681967
156. Xu CF, Johnson T, Garcia-Donas J, **Choueiri TK**, Sternberg CN, Davis ID, Bing N, Deen KC, Xue Z, McCann L, Esteban E, Whittaker JC, Spraggs CF, Rodríguez-Antona C, Pandite LN, Motzer RJ. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. *Br J Cancer*. 2015 Mar 31;112(7):1190-1198. PMID: 25695485, PMCID: PMC4385958
157. Krajewski KM, Nishino M, Ramaiya NH, **Choueiri TK**. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. *AJR Am J Roentgenol*. 2015 Mar;204(3):W282-W288. PMID: 25714313, PMCID: PMC4352691

158. Kyriakopoulos CE, Chittoria N, **Choueiri TK**, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI. Outcome of Patients with Metastatic Sarcomatoid Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Clin Genitourin Cancer*. 2015 Apr;13(2):e79-e85. PMID: 25450036
159. Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, **Choueiri TK**, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougerey R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. *Clin Genitourin Cancer*. 2015 Apr;13(2):185-192. PMID: 25458370
160. Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishampayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, **Choueiri TK**, Heng DY. Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. *Clin Genitourin Cancer*. 2015 Apr;13(2):150-155. PMID: 25458371
161. Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, Taplin ME, **Choueiri TK**, Hodi FS, Freeman GJ, Signoretti S. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. *Ann Oncol*. 2015 Apr;26(4):812-817. PMID: 25600565
162. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, **Choueiri TK**, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. *Lancet Oncol*. 2015 Apr;16(4):426-435. PMID: 25795408
163. Grünwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, **Choueiri TK**. Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma. *Eur Urol*. 2015 May;67(5):952-958. PMID: 25577718, PMCID: PMC4570832
164. Sonpavde G, Pond GR, Mullane S, Qu AQ, Di Lorenzo G, Federico P, Necchi A, Rosenberg JE, Bellmunt J, **Choueiri TK**. Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. *Clin Genitourin Cancer*. 2015 Jun;13(3):250-256. PMID: 25481485

165. Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, **Choueiri TK**, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF 3rd, Trinh QD, Nguyen PL. Who bears the greatest burden of aggressive treatment of indolent prostate cancer?. *Am J Med.* 2015 Jun;128(6):609-616. PMID: 25644324
166. Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, **Choueiri TK**, Loda M, Stack E, Rosenberg J. HER2 as a target in invasive urothelial carcinoma. *Cancer Med.* 2015 Jun;4(6):844-852. PMID: 25720673, PMCID: PMC4472207
167. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R, **Choueiri TK**. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. *Clin Cancer Res.* 2015 Jun 1;21(11):2471-2479. PMID: 25724518, PMCID: PMC4566854
168. Trinh QD, Nguyen PL, Leow JJ, Dalela D, Chao GF, Mahal BA, Nayak M, Schmid M, **Choueiri TK**, Aizer AA. Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. *J Natl Cancer Inst.* 2015 Jun;107(6):djv054. PMID: 25794888
169. McDermott DF, Drake CG, Sznol M, **Choueiri TK**, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, Pardoll DM, Wigginton JM, Kollia GD, Gupta A, McDonald D, Sankar V, Sosman JA, Atkins MB. Survival, Durable Response, and Long-Term Safety in Patients with Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. *J Clin Oncol.* 2015 Jun 20;33(18):2013-2020. PMID: 25800770, PMCID: PMC4517051
170. Bellmunt J, Werner L, Leow JJ, Mullane SA, Fay AP, Riester M, Van Hummelen P, Taplin ME, **Choueiri TK**, Van Allen E, Rosenberg J. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. *PLOS One.* 2015;10(6):e0124711. PMID: 26039708, PMCID: PMC4454515
171. Sammon JD, Abdollah F, Reznor G, Pucheril D, **Choueiri TK**, Hu JC, Kim SP, Schmid M, Sood A, Sun M, Kibel AS, Nguyen PL, Menon M, Trinh QD. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. *Eur Urol.* 2015 Jul;68(1):32-39. PMID: 25457017
172. Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezoslosky MD, **Choueiri TK**, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3

prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. *Urol Oncol*. 2015 Jul;33(7):330.e19-330.e25. PMID: 25990612

173. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, **Choueiri TK**, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. *J Urol*. 2015 Aug;194(2):343-349. PMID: 25681290
174. Ghatalia P, Je Y, Nguyen PL, Trinh QD, **Choueiri TK**, Sonpavde G. Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol*. 2015 Aug;95(2):251-263. PMID: 25900071
175. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, **Choueiri TK**, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. *BJU Int*. 2015 Sep;116(3):358-365. PMID: 25124891
176. Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, **Choueiri TK**, Heng DY. Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. *Eur Urol*. 2015 Sep;68(3):506-515. PMID: 25524810
177. Abdollah F, Sammon JD, Majumder K, Reznor G, Gandaglia G, Sood A, Hevelone N, Kibel AS, Nguyen PL, **Choueiri TK**, Selvaggi KJ, Menon M, Trinh QD. Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. *J Natl Compr Canc Netw*. 2015 Sep;13(9):1131-1138. PMID: 26358797
178. Anderson JC, Willey CD, Mehta A, Welaya K, Chen D, Duarte CW, Ghatalia P, Arafat W, Madan A, Sudarshan S, Naik G, Grizzle WE, **Choueiri TK**, Sonpavde G. High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. *PLoS One*. 2015;10(9):e0139267. PMID: 26406598, PMCID: PMC4583516
179. Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, **Choueiri TK**, McDermott DF, Freeman GJ, Signoretti S. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell

Renal Cell Carcinoma. *Cancer Immunol Res.* 2015 Oct;3(10):1158-1164. PMID: 26014095, PMCID: PMC4596765

180. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, **Choueiri TK**. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. *Cancer.* 2015 Oct 1;121(19):3435-3443. PMID: 26058385
181. Atkins MB, Gravis G, Drosik K, Demkow T, Tomczak P, Wong SS, Michaelson MD, **Choueiri TK**, Wu B, Navale L, Warner D, Ravaud A. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. *J Clin Oncol.* 2015 Oct 20;33(30):3431-3438. PMID: 26304872
182. Abdollah F, Sammon JD, Reznor G, Sood A, Schmid M, Klett DE, Sun M, Aizer AA, **Choueiri TK**, Hu JC, Kim SP, Kibel AS, Nguyen PL, Menon M, Trinh QD. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged 66 years. *Eur J Surg Oncol.* 2015 Nov;41(11):1529-1539. PMID: 26210655
183. Allard CB, Gelpi-Hammerschmidt F, Harshman LC, **Choueiri TK**, Faiena I, Modi P, Chung BI, Tinay I, Singer EA, Chang SL. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. *Urol Oncol.* 2015 Nov;33(11):496.e11-496.e16. PMID: 26210683, PMCID: PMC5178830
184. Markt SC, Shui IM, Unger RH, Urun Y, Berg CD, Black A, Brennan P, Bueno-de-Mesquita HB, Gapstur SM, Giovannucci E, Haiman C, Henderson B, Hoover RN, Hunter DJ, Key TJ, Khaw KT, Canzian F, Larranga N, Le Marchand L, Ma J, Naccarati A, Siddiq A, Stampfer MJ, Stattin P, Stevens VL, Stram DO, Tjønneland A, Travis RC, Trichopoulos D, Ziegler RG, Lindstrom S, Kraft P, Mucci LA, **Choueiri TK**, Wilson KM. ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). *Prostate.* 2015 Nov;75(15):1677-1681. PMID: 26268879, PMCID: PMC4578997
185. Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DY, Dariane C, DeVelasco G, Lester R, Escudier B, **Choueiri TK**. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. *Eur J Cancer.* 2015 Nov;51(17):2580-2586. PMID: 26346135
186. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, **Choueiri TK**, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P,

CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2015 Nov 5;373(19):1803-1813. PMID: 26406148, PMCID: PMC5719487

187. **Choueiri TK**, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2015 Nov 5;373(19):1814-1823. PMID: 26406150, PMCID: PMC5024539
188. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Taberero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, **Choueiri TK**, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. *Cancer Discov*. 2015 Nov;5(11):1164-1177. PMID: 26410082, PMCID: PMC4916970
189. Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, **Choueiri TK**, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. *Int J Radiat Oncol Biol Phys*. 2015 Nov 15;93(4):828-835. PMID: 26530751
190. Sammon JD, Abdollah F, **Choueiri TK**, Kantoff PW, Nguyen PL, Menon M, Trinh QD. Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. *JAMA*. 2015 Nov 17;314(19):2077-2079. PMID: 26575066
191. Schmid M, Ghani KR, **Choueiri TK**, Sood A, Kapoor V, Abdollah F, Chun FK, Leow JJ, Olugbade K Jr, Sammon JD, Menon M, Kibel AS, Fisch M, Nguyen PL, Trinh QD. An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer. *BJU Int*. 2015 Dec;116(6):911-919. PMID: 25099032
192. Muralidhar V, Ziehr DR, Mahal BA, Chen YW, Nezoslosky MD, Viswanathan VB, **Choueiri TK**, Sweeney CJ, Trinh QD, Nguyen PL. Association Between Older Age and Increasing Gleason Score. *Clin Genitourin Cancer*. 2015 Dec;13(6):525-530.e1. PMID: 26119229
193. Pucheril D, Sammon JD, Sood A, Abdollah F, **Choueiri TK**, Meyer C, Hanske J, Kim SP, Nguyen PL, Kibel AS, Weissman JS, Menon M, Trinh QD. Contemporary

nationwide patterns of self-reported prostate-specific antigen screening in US veterans. *Urol Oncol*. 2015 Dec;33(12):503.e7-503.15. PMID: 26319352

194. Cole AP, Dalela D, Hanske J, Mullane SA, **Choueiri TK**, Meyer CP, Nguyen PL, Menon M, Kibel AS, Preston MA, Bellmunt J, Trinh QD. Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. *Urol Oncol*. 2015 Dec;33(12):504.e9-504.17. PMID: 26320810
195. Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, **Choueiri TK**, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T, DATECAN Renal Cancer group. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. *Ann Oncol*. 2015 Dec;26(12):2392-2398. PMID: 26371288
196. Dinh KT, Muralidhar V, Mahal BA, Chen YW, Nezoslosky MD, Beard CJ, **Choueiri TK**, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Occult High-Risk Disease in Clinically Low-Risk Prostate Cancer with 50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. *Urology*. 2016 Jan;87:125-132. PMID: 26391387
197. Schmid M, Meyer CP, Reznor G, **Choueiri TK**, Hanske J, Sammon JD, Abdollah F, Chun FK, Kibel AS, Tucker-Seeley RD, Kantoff PW, Lipsitz SR, Menon M, Nguyen PL, Trinh QD. Racial Differences in the Surgical Care of Medicare Beneficiaries with Localized Prostate Cancer. *JAMA Oncol*. 2016 Jan;2(1):85-93. PMID: 26502115, PMCID: PMC5018381
198. de Velasco G, Krajewski KM, Albiges L, Awad MM, Bellmunt J, Hodi FS, **Choueiri TK**. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. *Cancer Immunol Res*. 2016 Jan;4(1):12-17. PMID: 26589768
199. McKay RR, Lin X, Albiges L, Fay AP, Kaymakcalan MD, Mickey SS, Ghoroghchian PP, Bhatt RS, Kaffenberger SD, Simantov R, **Choueiri TK**, Heng DY. Statins and survival outcomes in patients with metastatic renal cell carcinoma. *Eur J Cancer*. 2016 Jan;52:155-162. PMID: 26687834
200. Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, **Choueiri TK**, Necchi A, Di Lorenzo G, Bellmunt J. Improved 5-factor prognostic classification of patients receiving

salvage systemic therapy for advanced urothelial carcinoma. *J Urol*. 2016 Feb;195(2):277-282. PMID: 26292040, PMCID: PMC5025874

201. Nezoslosky MD, Dinh KT, Muralidhar V, Mahal BA, Chen YW, Beard CJ, **Choueiri TK**, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. *Urol Oncol*. 2016 Feb;34(2):57.e15-57.e22. PMID: 26476663
202. Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R, Sankin AI, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, **Choueiri TK**, Hsieh JJ, Klein RJ. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. *Cancer*. 2016 Feb 1;122(3):402-410. PMID: 26505625, PMCID: PMC4803437
203. Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, **Choueiri TK**. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Cancer*. 2016 Feb 1;122(3):411-419. PMID: 26540173
204. Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaiparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, **Choueiri TK**, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. *Cell Rep*. 2016 Mar 15;14(10):2476-2489. PMID: 26947078, PMCID: PMC4794376
205. Sonpavde G, Pond GR, **Choueiri TK**, Mullane S, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Buonerba C, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, Bellmunt J. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. *Eur Urol*. 2016 Apr;69(4):634-641. PMID: 26264159
206. Sammon JD, Dalela D, Abdollah F, **Choueiri TK**, Han PK, Hansen M, Nguyen PL, Sood A, Menon M, Trinh QD. Determinants of Prostate Specific Antigen Screening Among Black Men in the United States in the Contemporary Era. *J Urol*. 2016 Apr;195(4 Pt 1):913-918. PMID: 26598427

207. Sun M, **Choueiri TK**, Hamnvik OP, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. *JAMA Oncol.* 2016 Apr;2(4):500-507. PMID: 26720632
208. Meyer CP, Allard CB, Sammon JD, Hanske J, McNabb-Baltar J, Goldberg JE, Reznor G, Lipsitz SR, **Choueiri TK**, Nguyen PL, Weissman JS, Trinh QD. The impact of Medicare eligibility on cancer screening behaviors. *Prev Med.* 2016 Apr;85:47-52. PMID: 26763164
209. Abdollah F, Sun M, Sammon JD, **Choueiri TK**, Menon M, Weissman JS, Trinh QD. Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States: A Nationwide Survey Analysis. *JAMA Oncol.* 2016 Apr;2(4):543-545. PMID: 26794060
210. Muralidhar V, Catalano PJ, Reznor G, Mahal BA, **Choueiri TK**, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezoslosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. *J Natl Compr Canc Netw.* 2016 Apr;14(4):421-428. PMID: 27059190
211. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, **Choueiri TK**. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. *Eur Urol.* 2016 May;69(5):866-874. PMID: 26626617, PMCID: PMC4879109
212. Chao GF, Krishna N, Aizer AA, Dalela D, Hanske J, Li H, Meyer CP, Kim SP, Mahal BA, Reznor G, Schmid M, **Choueiri TK**, Nguyen PL, O'Leary M, Trinh QD. Asian Americans and prostate cancer: A nationwide population-based analysis. *Urol Oncol.* 2016 May;34(5):233.e7-233.15. PMID: 26725248
213. Kwiatkowski DJ, **Choueiri TK**, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen E, Krajewski KM, Porta C, Pal S, Bellmunt J, McDermott DF, Heng DY, Gray KP, Signoretti S. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. *Clin Cancer Res.* 2016 May 15;22(10):2445-2452. PMID: 26831717, PMCID: PMC4976069
214. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, **Choueiri TK**, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes

R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet*. 2016 May 14;387(10032):2008-2016. PMID: 26969090, PMCID: PMC4878938

215. Wang J, Papanicolau-Sengos A, Chintala S, Wei L, Liu B, Hu Q, Miles KM, Conroy JM, Glenn ST, Costantini M, Magi-Galluzzi C, Signoretti S, **Choueiri T**, Gallucci M, Sentinelli S, Fazio VM, Poeta ML, Liu S, Morrison C, Pili R. Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. *Oncotarget*. 2016 May 24;7(21):29901-29915. PMID: 27144525, PMCID: PMC5058651
216. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, **Choueiri TK**, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MCBV, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA, Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RGW. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. *Cancer Cell*. 2016 May 9;29(5):723-736. PMID: 27165744, PMCID: PMC4864952
- Erratum in: *Cancer Cell* 2016 Aug 8;30(2):363. PMID: 27505681.
217. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezoslosky MD, Beard CJ, **Choueiri TK**, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Risk of prostate cancer mortality in men with a history of prior cancer. *BJU Int*. 2016 Jun;117(6B):E20-E28. PMID: 25845283
218. Meyer CP, Allard CB, Sammon JD, Hanske J, McNabb-Baltar J, Goldberg JE, Reznor G, Lipsitz SR, **Choueiri TK**, Nguyen PL, Weissman JS, Trinh QD. Data on Medicare eligibility and cancer screening utilization. *Data Brief*. 2016 Jun;7:679-681. PMID: 27054176, PMCID: PMC4802418
219. Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezoslosky MD, **Choueiri TK**, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. *J Clin Oncol*. 2016 Jun 1;34(16):1905-1912. PMID: 27069075, PMCID: PMC4966343
220. Mullane SA, Werner L, Rosenberg J, Signoretti S, Callea M, **Choueiri TK**, Freeman GJ, Bellmunt J. Correlation of Apobec Mrna Expression with overall Survival and pd-11 Expression in Urothelial Carcinoma. *Sci Rep*. 2016 Jun 10;6:27702. PMID: 27283319, PMCID: PMC4901342

221. Bellmunt J, Zhou CW, Mullane SA, Werner L, Taplin ME, Fay AP, **Choueiri TK**, Orsola A, Takeda DY, Hahn WC, Kim J, Sonpavde G, Bowden M. Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. *Br J Cancer*. 2016 Jun 28;115(1):12-19. PMID: 27351382, PMCID: PMC4931368
222. Ho TH, **Choueiri TK**, Wang K, Karam JA, Chalmers Z, Frampton G, Elvin JA, Johnson A, Liu X, Lin Y, Joseph RW, Stanton ML, Miller VA, Stephens PJ, Ross JS, Ali SM, Pal SK. Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. *Eur Urol Focus*. 2016 Jun;2(2):204-209. PMID: 28723536
223. Mahal BA, Muralidhar V, Chen YW, **Choueiri TK**, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Trinh QD, Nguyen PL. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. *BJU Int*. 2016 Jul;118(1):95-9101. PMID: 26207642
224. Li B, Li T, Pignon JC, Wang B, Wang J, Shukla SA, Dou R, Chen Q, Hodi FS, **Choueiri TK**, Wu C, Hacohen N, Signoretti S, Liu JS, Liu XS. Landscape of tumor-infiltrating T cell repertoire of human cancers. *Nat Genet*. 2016 Jul;48(7):725-732. PMID: 27240091, PMCID: PMC5298896
225. **Choueiri TK**, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016 Jul;17(7):917-927. PMID: 27279544
226. Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, **Choueiri TK**. Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma. *J Natl Compr Canc Netw*. 2016 Jul;14(7):820-824. PMID: 27407122, PMCID: PMC5582541
227. Muralidhar V, Mahal BA, Nezoslosky MD, Beard CJ, Feng FY, Martin NE, Efstathiou JA, **Choueiri TK**, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. *BJU Int*. 2016 Aug;118(2):279-285. PMID: 26235660
228. Dalela D, Krishna N, Okwara J, Preston MA, Abdollah F, **Choueiri TK**, Reznor G, Sammon JD, Schmid M, Kibel AS, Nguyen PL, Menon M, Trinh QD. Suicide and

accidental deaths among patients with non-metastatic prostate cancer. *BJU Int.* 2016 Aug;118(2):286-297. PMID: 26305451

229. Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, **Choueiri TK**, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. *Clin Genitourin Cancer.* 2016 Aug;14(4):e299-e305. PMID: 26778006
230. Mullane SA, Werner L, Guancial EA, Lis RT, Stack EC, Loda M, Kantoff PW, **Choueiri TK**, Rosenberg J, Bellmunt J. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. *Clin Genitourin Cancer.* 2016 Aug;14(4):352-359. PMID: 26778300, PMCID: PMC5508512
231. Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, Broom R, Fay AP, Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, Kanesvaran R, Alimohamed N, Hermanns T, Wells JC, Amir E, **Choueiri TK**, Heng DY. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. *Eur Urol.* 2016 Aug;70(2):358-364. PMID: 26924770
232. Mahoney KM, Jacobus S, Bhatt RS, Song J, Carvo I, Cheng SC, Simpson M, Fay AP, Puzanov I, Michaelson MD, Atkins MB, McDermott DF, Signoretti S, **Choueiri TK**. Phase 2 Study of Bevacizumab and Temezirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer.* 2016 Aug;14(4):304-313.e6. PMID: 27036973
233. McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, **Choueiri TK**. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. *Cancer.* 2016 Aug 1;122(15):2389-2398. PMID: 27198170, PMCID: PMC5567751
234. Hanske J, Meyer CP, Sammon JD, **Choueiri TK**, Menon M, Lipsitz SR, Noldus J, Nguyen PL, Sun M, Trinh QD. The Influence of Marital Status on the Use of Breast, Cervical, and Colorectal Cancer Screening. *Prev Med.* 2016 Aug;89:140-145. PMID: 27215758

235. Trinh QD, Li H, Meyer CP, Hanske J, **Choueiri TK**, Reznor G, Lipsitz SR, Kibel AS, Han PK, Nguyen PL, Menon M, Sammon JD. Determinants of cancer screening in Asian-Americans. *Cancer Causes Control*. 2016 Aug;27(8):989-998. PMID: 27372292
236. Pal SK, **Choueiri TK**, Wang K, Khaira D, Karam JA, Van Allen E, Palma NA, Stein MN, Johnson A, Squillace R, Elvin JA, Chmielecki J, Yelensky R, Yakirevich E, Lipson D, Lin DI, Miller VA, Stephens PJ, Ali SM, Ross JS. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. *Eur Urol*. 2016 Sep;70(3):516-521. PMID: 26149668
237. Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, de Velasco G, Trinh QD, **Choueiri TK**. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. *J Clin Oncol*. 2016 Sep 20;34(27):3267-3275. PMID: 27325852, PMCID: PMC5024547
238. Ruiz-Morales JM, Swierkowski M, Wells JC, Fracon AP, Pasini F, Donskov F, Bjarnason GA, Lee JL, Sim HW, Sliwczynsk A, Ptak-Chmielewska A, Teter Z, Beuselinck B, Wood LA, Yuasa T, Pezaro C, Rini BI, Szczylik C, **Choueiri TK**, Heng DY. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur J Cancer*. 2016 Sep;65:102-108. PMID: 27487293
239. Cole AP, Leow JJ, Chang SL, Chung BI, Meyer CP, Kibel AS, Menon M, Nguyen PL, **Choueiri TK**, Reznor G, Lipsitz SR, Sammon JD, Sun M, Trinh QD. Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. *J Urol*. 2016 Oct;196(4):1090-1095. PMID: 27157376
240. Seisen T, Sun M, Leow JJ, Preston MA, Cole AP, Gelpi-Hammerschmidt F, Hanna N, Meyer CP, Kibel AS, Lipsitz SR, Nguyen PL, Bellmunt J, **Choueiri TK**, Trinh QD. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. *J Clin Oncol*. 2016 Oct 10;34(29):3529-3536. PMID: 27269944
241. de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, **Choueiri TK**. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. *Cancer Immunol Res*. 2016 Oct;4(10):820-822. PMID: 27538576, PMCID: PMC5050137
242. Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco

- G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, **Choueiri TK**. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. *J Clin Oncol*. 2016 Oct 20;34(30):3655-3663. PMID: 27601543, PMCID: PMC5065111
243. **Choueiri TK**, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. *Clin Cancer Res*. 2016 Nov 15;22(22):5461-5471. PMID: 27169994, PMCID: PMC5106340
244. Mahal BA, Chen YW, Muralidhar V, Mahal AR, **Choueiri TK**, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. *Cancer*. 2016 Nov 15;122(21):3371-3377. PMID: 27434225
245. Chen YW, Muralidhar V, Mahal BA, Nezoslosky MD, Beard CJ, **Choueiri TK**, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. *Brachytherapy*. 2016 Nov - Dec;15(6):695-700. PMID: 27528590, [https://doi.org/S1538-4721\(16\)30506-2](https://doi.org/S1538-4721(16)30506-2)
246. Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovskaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, **Choueiri TK**, Hsieh JJ, Sander C, Hakimi AA. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. *Genome Biol*. 2016 Nov 17;17(1):231. PMID: 27855702, PMCID: PMC5114739
- Erratum in *Genome Biol*. 2017 Mar 1;18(1):46. PMID: 28249590.
247. Sonpavde G, Pond GR, Di Lorenzo G, Buonerba C, Rozzi A, Lanzetta G, Necchi A, Giannatempo P, Raggi D, Matsumoto K, **Choueiri TK**, Mullane S, Niegisch G, Albers P, Lee JL, Kitamura H, Kume H, Bellmunt J. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. *Clin Genitourin Cancer*. 2016 Dec;14(6):494-498. PMID: 27262369
248. de Velasco G, Gray KP, Hamieh L, Urun Y, Carol HA, Fay AP, Signoretti S, Kwiatkowski DJ, McDermott DF, Freedman M, Pomerantz MM, **Choueiri TK**.

Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. *Eur Urol Focus*. 2016 Dec 15;2(6):633-639. PMID: 28723497, PMID: PMC5520643

249. Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, Agarwal N, Ernst DS, Pal SK, Wood LA, Bamias A, Alva AS, Kanavaras R, **Choueiri TK**, Heng DY. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur Urol*. 2017 Feb;71(2):204-209. PMID: 27318422
250. **Choueiri TK**, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. *J Clin Oncol*. 2017 Feb 20;35(6):591-597. PMID: 28199818, PMID: PMC5455807
251. Speed JM, Trinh QD, **Choueiri TK**, Sun M. Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. *Curr Urol Rep*. 2017 Feb;18(2):15. PMID: 28213859
252. Seisen T, Krasnow RE, Bellmunt J, Rouprêt M, Leow JJ, Lipsitz SR, Vetterlein MW, Preston MA, Hanna N, Kibel AS, Sun M, **Choueiri TK**, Trinh QD, Chang SL. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. *J Clin Oncol*. 2017 Mar 10;35(8):852-860. PMID: 28045620
253. Jay R, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, **Choueiri TK**. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, **Choueiri TK**. *Cancer*. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503. *Urol Oncol*. 2017 Mar;35(3):117-118. PMID: 28159495
254. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, **Choueiri TK**, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF, KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *N Engl J Med*. 2017 Mar 16;376(11):1015-1026. PMID: 28212060, PMID: PMC5635424

255. de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, **Choueiri TK**. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. *Oncologist*. 2017 Mar;22(3):286-292. PMID: 28220024, PMCID: PMC5344647
256. Hamieh L, McKay RR, Lin X, Moreira RB, Simantov R, **Choueiri TK**. Effect of Metformin Use on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2017 Apr;15(2):221-229. PMID: 27460432
257. de Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, **Choueiri TK**. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. *Cancer Immunol Res*. 2017 Apr;5(4):312-318. PMID: 28246107, PMCID: PMC5418853
- Erratum in: *Cancer Immunol Res*. 2018 Apr;6(4):498-9. PMID: 29559478.
258. Seisen T, Jindal T, Karabon P, Sood A, Bellmunt J, Rouprêt M, Leow JJ, Vetterlein MW, Sun M, Alanee S, **Choueiri TK**, Trinh QD, Menon M, Abdollah F. Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. *Eur Urol*. 2017 May;71(5):714-718. PMID: 27912971
259. Connor Wells J, Donskov F, Fracon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, **Choueiri TK**, Heng DY. Characterizing the Outcomes of Metastatic Papillary Renal Cell Carcinoma. *Cancer Med*. 2017 May;6(5):902-909. PMID: 28414866, PMCID: PMC5430092
260. Mahal BA, Chen YW, Muralidhar V, Mahal AR, **Choueiri TK**, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. Racial Disparities in Prostate Cancer Outcome Among Prostate-Specific Antigen Screening Eligible Populations in the United States. *Ann Oncol*. 2017 May 1;28(5):1098-1104. PMID: 28453693
261. Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, **Choueiri TK**, Heng DY. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. *Eur Urol*. 2017 Jun;71(6):970-978. PMID: 27771126

262. Tripathi A, Jacobus S, Feldman H, **Choueiri TK**, Harshman LC. Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment with VEGF-directed Therapy. *Clin Genitourin Cancer*. 2017 Jun;15(3):396-402. PMID: 28040423
263. de Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanavarar R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DY, **Choueiri TK**. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2017 Jun;15(3):403-410.e2. PMID: 28254206
264. Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezoslosky MD, Vastola ME, King MT, Martin NE, Orio PF 3rd, **Choueiri TK**, Trinh QD, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. *Int J Radiat Oncol Biol Phys*. 2017 Jun 1;98(2):338-343. PMID: 28463152
265. Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, **Choueiri TK**, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. *Cancer Cell*. 2017 Jun 12;31(6):820-832.e3. PMID: 28528867, PMCID: PMC5502825
266. Scelo G, Purdie MP, Brown KM, Johansson M, Wang Z, Eckel-Passow JE, Ye Y, Hofmann JN, Choi J, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Sampson JN, Abedi-Ardekani B, Besse C, Blanche H, Boland A, Burdette L, Chabrier A, Durand G, Le Calvez-Kelm F, Prokhorchouk E, Robinot N, Skryabin KG, Wozniak MB, Yeager M, Basta-Jovanovic G, Dzamic Z, Foretova L, Holcatova I, Janout V, Mates D, Mukeriyana A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jirina V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Baglietto L, Boeing H, Khaw KT, Weiderpass E, Ljungberg B, Sitaram RT, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L,

- Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, **Choueiri TK**, Mark Lathrop G, Rothman N, Deleuze JF, McKay JD, Parker AS, Wu X, Houlston RS, Brennan P, Chanock SJ. Genome-wide association study identifies multiple risk loci for renal cell carcinoma. *Nat Commun*. 2017 Jun 9;8:15724. PMID: 28598434, PMCID: PMC5472706
267. Harshman LC, Drake CG, Haas NB, Manola J, Puligandla M, Signoretti S, Cella D, Gupta RT, Bhatt R, Van Allen E, Lara P, **Choueiri TK**, Kapoor A, Heng DYC, Shuch B, Jewett M, George D, Michaelson D, Carducci MA, McDermott D, Allaf M. Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward. *Kidney Cancer*. 2017 Jul 26;1(1):31-40. PMID: 30334002, PMCID: PMC6179104
268. Yip SM, Ruiz Morales JM, Donskov F, Fraccon A, Basso U, Rini BI, Lee JL, Bjarnason GA, Sim HW, Beuselinck B, Kanesvaran R, Brugarolas J, Koutsoukos K, Fu SYF, Yuasa T, Davis I, Alva A, Kollmannsberger C, **Choueiri TK**, Heng DYC. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). *Kidney Cancer*. 2017 Jul 26;1(1):41-47. PMID: 30334003, PMCID: PMC6179119
269. Meyer CP, Sun M, Karam JA, Leow JJ, de Velasco G, Pal SK, Chang SL, Trinh QD, **Choueiri TK**. Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. *Eur Urol*. 2017 Aug;72(2):171-174. PMID: 28359734
270. Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, **Choueiri TK**, Gibbons DL, Ittmann M, Creighton CJ. Pan-Urologic Cancer Genomic Subtypes that Transcend Tissue of Origin. *Nat Commun*. 2017 Aug 4;8(1):199. PMID: 28775315, PMCID: PMC5543131
271. Vetterlein MW, Seisen T, Leow JJ, Preston MA, Sun M, Friedlander DF, Meyer CP, Chun FK, Lipsitz SR, Menon M, Kibel AS, Bellmunt J, **Choueiri TK**, Trinh QD. Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-Invasive Urinary Bladder Cancer. *Clin Genitourin Cancer*. 2017 Aug 24. PMID: 28899722
272. Hamieh L, McKay RR, Lin X, Simantov R, **Choueiri TK**. Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database. *Clin Genitourin Cancer*. 2017 Aug 12. PMID: 28918175
273. Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, **Choueiri TK**. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated

Results of a High-Risk Subset of the ASSURE Randomized Trial. *JAMA Oncol.* 2017 Sep 1;3(9):1249-1252. PMID: 28278333, PMCID: PMC5591751

274. Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, **Choueiri TK**, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, George S. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. *Eur Urol.* 2017 Sep;72(3):368-376. PMID: 28410865
275. Yang DD, Muralidhar V, Mahal BA, Nezoslosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, **Choueiri TK**, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. Low Rates of Androgen Deprivation Therapy Use with Salvage Radiation Therapy in Patients with Prostate Cancer after Radical Prostatectomy. *Urol Oncol.* 2017 Sep;35(9):542.e25-542.e32. PMID: 28533151
276. **Choueiri TK**, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. *J Clin Oncol.* 2017 Sep 10;35(26):2993-3001. PMID: 28644771
277. Seisen T, Sun M, Lipsitz SR, Abdollah F, Leow JJ, Menon M, Preston MA, Harshman LC, Kibel AS, Nguyen PL, Bellmunt J, **Choueiri TK**, Trinh QD. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-Invasive Urothelial Carcinoma of the Bladder. *Eur Urol.* 2017 Oct;72(4):483-487. PMID: 28412065
278. Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, **Choueiri TK**. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. *Eur Urol.* 2017 Oct;72(4):557-564. PMID: 28413127
279. Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezoslosky MD, Efsthathiou JA, Beard CJ, Martin NE, Orio PF 3rd, Trinh QD, **Choueiri TK**, Sweeney CJ, Nguyen PL. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. *Clin Genitourin Cancer.* 2017 Oct;15(5):563-569.e3. PMID: 28462857
280. Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, **Choueiri TK**, de Torres I, Morote J, Freeman GJ, Signoretti S, Bellmunt J. Differential Expression of PD-L1 In High Grade T1 Vs Muscle Invasive Bladder Carcinoma And Its Prognostic Implications. *J Urol.* 2017 Oct;198(4):817-823. PMID: 28487100
281. Moreira RB, Debiassi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, Fay AP, Bellmunt J, **Choueiri TK**, Schutz FA. Differential side effects profile in patients with

mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. *Oncotarget*. 2017 Oct 13;8(48):84572-84578. PMID: 29137449, PMCID: PMC5663621

282. Lalani AA, Bossé D, McGregor BA, **Choueiri TK**. Immunotherapy in the Elderly. *Eur Urol Focus*. 2017 Oct;3(4-5):403-412. PMID: 29183736, [https://doi.org/S2405-4569\(17\)30264-X](https://doi.org/S2405-4569(17)30264-X)

283. Feldman AS, Meyer CP, Sanchez A, Krasnova A, Reznor G, Menon M, Kibel AS, **Choueiri TK**, Lipsitz SR, Sun M, Trinh QD. Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. *J Urol*. 2017 Nov;198(5):1061-1068. PMID: 28552709

284. Vetterlein MW, Wankowicz SAM, Seisen T, Lander R, Löppenberg B, Chun FK, Menon M, Sun M, Barletta JA, **Choueiri TK**, Bellmunt J, Trinh QD, Preston MA. Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer with Variant Histology. *Cancer*. 2017 Nov 15;123(22):4346-4355. PMID: 28743155

285. Machiela MJ, Hofmann JN, Carreras-Torres R, Brown KM, Johansson M, Wang Z, Foll M, Li P, Rothman N, Savage SA, Gaborieau V, McKay JD, Ye Y, Henrion M, Bruinsma F, Jordan S, Severi G, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Mannisto S, Weinstein S, Clark PE, Edwards TE, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Gaziano JM, Sesso HS, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Colli LM, Sampson JN, Besse C, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Mijuskovic M, Ognjanovic M, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Bueno-de-Mesquita HB, Canzian F, Duell EJ, Ljungberg B, Sitaram RT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Larkin J, **Choueiri TK**, Lathrop GM, Teh BT, Deleuze JF, Wu X, Houlston RS, Brennan P, Chanock SJ, Scelo G, Purdue MP. Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. *Eur Urol*. 2017 Nov;72(5):747-754. PMID: 28797570, PMCID: PMC5641242

Corrigendum in *Eur Urol*. 2018 Sep;74(3):e85-6. PMID: 29853305.

286. Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, **Choueiri TK**, Signoretti S. Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. *Oncotarget*. 2017 Nov 28;8(61):103428-103436. PMID: 29262573, PMCID: PMC5732739
287. de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, **Choueiri TK**. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. *Clin Genitourin Cancer*. 2017 Dec;15(6):652-660.e1. PMID: 28410911
288. Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, **Choueiri TK**. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2017 Dec;15(6):724-732. PMID: 28645482
289. Cole AP, Jiang W, Lipsitz SR, Learn PA, Sun M, **Choueiri TK**, Nguyen PL, Kibel AS, Menon M, Sammon JD, Koehlmoos T, Haider A, Trinh QD. The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE Military Database. *J Urol*. 2017 Dec;198(6):1295-1300. PMID: 28716650
290. Giles RH, **Choueiri TK**, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A. Recommendations for the Management of Rare Kidney Cancers. *Eur Urol*. 2017 Dec;72(6):974-983. PMID: 28720391
291. Sevillano E, Werner L, Bossé D, Lalani AA, Wankowicz SAM, de Velasco G, Farina M, Lundgren K, **Choueiri TK**, González Del Alba A, Bellmunt J. Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis. *Clin Genitourin Cancer*. 2017 Dec;15(6):e1089-e1094. PMID: 28864222
292. Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, **Choueiri TK**, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN, PROTECT investigators. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma. *J Clin Oncol*. 2017 Dec 10;35(35):3916-3923. PMID: 28902533, PMCID: PMC6018511
293. Urun Y, Leow JJ, Fay AP, Albiges L, **Choueiri TK**, Bellmunt J. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with

platinum based chemotherapy: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2017 Dec;120:120-126. PMID: 29198325

294. Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, **Choueiri TK**, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. *Eur Urol*. 2018 Jan;73(1):71-78. PMID: 28592388
295. Löppenber B, Friedlander DF, Krasnova A, Tam A, Leow JJ, Nguyen PL, Barry H, Lipsitz SR, Menon M, Abdollah F, Sammon JD, Sun M, **Choueiri TK**, Kibel AS, Trinh QD. Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer. *Cancer*. 2018 Jan 1;124(1):55-64. PMID: 28902401
296. Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, **Choueiri TK**. Change in Neutrophil-to-Lymphocyte Ratio (NLR) in Response to Immune Checkpoint Blockade for Metastatic Renal Cell Carcinoma. *J Immunother Cancer*. 2018 Jan 22;6(1):5. PMID: 29353553, PMCID: PMC5776777
297. Kamran SC, Seisen T, Markt SC, Preston MA, Trinh QD, Frazier LA, **Choueiri TK**, Martin NE, Nguyen PL, Beard CJ. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. *Eur Urol*. 2018 Feb;73(2):262-270. PMID: 28687143
298. Seisen T, Jamzadeh A, Leow JJ, Rouprêt M, Cole AP, Lipsitz SR, Kibel AS, Nguyen PL, Sun M, Menon M, Bellmunt J, **Choueiri TK**, Trinh QD. Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated with Neoadjuvant Chemotherapy. *JAMA Oncol*. 2018 Feb 1;4(2):225-229. PMID: 28837718, PMCID: PMC5838707
299. Yang DD, Krasnova A, Nead KT, **Choueiri TK**, Hu JC, Hoffman KE, Yu JB, Spratt DE, Feng FY, Trinh QD, Nguyen PL. Androgen Deprivation Therapy and Risk of Rheumatoid Arthritis in Patients with Localized Prostate Cancer. *Ann Oncol*. 2018 Feb 1;29(2):386-391. PMID: 29267861
300. Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME, Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG Jr, **Choueiri TK**, Van Allen EM. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science*. 2018 Feb 16;359(6377):801-806. PMID: 29301960, PMCID: PMC6035749

301. Friedlander DF, Trinh QD, Krasnova A, Lipsitz SR, Sun M, Nguyen PL, Kibel AS, **Choueiri TK**, Weissman JS, Menon M, Abdollah F. Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. *Eur Urol*. 2018 Mar;73(3):445-451. PMID: 28778619
302. Leow JJ, Cole AP, Seisen T, Bellmunt J, Mossanen M, Menon M, Preston MA, **Choueiri TK**, Kibel AS, Chung BI, Sun M, Chang SL, Trinh QD. Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. *Eur Urol*. 2018 Mar;73(3):374-382. PMID: 28803034
303. Seisen T, Vetterlein MW, Karabon P, Jindal T, Sood A, Nocera L, Nguyen PL, **Choueiri TK**, Trinh QD, Menon M, Abdollah F. Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. *Eur Urol*. 2018 Mar;73(3):452-461. PMID: 28890245
304. Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, **Choueiri TK**. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. *J Clin Oncol*. 2018 Mar 20;36(9):867-874. PMID: 29257710, PMCID: PMC5946714
305. Harshman LC, Xie W, Moreira RB, Bossé D, Ruiz Ares GJ, Sweeney CJ, **Choueiri TK**. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. *Cancer*. 2018 Mar 1;124(5):925-933. PMID: 29266178
306. Hanna N, Leow JJ, Sun M, Friedlander DF, Seisen T, Abdollah F, Lipsitz SR, Menon M, Kibel AS, Bellmunt J, **Choueiri TK**, Trinh QD. Comparative effectiveness of robot-assisted vs. open radical cystectomy. *Urol Oncol*. 2018 Mar;36(3):88.e1-88.e9. PMID: 29277584
307. Escudier B, Powles T, Motzer RJ, Olencki T, Arén Frontera O, Oudard S, Rolland F, Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J, Loughheed JC, Bracarda S, **Choueiri TK**. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. *J Clin Oncol*. 2018 Mar 10;36(8):765-772. PMID: 29309249, PMCID: PMC6804840
308. Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, **Choueiri TK**. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With

Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. *J Clin Oncol*. 2018 Mar 10;36(8):757-764. PMID: 29377755, PMCID: PMC6804841

309. Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE, Tarazi JC, Rosbrook B, Fernandez KC, Lechuga M, **Choueiri TK**. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. *Lancet Oncol*. 2018 Mar;19(3):405-415. PMID: 29439857, PMCID: PMC6860026
310. Stukalin I, Wells JC, Fracon, A, Pasini F, Pora C, Lalani AKA, Srinivas S, Bowman IA, Brugarolas J, Lee JL, Donskov F, Beuselinck B, Bamias A, Rini BI, Sim HW, Agarwal N, Rha SY, Kanavarar R, **Choueiri TK**, Heng DY. Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). *Kidney Cancer*. 2018 Mar 30;2(1):31-6. PMID: N/A.
311. Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homt Moreno B, Perini RF, **Choueiri TK**, Ribas A. Pembrolizumab Plus Pegylated Interferon Alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. *Clin Cancer Res*. 2018 Apr 15;24(8):1805-1815. PMID: 29358500
312. Viteri Malone MA, Ares GR, De Velasco G, Brandão R, Lin X, Norton C, Simantov R, Moslehi J, Krajewski KM, **Choueiri TK**, McKay RR. The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. *Clin Genitourin Cancer*. 2018 Apr;16(2):e327-e333. PMID: 29361425
313. Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, **Choueiri TK**. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. *Cancer Immunol Res*. 2018 Apr;6(4):402-408. PMID: 29437040
314. **Choueiri TK**, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI. Preliminary results for Avelumab plus Axitinib as First-Line Therapy in Patients with Advanced Clear-Cell Renal-Cell Carcinoma (JAVELIN Renal 100): an open-label, dose-finding

and dose-expansion, phase 1b trial. *Lancet Oncol.* 2018 Apr;19(4):451-460. PMID: 29530667

315. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, **Choueiri TK**, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med.* 2018 Apr 5;378(14):1277-1290. PMID: 29562145, PMCID: PMC5972549
316. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, **Choueiri TK**, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Rep.* 2018 Apr 3;23(1):313-326.e5. PMID: 29617669, PMCID: PMC6075733
- Erratum in *Cell Rep.* 2018 Jun 19;23(12):3698. PMID: 29925010.
317. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Peadarallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, **Choueiri TK**, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The Immune Landscape of Cancer. *Immunity.* 2018 Apr 17;48(4):812-830.e14. PMID: 29628290, PMCID: PMC5982584
318. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, **Choueiri TK**, Angell TE. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. *Thyroid.* 2018 Apr;28(4):445-453. PMID: 29652597
319. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, **Choueiri TK**, Angell TE. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor

Therapy in Advanced Nonthyroidal Cancer Patients. *Thyroid*. 2018 Apr;28(4):437-444. PMID: 29652599

320. Fletcher SA, Gild P, Cole AP, Vetterlein MW, Kibel AS, **Choueiri TK**, Sonpavde GP, Preston MA, Pucheril D, Menon M, Sun M, Lipsitz SR, Trinh QD. The Effect of Treatment at Minority-Serving Hospitals on Outcomes for Bladder Cancer. *Urol Oncol*. 2018 May;36(5):238.e7-238.e238.e17. PMID: 29454591

321. **Choueiri TK**, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-Free Survival by Independent Review and Overall Survival Update. *Eur J Cancer*. 2018 May;94:115-125. PMID: 29550566, PMCID: PMC6057479

Corrigendum in *Eur J Cancer*. 2018 Nov;103:287. PMID: 30270112.

322. Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, **Choueiri TK**, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. *Am J Med*. 2018 May;131(5):517-523. PMID: 29555248

323. Motzer RJ, Escudier B, Powles T, Scheffold C, **Choueiri TK**. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. *Br J Cancer*. 2018 May;118(9):1176-1178. PMID: 29576624, PMCID: PMC5943250

324. de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, **Choueiri TK**. Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. *Br J Cancer*. 2018 May;118(9):1238-1242. PMID: 29674707, PMCID: PMC5943584

325. Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, **Choueiri TK**. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). *Br J Cancer*. 2018 May;118(11):1434-1441. PMID: 29765151, PMCID: PMC5988804

326. Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, Lipsitz SR, Bellmunt J, Menon M, **Choueiri TK**, Abdollah F. Effectiveness of Neoadjuvant

Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol. 2018 May;1(1):83-90. PMID: 31100232

327. Nassar AH, Lundgren K, Pomerantz M, Van Allen E, Harshman L, Choudhury AD, Preston MA, Steele GS, Mouw KW, Wei XX, McGregor BA, **Choueiri TK**, Bellmunt J, Kwiatkowski DJ, Sonpavde GP. Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. *JCO Precis Oncol.* 2018;2. PMID: 33604498, PMCID: PMC7885955
328. Kuswanto WF, MacFarlane LA, Gedmintas L, Mulloy A, **Choueiri TK**, Bermas BL. Rheumatologic Symptoms in Oncologic Patients on PD-1 Inhibitors. *Semin Arthritis Rheum.* 2018 Jun;47(6):907-910. PMID: 29191375
329. Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, Ahern DK, Kibel AS, **Choueiri TK**, Trinh QD. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. *J Urol.* 2018 Jun;199(6):1417-25. PMID: 29410294, [https://doi.org/S0022-5347\(18\)30109-5](https://doi.org/S0022-5347(18)30109-5)
330. Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, **Choueiri TK**, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. *J Clin Oncol.* 2018 Jun 1;36(16):1579-1587. PMID: 29590008
- 331. McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer Immunol Res.** 2018 Jul;6(7):758-765. PMID: 29748390, PMCID: PMC6712567
332. Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orrio PF 3rd, **Choueiri TK**, Taplin ME, Trinh QD, Feng FY, Nguyen PL. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. *Eur Urol.* 2018 Aug;74(2):146-154. PMID: 29478736, PMCID: PMC6615042
333. Sonpavde G, Pond GR, Rosenberg JE, **Choueiri TK**, Bellmunt J, Regazzi AM, Mullane SA, Necchi A, Raggi D, Lee JL, Lee S, Simpson J, Derleth CL, Lin SW, Bajorin DF. Nomogram to Assess the Survival Benefit of New Salvage Agents for

Metastatic Urothelial Carcinoma in the Era of Immunotherapy. *Clin Genitourin Cancer*. 2018 Aug;16(4):e961-e967. PMID: 29706503, PMCID: PMC6697267

334. Bergerot PG, Bergerot CD, Dizman N, Zequi S, Fay A, Dara Y, Maia MC, Cotta BN, Gonçalves EP, Formiga MN, Tariki MS, Clavijo DA, **Choueiri TK**, Lopes G, Pal SK. Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. *J Glob Oncol*. 2018 Sep;4:1-8. PMID: 29281478, PMCID: PMC6180782
335. Gild P, Cole AP, Krasnova A, Dickerman BA, von Landenberg N, Sun M, Mucci LA, Lipsitz SR, Chun FK, Nguyen PL, Kibel AS, **Choueiri TK**, Basaria S, Trinh QD. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. *J Urol*. 2018 Sep;200(3):573-581. PMID: 29673944
336. McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, **Choueiri TK**. Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. *Clin Cancer Res*. 2018 Sep 1;24(17):4081-4088. PMID: 29848570, PMCID: PMC6688176
337. Thompson JA, Motzer RJ, Molina AM, **Choueiri TK**, Heath EI, Redman BG, Sangha RS, Ernst DS, Pili R, Kim SK, Reyno L, Wiseman A, Trave F, Anand B, Morrison K, Doñate F, Kollmannsberger CK. Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. *Clin Cancer Res*. 2018 Sep 15;24(18):4399-4406. PMID: 29848572, PMCID: PMC6731023
338. Sun M, Meyer CP, Karam JA, de Velasco G, Chang SL, Pal SK, Trinh QD, **Choueiri TK**. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. *Eur J Surg Oncol*. 2018 Sep;44(9):1439-1445. PMID: 29935840
339. Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, **Choueiri TK**, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. *Nat Genet*. 2018 Sep;50(9):1271-1281. PMID: 30150660, PMCID: PMC6119118
340. Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsens PF, Gross-Goupil M, Grande E, Suarez C, Markby DW, Arroyo A, Dean M, **Choueiri TK**, George D. Outcomes based on prior therapy in the phase 3

- METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. *Br J Cancer*. 2018 Sep;119(6):663-669. PMID: 30197417, PMCID: PMC6173766
341. Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, **Choueiri TK**, Rosenberg JE. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. *Br J Cancer*. 2018 Sep;119(6):707-712. PMID: 30220708, PMCID: PMC6173710
342. Fay AP, McKay RR, Lin X, Simantov R, **Choueiri TK**. Impact of Geographic Regions on Overall Survival in Patients with Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database. *J Glob Oncol*. 2018 Sep;4:1-14. PMID: 30241151, PMCID: PMC6223429
343. Hamieh L, **Choueiri TK**, Ogórek B, Khabibullin D, Rosebrock D, Livitz D, Fay A, Pignon JC, McDermott DF, Agarwal N, Gao W, Signoretti S, Kwiatkowski DJ. Mechanisms of Acquired Resistance to Rapalogs in Metastatic Renal Cell Carcinoma. *PLoS Genet*. 2018 Sep;14(9):e1007679. PMID: 30256787, PMCID: PMC6181431
344. Berg S, Cole AP, Fletcher SA, Pucheril D, Nabi J, Lipsitz SR, Chang SL, Sun M, Noldus J, Harshman LC, **Choueiri TK**, Trinh QD. Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. *Urol Oncol*. 2018 Sep;36(9):400.e15-400.e22. PMID: 30274640
345. Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, **Choueiri TK**, Heng DY. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Cancer*. 2018 Sep 15;124(18):3677-3683. PMID: 30307610
346. Gao X, Jegede O, Gray C, Catalano PJ, Novak J, Kwiatkowski DJ, McKay RR, George DJ, **Choueiri TK**, McDermott DF, Signoretti S, Bhatt RS. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2018 Oct;16(5):341-348. PMID: 29754934, PMCID: PMC6175670
347. Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, **Choueiri TK**, Bex A. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. *Eur Urol*. 2018 Nov;74(5):611-620. PMID: 29784193, PMCID: PMC7515772

348. Fletcher SA, Harmouch SS, Krimphove MJ, Cole AP, Berg S, Gild P, Preston MA, Sonpavde GP, Kibel AS, Sun M, **Choueiri TK**, Trinh QD. Characterizing Trends in Treatment Modalities for Localized Muscle-Invasive Bladder Cancer in the Pre-Immunotherapy Era. *World J Urol.* 2018 Nov;36(11):1767-1774. PMID: 29948050
349. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, **Choueiri TK**, Nickles D, Jhunjhunwala S, Piau-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med.* 2018 Dec;24(12):1941. PMID: 30291359
- Corrected and republished from: *Nat Med.* 2018 Jun;24(6):749-57. PMID: 29867230.
350. Gupta S, Cole AP, Marchese M, Wang Y, Speed JM, Fletcher SA, Nabi J, Berg S, Lipsitz SR, **Choueiri TK**, Chang SL, Kibel AS, Uhlig A, Trinh QD. Use of Preventive Health Services Among Cancer Survivors in the U.S. *Am J Prev Med.* 2018 Dec;55(6):830-838. PMID: 30352719
351. Voss MH, Reising A, Cheng Y, Patel P, Marker M, Kuo F, Chan TA, **Choueiri TK**, Hsieh JJ, Hakimi AA, Motzer RJ. Genomically Annotated Risk Model for Advanced Renal-Cell Carcinoma: A Retrospective Cohort Study. *Lancet Oncol.* 2018 Dec;19(12):1688-1698. PMID: 30416077, PMCID: PMC6701184
352. Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilén MA, Bosse D, Coulomb-L'hermine A, Su X, **Choueiri TK**, Tannir NM, Malouf GG. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders. *J Immunother Cancer.* 2018 Dec 27;6(1):159. PMID: 30591082, PMCID: PMC6307255
353. Lalani AA, McGregor BA, Albiges L, **Choueiri TK**, Motzer R, Powles T, Wood C, Bex A. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. *Eur Urol.* 2019 Jan;75(1):100-110. PMID: 30327274
354. McClintock TR, von Landenberg N, Cole AP, Lipsitz SR, Gild P, Sun M, Fletcher SA, Roghmann F, Menon M, Nguyen PL, Noldus J, **Choueiri TK**, Kibel AS, Trinh QD. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent

Trends in Utilization and Association with Postoperative Surgical Margin Status. *Ann Surg Oncol*. 2019 Jan;26(1):297-305. PMID: 30430324

355. Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, **Choueiri TK**, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. *Eur Urol*. 2019 Jan;75(1):35-41. PMID: 30554605
356. Johansson M, Carreras-Torres R, Scelo G, Purdue MP, Mariosa D, Muller DC, Timpson NJ, Haycock PC, Brown KM, Wang Z, Ye Y, Hofmann JN, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Garnier JG, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Radojevic-Skodric S, Ognjanovic S, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Benhamou S, Cancel-Tassin G, Cussenot O, Weiderpass E, Ljungberg B, Tumkur Sitaram R, Häggström C, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Andreotti G, Beane Freeman LE, Koutros S, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Wilson KM, Gaziano JM, Sesso HD, Freedman ND, Parker AS, Eckel-Passow JE, Huang WY, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, **Choueiri TK**, Lathrop GM, Deleuze JF, Gunter M, McKay JD, Wu X, Houlston RS, Chanock SJ, Relton C, Richards JB, Martin RM, Davey Smith G, Brennan P. The Influence of Obesity-Related Factors in the Etiology of Renal Cell Carcinoma-A Mendelian Randomization Study. *PLoS Med*. 2019 Jan;16(1):e1002724. PMID: 30605491, PMCID: PMC6317776
357. Chakraborty S, Balan M, Flynn E, Zurakowski D, **Choueiri TK**, Pal S. Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. *Oncogenesis*. 2019 Jan 15;8(2):7. PMID: 30647407, PMCID: PMC6333845
358. **Choueiri TK**, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. *Oncologist*. 2019 Feb;24(2):202-210. PMID: 30190302, PMCID: PMC6369938
359. Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stühler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, **Choueiri TK**, Chin Heng DY. Active Smoking Is Associated with Worse Prognosis in Metastatic

Renal Cell Carcinoma Patients Treated with Targeted Therapies. Clin Genitourin Cancer. 2019 Feb;17(1):65-71. PMID: 30341028

360. Krimphove MJ, Cole AP, Fletcher SA, Harmouch SS, Berg S, Lipsitz SR, Sun M, Nabi J, Nguyen PL, Hu JC, Kibel AS, **Choueiri TK**, Kluth LA, Trinh QD. Evaluation of the Contribution of Demographics, Access to Health Care, Treatment, and Tumor Characteristics to Racial Differences in Survival of Advanced Prostate Cancer. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):125-136. PMID: 30171227
361. Grünwald V, Powles T, **Choueiri TK**, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncol. 2019 Mar;15(9):929-941. PMID: 30689402
362. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, **Choueiri TK**. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar 21;380(12):1103-1115. PMID: 30779531, PMCID: PMC6716603
363. Tan WS, Berg S, Cole AP, Krimphove M, Marchese M, Lipsitz SR, Nabi J, Sammon JD, **Choueiri TK**, Kibel AS, Sun M, Chang S, Trinh QD. Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI Cancer Spectr. 2019 Mar;3(1):pkz003. PMID: 31360891, PMCID: PMC6649692
- Retraction in: JNCI Cancer Spectr. 2020 Oct 17;4(4):pkaa056. PMID: 33094268.
364. Krimphove MJ, Fletcher SA, Cole AP, Berg S, Sun M, Lipsitz SR, Mahal BA, Nguyen PL, **Choueiri TK**, Kibel AS, Kluth LA, Weissman JS, Trinh QD. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 Apr;201(4):735-741. PMID: 30414956
365. Berg S, Cole AP, Krimphove MJ, Nabi J, Marchese M, Lipsitz SR, Noldus J, **Choueiri TK**, Kibel AS, Trinh QD. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. 2019 Apr;75(4):552-555. PMID: 30420255
366. Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW, **Choueiri TK**, Sonpavde G, Kwiatkowski DJ.

Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clin Cancer Res. 2019 Apr 15;25(8):2458-2470. PMID: 30593515

367. Friedlander DF, von Landenberg N, Löppenber B, Noldus J, Lipsitz SR, Cole AP, Abdollah F, Nguyen PL, **Choueiri TK**, Kibel AS, Trinh QD. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 Apr;201(4):728-734. PMID: 30633112, PMCID: PMC7416645
368. Cole AP, Fletcher SA, Berg S, Nabi J, Mahal BA, Sonpavde GP, Nguyen PL, Lipsitz SR, Sun M, **Choueiri TK**, Preston MA, Kibel AS, Trinh QD. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. Cancer. 2019 Apr 15;125(8):1319-1329. PMID: 30633323
369. Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, **Choueiri TK**, Wu CJ, Atkins MB, McDermott DF, Signoretti S. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. PMID: 30670497, PMCID: PMC6445699
370. Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, **Choueiri TK**, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 Apr;20(4):581-590. PMID: 30827746, PMCID: PMC6849381
371. Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, Leshchiner ES, Viswanathan VS, Signoretti S, **Choueiri TK**, Boehm JS, Wagner BK, Doench JG, Clish CB, Clemons PA, Schreiber SL. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019 Apr 8;10(1):1617. PMID: 30962421, PMCID: PMC6453886, <https://doi.org/10.1038/s41467-019-09277-9>
372. Stukalin I, Wells JC, Graham J, Yuasa T, Beuselinck B, Kollmansberger C, Ernst DS, Agarwal N, Le T, Donskov F, Hansen AR, Bjarnason GA, Srinivas S, Wood LA, Alva AS, Kaneshwaran R, Fu SYF, Davis ID, **Choueiri TK**, Heng DYC. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the

International Metastatic Renal Cell Carcinoma Database Consortium. *Curr Oncol.* 2019 Apr;26(2):e175-e179. PMID: 31043824, PMCID: PMC6476457

373. Sun M, de Velasco G, Brastianos PK, Aizer AA, Martin A, Moreira R, Nguyen PL, Trinh QD, **Choueiri TK**. The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. *Eur Urol Focus.* 2019 May;5(3):474-481. PMID: 29311016
374. Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, **Choueiri TK**, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. *Future Oncol.* 2019 May;15(15):1683-1695. PMID: 30968729, PMCID: PMC6595543
375. McKay R, Mills H, Werner L, Choudhury A, **Choueiri T**, Jacobus S, Pace A, Polacek L, Pomerantz M, Prisby J, Sweeney C, Walsh M, Taplin ME. Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. *J Med Internet Res.* 2019 May 2;21(5):e12044. PMID: 31045501, PMCID: PMC6538310
376. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, **Choueiri TK**, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. *Ann Oncol.* 2019 Jun 1;30(6):970-976. PMID: 31050707, PMCID: PMC6594457
377. Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, **Choueiri TK**, Parnis F, Khaznadar T, Thobhani A, Li S, Piau-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ, IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *Lancet.* 2019 Jun 15;393(10189):2404-2415. PMID: 31079938
378. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, **Choueiri TK**, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case

Definitions for Emerging Clinical Syndromes in Cardio-Oncology. *Circulation*. 2019 Jul 2;140(2):80-91. PMID: 31390169, PMCID: PMC6779326

379. Harding JJ, Zhu AX, Bauer TM, **Choueiri TK**, Drilon A, Voss MH, Fuchs CS, Abou-Alfa GK, Wijayawardana SR, Wang XA, Moser BA, Uruñuela A, Wacheck V, Bendell JC. A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. *Clin Cancer Res*. 2019 Sep 1;25(17):5202-5211. PMID: 31142504
380. Cole AP, Lu C, Krimphove MJ, Szymaniak J, Sun M, Fletcher SA, Lipsitz SR, Mahal BA, Nguyen PL, **Choueiri TK**, Kibel AS, Haider AH, Trinh QD. Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. *J Natl Compr Canc Netw*. 2019 Sep 1;17(9):1049-1058. PMID: 31487683
381. Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, Schreiber SL, Stephen Hodi F, Sellers WR, Garraway LA, Clish CB, **Choueiri TK**, Giannakis M. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. *Nat Commun*. 2019 Sep 25;10(1):4346. PMID: 31554815, PMCID: PMC6761178
382. Laskar RS, Muller DC, Li P, Machiela MJ, Ye Y, Gaborieau V, Foll M, Hofmann JN, Colli L, Sampson JN, Wang Z, Bacq-Daian D, Boland A, Abedi-Ardekani B, Durand G, Le Calvez-Kelm F, Robinot N, Blanche H, Prokhortchouk E, Skryabin KG, Burdett L, Yeager M, Radojevic-Skodric S, Savic S, Foretova L, Holcatova I, Janout V, Mates D, Rascu S, Mukeria A, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Świątkowska B, Benhamou S, Cancel-Tassin G, Cussenot O, Trichopoulou A, Riboli E, Overvad K, Panico S, Ljungberg B, Sitaram RT, Giles GG, Milne RL, Severi G, Bruinsma F, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Beane Freeman LE, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Chow WH, Moore LE, **Choueiri TK**, Wood C, Johansson M, McKay JD, Brown KM, Rothman N, Lathrop MG, Deleuze JF, Wu X, Brennan P, Chanock SJ, Purdue MP, Scelo G. Sex specific associations in genome wide association analysis of renal cell carcinoma. *Eur J Hum Genet*. 2019 Oct;27(10):1589-1598. PMID: 31231134, PMCID: PMC6777615
383. Tan WS, Krimphove MJ, Cole AP, Marchese M, Berg S, Lipsitz SR, Löppenber B, Nabi J, Abdollah F, **Choueiri TK**, Kibel AS, Sooriakumaran P, Trinh QD. Variation in

Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. *Clin Genitourin Cancer*. 2019 Oct;17(5):e1060-e1068. PMID: 31303561

384. Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, **Choueiri TK**, Signoretti S. PD-L1 expression and clinical outcomes to cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN. *Clin Cancer Res*. 2019 Oct 15;25(20):6080-6088. PMID: 31371341, PMCID: PMC6801080

385. Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, **Choueiri TK**, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM, CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2019 Oct;20(10):1370-1385. PMID: 31427204, PMCID: PMC7497870

Erratum in: *Lancet Oncol*. 2019 Oct;20(10):e559. PMID: 31445962

386. George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, **Choueiri TK**. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. *Oncologist*. 2019 Nov;24(11):1497-1501. PMID: 31399500, PMCID: PMC6853096

387. Graham J, Wells JC, Donskov F, Lee JL, Fracon A, Pasini F, Porta C, Bowman IA, Bjarnason GA, Ernst DS, Rha SY, Beuselinck B, Hansen A, North SA, Kollmannsberger CK, Wood LA, Vaishampayan UN, Pal SK, **Choueiri TK**, Heng DYC. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur Urol Oncol*. 2019 Nov;2(6):643-648. PMID: 31411994, PMCID: PMC6886238

388. Braun DA, Ishii Y, Walsh AM, Van Allen EM, Wu CJ, Shukla SA, **Choueiri TK**. Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. *JAMA Oncol*. 2019 Nov 1;5(11):1631-1633. PMID: 31486842, PMCID: PMC6735411

389. Krimphove MJ, Tully KH, Friedlander DF, Marchese M, Ravi P, Lipsitz SR, Kilbridge KL, Kibel AS, Kluth LA, Ott PA, **Choueiri TK**, Trinh QD. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. *J Immunother Cancer*. 2019 Nov 7;7(1):289. PMID: 31699149, PMCID: PMC6836520
390. Cole AP, Krasnova A, Ramaswamy A, Friedlander DF, Fletcher SA, Sun M, **Choueiri TK**, Weissman JS, Kibel AS, Trinh QD. Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. *Prostate Cancer Prostatic Dis*. 2019 Dec;22(4):593-599. PMID: 30980025
391. Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan UN, Wood LA, Liow E, Yan F, Yuasa T, Bjarnason GA, **Choueiri TK**, Heng DY. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. *Eur Urol*. 2019 Dec;76(6):861-867. PMID: 31445844, PMCID: PMC6858928
392. Bossé D, Lin X, Simantov R, Lalani AA, Derweesh I, Chang SL, **Choueiri TK**, McKay RR. Response of Primary Renal Cell Carcinoma to Systemic Therapy. *Eur Urol*. 2019 Dec;76(6):852-860. PMID: 31594707
393. Sternberg CN, Motzer RJ, Hutson TE, **Choueiri TK**, Kollmannsberger C, Bjarnason GA, Paul Nathan undefined, Porta C, Grünwald V, Dezzani L, Han J, Tannir NM. COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2019 Dec;17(6):425-435.e4. PMID: 31601514, PMCID: PMC7518515
394. McKay RR, Vu P, Albiges LK, Lin X, Simantov R, Temel JS, **Choueiri TK**. The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2019 Dec;17(6):443-450.e1. PMID: 31601515
395. McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, Signoretti S, Hirsch MS, Steinharter JA, Bakouny Z, Flippot R, Wei XX, Choudhury A, Kilbridge K, Freeman GJ, Van Allen EM, Harshman LC, McDermott DF, Vaishampayan U, **Choueiri TK**. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. *J Clin Oncol*. 2020 Jan 1;38(1):63-70. PMID: 31721643, PMCID: PMC7051851
396. Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, **Choueiri TK**, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ,

- Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. *Cancer Discov.* 2020 Jan;10(1):40-53. PMID: 31732494, PMCID: PMC6954326
397. Agrawal S, Haas NB, Bagheri M, Lane BR, Coleman J, Hammers H, Bratslavsky G, Chauhan C, Kim L, Krishnasamy VP, Marko J, Maher VE, Ibrahim A, Cross F Jr, Liu K, Beaver JA, Pazdur R, Blumenthal GM, Singh H, Plimack ER, **Choueiri TK**, Uzzo R, Apolo AB. Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. *JAMA Oncol.* 2020 Jan 1;6(1):133-141. PMID: 31750870, PMCID: PMC8127869
398. Nassar AH, Hamieh L, Gray KP, Thorner AR, Fay AP, Lasseter KD, Abou Alaiwi S, Nuzzo PV, Flippot R, Krajewski KM, Signoretti S, **Choueiri TK**, Kwiatkowski DJ. Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. *Mol Cancer Ther.* 2020 Feb;19(2):690-696. PMID: 31653662
399. DiNatale RG, Xie W, Becerra MF, Silagy AW, Attalla K, Sanchez A, Mano R, Marcon J, Blum KA, Benfante NE, Voss MH, Motzer RJ, Coleman J, **Choueiri TK**, Reznik E, Russo P, Heng DYC, Hakimi AA. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. *Eur Urol Oncol.* 2020 Feb;3(1):47-56. PMID: 31735646, PMCID: PMC7236081
400. Nassar AH, Mouw KW, Jegede O, Shinagare AB, Kim J, Liu CJ, Pomerantz M, Harshman LC, Van Allen EM, Wei XX, McGregor B, Choudhury AD, Preston MA, Dong F, Signoretti S, Lindeman NI, Bellmunt J, **Choueiri TK**, Sonpavde G, Kwiatkowski DJ. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. *Br J Cancer.* 2020 Feb;122(4):555-563. PMID: 31857723, PMCID: PMC7028947
401. Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, **Choueiri TK**. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. *Eur J Cancer.* 2020 Feb;126:1-10. PMID: 31887537, PMCID: PMC7521477
402. Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez-Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilan MA, **Choueiri TK**, Harshman LC. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events

in metastatic renal cell carcinoma. *J Immunother Cancer*. 2020 Feb;8(1). PMID: 32066646, PMCID: PMC7057439

403. Bossé D, Xie W, Lin X, Simantov R, Lalani AA, Graham J, Wells JC, Donskov F, Rini B, Beuselinck B, Alva A, Hansen A, Wood L, Soulières D, Kollmannsberger C, Patenaude F, Heng DYC, **Choueiri TK**, McKay RR. Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. *JCO Glob Oncol*. 2020 Feb;6:293-306. PMID: 32109159, PMCID: PMC7055470
404. Fletcher SA, von Landenberg N, Cole AP, Gild P, **Choueiri TK**, Lipsitz SR, Trinh QD, Kibel AS. Contemporary national trends in prostate cancer risk profile at diagnosis. *Prostate Cancer Prostatic Dis*. 2020 Mar;23(1):81-87. PMID: 31235801
405. Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, Uemura H, **Choueiri TK**, Motzer RJ, Fujii Y, Kamei Y, Umeyama Y, di Pietro A, Oya M. Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. *Cancer Sci*. 2020 Mar;111(3):907-923. PMID: 31883418, PMCID: PMC7060483
406. Rassy E, Bakouny Z, **Choueiri TK**, Van Allen EM, Fizazi K, Greco FA, Pavlidis N. The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. *Eur J Cancer*. 2020 Mar;127:118-122. PMID: 32007711
407. Fletcher SA, Marchese M, Cole AP, Mahal BA, Friedlander DF, Krimphove M, Kilbridge KL, Lipsitz SR, Nguyen PL, **Choueiri TK**, Kibel AS, Trinh QD. Geographic Distribution of Racial Differences in Prostate Cancer Mortality. *JAMA Netw Open*. 2020 Mar 2;3(3):e201839. PMID: 32232449, PMCID: PMC7109596
408. Nuzzo PV, Pond GR, Abou Alaiwi S, Nassar AH, Flippot R, Curran C, Kilbridge KL, Wei XX, McGregor BA, **Choueiri T**, Harshman LC, Sonpavde G. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. *J Immunother Cancer*. 2020 Mar;8(1). PMID: 32234849, PMCID: PMC7174062
409. Nassar AH, Abou Alaiwi S, AlDubayan SH, Moore N, Mouw KW, Kwiatkowski DJ, **Choueiri TK**, Curran C, Berchuck JE, Harshman LC, Nuzzo PV, Chanza NM, Van Allen E, Esplin ED, Yang S, Callis T, Garber JE, Rana HQ, Sonpavde G. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. *Genet Med*. 2020 Apr;22(4):709-718. PMID: 31844177, PMCID: PMC7118025
410. Lalani AA, Xie W, Braun DA, Kaymakcalan M, Bossé D, Steinharter JA, Martini DJ, Simantov R, Lin X, Wei XX, McGregor BA, McKay RR, Harshman LC, **Choueiri TK**

Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. *Eur Urol Oncol.* 2020 Jun;3(3):372-381. PMID: 31562048, PMCID: PMC9163676

411. Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, **Choueiri TK**. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. *Nat Med.* 2020 Jun;26(6):909-918. PMID: 32472114, PMCID: PMC7499153
412. Kuderer NM, **Choueiri TK**, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet.* 2020 Jun 20;395(10241):1907-1918. PMID: 32473681, PMCID: PMC7255743
413. Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Suárez C, Lam ET, **Choueiri TK**, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis E, Powles T. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. *BJU Int.* 2020 Jul;126(1):73-82. PMID: 32233107, PMCID: PMC8415097
414. Nuzzo PV, Berchuck JE, Korthauer K, Spisak S, Nassar AH, Abou Alaiwi S, Chakravarthy A, Shen SY, Bakouny Z, Boccardo F, Steinharter J, Bouchard G, Curran CR, Pan W, Baca SC, Seo JH, Lee GM, Michaelson MD, Chang SL, Waikar SS, Sonpavde G, Irizarry RA, Pomerantz M, De Carvalho DD, **Choueiri TK**, Freedman ML. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. *Nat Med.* 2020 Jul;26(7):1041-1043. PMID: 32572266, PMCID: PMC8288043

Erratum in: *Nat Med.* 2020 Sep 7. Epub ahead of print. PMID: 32895574.

415. Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER, Barthélémy P, Hammers HJ, George S, Grünwald V, Porta C, Neiman V, Ravaud A, **Choueiri TK**, Rini BI, Salman P, Kollmannsberger CK, Tykodi SS, Grimm MO, Gurney H, Leibowitz-Amit R, Geertsens PF, Amin A, Tomita Y, McHenry MB, Saggi SS, Tannir NM. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. *J Immunother Cancer*. 2020 Jul;8(2). PMID: 32661118, PMCID: PMC7359377
416. Wells JC, Graham J, Beuselinck B, Bjarnason GA, Donskov F, Hansen AR, McKay RR, Vaishampayan U, De Velasco G, Duh MS, Huynh L, Nguyen C, Zanotti G, Ramaswamy K, **Choueiri TK**, Heng DYC. Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2020 Aug;18(4):e350-e359. PMID: 31926879
417. Donskov F, Xie W, Overby A, Wells JC, Fracon AP, Sacco CS, Porta C, Stukalin I, Lee JL, Koutsoukos K, Yuasa T, Davis ID, Pezaro C, Kanavaras R, Bjarnason GA, Sim HW, Rathi N, Kollmannsberger CK, Canil CM, **Choueiri TK**, Heng DYC. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur Urol Oncol*. 2020 Aug;3(4):530-539. PMID: 32037304
418. Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, Margolis CA, Vokes NI, Du H, Shukla SA, Cherniack AD, Sonpavde G, Haddad RI, Awad MM, Giannakis M, Hodi FS, Liu XS, Signoretti S, Kadoch C, Freedman ML, Kwiatkowski DJ, Van Allen EM, **Choueiri TK**. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. *Cancer Immunol Res*. 2020 Aug;8(8):1075-1084. PMID: 32321774, PMCID: PMC7415546
419. **Choueiri TK**, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, Grimm MO, Gurney H, Schmidinger M, Larkin J, Atkins MB, Pal SK, Wang J, Mariani M, Krishnaswami S, Cislo P, Chudnovsky A, Fowst C, Huang B, di Pietro A, Albiges L. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. *Ann Oncol*. 2020 Aug;31(8):1030-1039. PMID: 32339648, PMCID: PMC8436592
420. Lasseter K, Nassar AH, Hamieh L, Berchuck JE, Nuzzo PV, Korthauer K, Shinagare AB, Ogorek B, McKay R, Thorner AR, Lee GM, Braun DA, Bhatt RS, Freedman M, **Choueiri TK**, Kwiatkowski DJ. Plasma cell-free DNA variant analysis compared with

methylated DNA analysis in renal cell carcinoma. *Genet Med.* 2020 Aug;22(8):1366-1373. PMID: 32341571

421. **Choueiri TK**, Heng DY, Lee JL, Cancel M, Verheijen RB, Mellema A, Ottesen LH, Frigault MM, L'Hernault A, Szigyarto Z, Signoretti S, Albiges L. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 2020 Aug 1;6(8):1247-1255. PMID: 32469384, PMCID: PMC7260692
422. McGregor BA, Lalani AA, Xie W, Steinharter JA, E Bakouny Z, Martini DJ, Fleischer JH, Abou-Alaiwi S, Nassar A, Nuzzo PV, Kaymakcalan MD, Braun DA, Wei XX, Harshman LC, Bilen MA, **Choueiri TK**. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. *Eur J Cancer.* 2020 Aug;135:203-210. PMID: 32599410
423. Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, Gusev A, Korthauer KD, Severson TM, Ha G, Viswanathan SR, Seo JH, Nguyen HM, Zhang B, Pasaniuc B, Giambartolomei C, Alaiwi SA, Bell CA, O'Connor EP, Chabot MS, Stillman DR, Lis R, Font-Tello A, Li L, Cejas P, Bergman AM, Sanders J, van der Poel HG, Gayther SA, Lawrenson K, Fonseca MAS, Reddy J, Corona RI, Martovetsky G, Egan B, **Choueiri T**, Ellis L, Garraway IP, Lee GM, Corey E, Long HW, Zwart W, Freedman ML. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. *Nat Genet.* 2020 Aug;52(8):790-799. PMID: 32690948
424. Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, McKay RR, Pels K, Schmidt A, Doroshov DB, Schütz F, Albiges L, Lopes G, Catto JWF, Peters S, **Choueiri TK**. Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. *JCO Glob Oncol.* 2020 Aug;6:1248-1257. PMID: 32755479, PMCID: PMC7456315
425. Krasnova A, Epstein M, Marchese M, Dickerman BA, Cole AP, Lipsitz SR, Nguyen PL, Kibel AS, **Choueiri TK**, Basaria S, Mucci LA, Sun M, Trinh QD. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. *Prostate Cancer Prostatic Dis.* 2020 Sep;23(3):410-418. PMID: 31784699
426. Huang B, Tian L, McCaw ZR, Luo X, Talukder E, Rothenberg M, Xie W, **Choueiri TK**, Kim DH, Wei LJ. Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. *Ann Intern Med.* 2020 Sep 1;173(5):368-374. PMID: 32628533, PMCID: PMC7773521
427. Yang DD, Muralidhar V, Mahal BA, Vastola ME, Boldbaatar N, Labe SA, Nezoslosky MD, Martin NE, King MT, Mouw KW, **Choueiri TK**, Trinh QD, Nguyen PL, Orio PF 3rd. Impact of percent positive biopsy cores on cancer-specific mortality for patients

with high-risk prostate cancer. *Urol Oncol*. 2020 Sep;38(9):735.e9-735.e735.e15.
PMID: 32654951

428. Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Procopio G, McDermott DF, Castellano D, **Choueiri TK**, Donskov F, Gurney H, Oudard S, Richardet M, Peltola K, Alva AS, Carducci M, Wagstaff J, Chevreau C, Fukasawa S, Tomita Y, Gauler TC, Kollmannsberger CK, Schutz FA, Larkin J, Cella D, McHenry MB, Saggi SS, Tannir NM. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. *Cancer*. 2020 Sep 15;126(18):4156-4167. PMID: 32673417, PMCID: PMC8415096
429. Panian J, Lin X, Simantov R, Derweesh I, **Choueiri TK**, McKay RR. The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. *Clin Genitourin Cancer*. 2020 Oct;18(5):e598-e609. PMID: 32280027
430. Bhindi B, Graham J, Wells JC, Bakouny Z, Donskov F, Fracon A, Pasini F, Lee JL, Basappa NS, Hansen A, Kollmannsberger CK, Kanesvaran R, Yuasa T, Ernst DS, Srinivas S, Rini BI, Bowman I, Pal SK, **Choueiri TK**, Heng DYC. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. *Eur Urol*. 2020 Oct;78(4):615-623. PMID: 32362493
431. Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, Bakouny Z, Agarwal N, Zakharia Y, Costello BA, McKay RR, Narayan V, Alva A, McGregor BA, Gao X, McDermott DF, **Choueiri TK**. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. *JAMA Oncol*. 2020 Oct 1;6(10):1606-1610. PMID: 32469396, PMCID: PMC7260689
432. Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, **Choueiri TK**, de Lima Lopes G Jr, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshov DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky MD, Goel S, Gupta S, Halfdanarson TR, Halmos B, Hawley JE, Khaki AR, Lemmon CA, Mishra S, Olszewski AJ, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, Shyr Y, Lyman GH, Warner JL, COVID-19 and Cancer Consortium. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. *Cancer Discov*. 2020 Oct;10(10):1514-1527. PMID: 32699031, PMCID: PMC7541683
433. Martini JF, Plimack ER, **Choueiri TK**, McDermott DF, Puzanov I, Fishman MN, Cho DC, Vaishampayan U, Rosbrook B, Fernandez KC, Tarazi JC, George S, Atkins MB. Angiogenic and Immune-Related Biomarkers and Outcomes Following

Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clin Cancer Res. 2020 Nov 1;26(21):5598-5608. PMID: 32816890

434. Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA, Uemura M, Pal SK, Alekseev B, Gravis G, Campbell MT, Penkov K, Lee JL, Hariharan S, Wang X, Zhang W, Wang J, Chudnovsky A, di Pietro A, Donahue AC, **Choueiri TK**. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med. 2020 Nov;26(11):1733-1741. PMID: 32895571, PMCID: PMC8493486
435. Tripathi A, Lin E, Xie W, Flaifel A, Steinharter JA, Stern Gatof EN, Bouchard G, Fleischer JH, Martinez-Chanza N, Gray C, Mantia C, Thompson L, Wei XX, Giannakis M, McGregor BA, **Choueiri TK**, Agarwal N, McDermott DF, Signoretti S, Harshman LC. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Cancer. 2020 Nov;8(2). PMID: 33177176, PMCID: PMC7661372
436. Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, **Choueiri TK**, Saggi SS, McHenry MB, Motzer RJ. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020 Nov;5(6):e001079. PMID: 33246931, PMCID: PMC7703447
437. McGregor BA, Gordon M, Flippot R, Agarwal N, George S, Quinn DI, Rogalski M, Hawthorne T, Keler T, **Choueiri TK**. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Invest New Drugs. 2020 Dec;38(6):1807-1814. PMID: 32472319, PMCID: PMC7578086
438. Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D, Makari D, Gupta A, Abdullah SE, Niegisch G, Rosenberg JE, Bajorin DF, Grivas P, Apolo AB, Dreicer R, Hahn NM, Galsky MD, Necchi A, Srinivas S, Powles T, **Choueiri TK**, Pond GR. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. J Urol. 2020 Dec;204(6):1173-1179. PMID: 32552295, PMCID: PMC7655635
439. Chen RC, **Choueiri TK**, Feuilly M, Meng J, Lister J, Marteau F, Falchook AD, Morris MJ, George DJ, Feldman DR. Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). Cancer. 2020 Dec 15;126(24):5311-5318. PMID: 33022096, PMCID: PMC7756547

440. McKay RR, McGregor BA, Xie W, Braun DA, Wei X, Kyriakopoulos CE, Zakharia Y, Maughan BL, Rose TL, Stadler WM, McDermott DF, Harshman LC, **Choueiri TK**. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). *J Clin Oncol*. 2020 Dec 20;38(36):4240-4248. PMID: 33108238, PMCID: PMC7768333
441. Schmidt AL, Bakouny Z, Bhalla S, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, Kelleher KM, Seidman D, Huang HH, Anderson-Keightly HM, Abou Alaiwi S, Rosenbloom TD, Stewart PS, Galsky MD, **Choueiri TK**, Doroshow DB. Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. *Cancer Cell*. 2020 Dec 14;38(6):769-770. PMID: 33176161, PMCID: PMC7609043
442. Tannir NM, Signoretti S, **Choueiri TK**, McDermott DF, Motzer RJ, Flai fel A, Pignon JC, Ficial M, Frontera OA, George S, Powles T, Donskov F, Harrison MR, Barthélémy P, Tykodi SS, Kocsis J, Ravaud A, Rodriguez-Cid JR, Pal SK, Murad AM, Ishii Y, Saggi SS, McHenry MB, Rini BI. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. *Clin Cancer Res*. 2021 Jan 1;27(1):78-86. PMID: 32873572, PMCID: PMC8589223
443. Khanna P, Soh HJ, Chen CH, Saxena R, Amin S, Naughton M, Joslin PN, Moore A, Bakouny Z, O'Callaghan C, Catalano P, Signoretti S, McKay R, **Choueiri TK**, Bhasin M, Walther T, Bhatt RS. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. *Sci Transl Med*. 2021 Jan 20;13(577). PMID: 33472951
444. Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, Fracon A, Pasini F, Lee JL, Hansen A, Bjarnason GA, Beuselinck B, Pal SK, Yuasa T, Kroeger N, Kanavarar R, Reaume MN, Canil C, **Choueiri TK**, Heng DY. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. *JAMA Netw Open*. 2021 Jan 4;4(1):e2021869. PMID: 33475752, PMCID: PMC7821027
445. Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, **Choueiri TK**, Tannir NM, Heng DY. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. *Eur Urol Oncol*. 2021 Feb;4(1):102-111. PMID: 31786162

446. Sun M, Marchese M, Friedlander DF, Nguyen DD, Cole AP, Fletcher SA, Mahal BA, Nguyen PL, **Choueiri TK**, Kibel AS, Trinh QD. Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. *Urol Oncol*. 2021 Feb;39(2):130.e17-130.e24. PMID: 33309298
447. Gan CL, Dudani S, Wells JC, Donskov F, Pal SK, Dizman N, Rathi N, Beuselinck B, Yan F, Lalani AA, Hansen A, Szabados B, de Velasco G, Tran B, Lee JL, Vaishampayan UN, Bjarnason GA, Subasri M, **Choueiri TK**, Heng DYC. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Cancer Med*. 2021 Feb;10(4):1212-1221. PMID: 33463028, PMCID: PMC7926018
448. Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, **Choueiri TK**. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. *Nat Commun*. 2021 Feb 5;12(1):808. PMID: 33547292, PMCID: PMC7865061
449. Motwani SS, **Choueiri TK**, Partridge AH, Hu J, Kaymakcalan MD, Waikar SS, Curhan GC. Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury. *Kidney360*. 2021 Feb 25;2(2):205-214. PMID: 35373014, PMCID: PMC8741004
450. McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bublely GJ, Siefker-Radtke AO, McKay RR, **Choueiri TK**. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. *Cancer*. 2021 Mar 15;127(6):840-849. PMID: 33216356
451. Ficial M, Jegede OA, Sant'Angelo M, Hou Y, Flaifel A, Pignon JC, Braun DA, Wind-Rotolo M, Sticco-Ivins MA, Catalano PJ, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Wu CJ, Atkins MB, McDermott DF, Shukla SA, **Choueiri TK**, Signoretti S. Expression of T-cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. *Clin Cancer Res*. 2021 Mar 1;27(5):1371-1380. PMID: 33219016, PMCID: PMC8443005

452. Kollmannsberger C, **Choueiri TK**, Heng DY, George S, Jie F, Croitoru R, Poondru S, Thompson JA. A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. *Oncologist*. 2021 Mar;26(3):182-18e361. PMID: 33289953, PMCID: PMC7930403
453. Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Tarazi JC, Duggan W, Perini R, Thakur M, Fernandez KC, **Choueiri TK**. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. *Eur J Cancer*. 2021 Mar;145:1-10. PMID: 33412465
454. Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, **Choueiri TK**, Trinh QD. Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. *JAMA Oncol*. 2021 Mar 1;7(3):458-460. PMID: 33443549, PMCID: PMC7809614
455. Motzer RJ, Russo P, Haas N, Doehn C, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Lim HY, Melichar B, Zemanova M, Rini B, **Choueiri TK**, Wood L, Reaume MN, Stenzl A, Chowdhury S, McDermott R, Michael A, Izquierdo M, Aimone P, Zhang H, Sternberg CN, PROTECT study investigators. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. *Eur Urol*. 2021 Mar;79(3):334-338. PMID: 33461782, PMCID: PMC8407394
456. **Choueiri TK**, Powles T, Burotto M, Escudier B, Bournalon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ, CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2021 Mar 4;384(9):829-841. PMID: 33657295, PMCID: PMC8436591
457. Ross-Macdonald P, Walsh AM, Chasalow SD, Ammar R, Papillon-Cavanagh S, Szabo PM, **Choueiri TK**, Sznol M, Wind-Rotolo M. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. *J Immunother Cancer*. 2021 Mar;9(3). PMID: 33658305, PMCID: PMC7931766
458. Abou Alaiwi S, Nassar AH, Adib E, Groha SM, Akl EW, McGregor BA, Esplin ED, Yang S, Hatchell K, Fusaro V, Nielsen S, Kwiatkowski DJ, Sonpavde GP, Pomerantz M, Garber JE, Freedman ML, Rana HQ, Gusev A, **Choueiri TK**. Trans-ethnic variation in germline variants of patients with renal cell carcinoma. *Cell Rep*. 2021 Mar 30;34(13):108926. PMID: 33789101

459. Pan W, Zhang Z, Kimball H, Qu F, Berlind K, Stopsack KH, Lee GM, **Choueiri TK**, Kantoff PW. Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. *Clin Cancer Res.* 2021 Apr 1;27(7):2087-2099. PMID: 33495313, PMCID: PMC8026555
460. Marconi L, Sun M, Beisland C, Klatte T, Ljungberg B, Stewart GD, Dabestani S, **Choueiri TK**, Bex A. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. *Clin Genitourin Cancer.* 2021 Apr;19(2):e92-e99. PMID: 33526329
461. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoia T, Merchan JR, Winkquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, **Choueiri TK**, CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med.* 2021 Apr 8;384(14):1289-1300. PMID: 33616314
462. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, **Choueiri TK**, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. *Nat Med.* 2021 Apr;27(4):601-615. PMID: 33753937, PMCID: PMC8893149
463. Lalani AA, Bakouny Z, Farah S, Donskov F, Dudani S, Heng DY, **Choueiri TK**. Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. *JAMA Oncol.* 2021 May 1;7(5):773-775. PMID: 33662110, PMCID: PMC7934079
464. Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth J, Stadler WM, Hutson TE, Ravaud A, Bracarda S, Suarez C, **Choueiri TK**, Reeves J, Cohn A, Ding B, Leng N, Hashimoto K, Huseni M, Schiff C, McDermott DF. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. *Eur Urol.* 2021 May;79(5):665-673. PMID: 33678522, PMCID: PMC9357270
465. Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes

NI, Shannon E, Sun M, Park J, Chang SL, McGregor BA, Haq R, Denize T, Signoretti S, Guerriero JL, Vigneau S, Rozenblatt-Rosen O, Rotem A, Regev A, **Choueiri TK**, Van Allen EM. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. *Cancer Cell*. 2021 May 10;39(5):649-661.e5. PMID: 33711272, PMCID: PMC8115394

466. Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, **Choueiri TK**, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. *Cancer Cell*. 2021 May 10;39(5):632-648.e8. PMID: 33711273, PMCID: PMC8138872

467. **Choueiri TK**, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E. Inhibition of hypoxia-inducible factor-2 α in renal cell carcinoma with belzutifan: a phase I trial and biomarker analysis. *Nat Med*. 2021 May;27(5):802-805. PMID: 33888901, PMCID: PMC9128828

Erratum in: *Nat Med*. 2021 Oct;27(10):1849. PMID: 34453144.

468. Araujo DV, Wells JC, Hansen AR, Dizman N, Pal SK, Beuselinck B, Donskov F, Gan CL, Yan F, Tran B, Kollmannsberger CK, de Velasco G, Yuasa T, Reaume MN, Ernst DS, Powles T, Bjarnason GA, **Choueiri TK**, Heng DY, Dudani S. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. *J Geriatr Oncol*. 2021 Jun;12(5):820-826. PMID: 33674246

469. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, **Choueiri TK**, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshov DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah

SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. *Ann Oncol*. 2021 Jun;32(6):787-800. PMID: 33746047, PMCID: PMC7972830

470. **Choueiri TK**, Larkin J, Pal S, Motzer RJ, Rini BI, Venugopal B, Alekseev B, Miyake H, Gravis G, Bilen MA, Hariharan S, Chudnovsky A, Ching KA, Mu XJ, Mariani M, Robbins PB, Huang B, di Pietro A, Albiges L. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. *ESMO Open*. 2021 Jun;6(3):100101. PMID: 33901870, PMCID: PMC8099757

Erratum in: *ESMO Open*. 2021 Aug;6(4). PMID: 34474809; PMCID: PMC8411062.

471. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, **Choueiri TK**, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL, COVID-19 and Cancer Consortium. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA Oncol*. 2021 Jun 17;7(8):1167-1175. PMID: 34137799, PMCID: PMC8377563

Erratum in: *JAMA Oncol*. 2021 Aug 1;7(8):1249. PMID: 34410334.

472. **Choueiri TK**, Zakharia Y, Pal S, Kocsis J, Pachynski R, Poprach A, Nixon AB, Liu Y, Starr M, Lyu J, Owzar K, deShazo M, Lara P, Geczi L, Ho TH, Walsh M, Adams B, Robertson L, Darif M, Theuer C, Agarwal N. Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). *Oncologist*. 2021 Jul;26(7):560-5e1103. PMID: 33829609, PMCID: PMC8265348

473. Gan CL, Stukalin I, Meyers DE, Dudani S, Grosjean HAI, Dolter S, Ewanchuk BW, Goutam S, Sander M, Wells C, Pabani A, Cheng T, Monzon J, Morris D, Basappa NS, Pal SK, Wood LA, Donskov F, **Choueiri TK**, Heng DY. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. *Eur J Cancer*. 2021 Jul;151:115-125. PMID: 33975059

474. Adib E, Nassar AH, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Shukla SA, Gusev A, Braun DA,

Choueiri TK, Kwiatkowski DJ. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. *Clin Cancer Res.* 2021 Jul 15;27(14):4025-4035. PMID: 34074656, PMCID: PMC8900067

475. **Choueiri TK**, Atkins MB, Rose TL, Alter RS, Ju Y, Niland K, Wang Y, Arbeit R, Parasuraman S, Gan L, McDermott DF. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. *Invest New Drugs.* 2021 Aug;39(4):1019-1027. PMID: 33507454
476. Labaki C, Bakouny Z, Schmidt A, Lipsitz SR, Rebbeck TR, Trinh QD, **Choueiri TK**. Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. *Cancer Cell.* 2021 Aug 9;39(8):1042-1044. PMID: 34265251, PMCID: PMC8245382
477. Powles T, **Choueiri TK**, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. *BMC Cancer.* 2021 Aug 7;21(1):904. PMID: 34364385, PMCID: PMC8349489
- Erratum in: *BMC Cancer.* 2021 Sep 15;21(1):1023. PMID: 34525968.
478. **Choueiri TK**, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T, KEYNOTE-564 Investigators. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. *N Engl J Med.* 2021 Aug 19;385(8):683-694. PMID: 34407342
479. Shee K, Pal SK, Wells JC, Ruiz-Morales JM, Russell K, Dudani S, **Choueiri TK**, Heng DY, Gore JL, Odisho AY. Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. *JCO Clin Cancer Inform.* 2021 Aug;5:912-920. PMID: 34464153
480. Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, **Choueiri TK**, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. *Clin Cancer Res.* 2021 Sep 1;27(17):4807-4813. PMID: 34130999

481. Sperger JM, Enamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bublely G, Feng FY, Scher HI, Rathkopf D, Dehm SM, **Choueiri TK**, Halabi S, Armstrong AJ, Wyatt AW, Taplin ME, Zhao SG, Lang JM. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. *J Clin Oncol*. 2021 Sep 10;39(26):2926-2937. PMID: 34197212, PMCID: PMC8425833
482. Meade A, Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD, Albiges L, Bex A, **Choueiri TK**, Davis ID, Eisen T, Fielding A, Harrison DJ, McWhirter A, Mulhere S, Nathan P, Rini B, Ritchie A, Scovell S, Shakeshaft C, Stockler MR, Thorogood N, Larkin J, Parmar MKB. RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. *Contemp Clin Trials*. 2021 Sep;108:106481. PMID: 34538401
483. Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD, Albiges L, Bex A, **Choueiri TK**, Davis ID, Eisen T, Fielding A, Harrison D, McWhirter A, Mulhere S, Nathan P, Rini B, Ritchie A, Scovell S, Shakeshaft C, Stockler MR, Thorogood N, Parmar MKB, Larkin J, Meade A. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. *Contemp Clin Trials*. 2021 Sep;108:106482. PMID: 34538402, PMCID: PMC8520913
484. Rini BI, Atkins MB, **Choueiri TK**, Thomaidou D, Rosbrook B, Thakur M, Hutson TE. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2021 Oct;19(5):e306-e312. PMID: 33947608
485. Yekedüz E, Trapani D, Xu W, de Vries EGE, Labaki C, Gyawali B, Gulati S, Nabhan C, Utkan G, Curigliano G, **Choueiri TK**, Ürün Y. Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. *Int J Cancer*. 2021 Oct 1;149(7):1455-1462. PMID: 34124786
486. Bakouny Z, Yekedüz E, Braun DA, Berchuck JE, Hirsch L, Utkan G, Lee Y, Trinh QD, **Choueiri TK**, Ürün Y. Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2021 Oct;166:103463. PMID: 34461269
487. Bhalla S, Bakouny Z, Schmidt AL, Labaki C, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, Kelleher KM, Seidman D, Huang HH, Anderson-Keightly HM, El Zarif T, Abou Alaiwi S, Rosenbloom TD, Stewart PS, Galsky MD, **Choueiri TK**, Doroshov DB. Care disruptions among patients

with lung cancer: A COVID-19 and cancer outcomes study. *Lung Cancer*. 2021 Oct;160:78-83. PMID: 34461400, PMCID: PMC8284065

488. Seethapathy H, Street S, Strohhahn I, Lee M, Zhao SH, Rusibamayila N, Chute DF, Gao X, Michaelson MD, Rahma OE, **Choueiri TK**, McGregor B, Sonpavde G, Salabao C, Kaymakalan MD, Wei X, Gupta S, Motwani S, Leaf DE, Reynolds KL, Sise ME. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. *Eur J Cancer*. 2021 Nov;157:50-58. PMID: 34482189
489. Pal SK, McGregor B, Suárez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, **Choueiri TK**, Agarwal N. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. *J Clin Oncol*. 2021 Nov 20;39(33):3725-3736. PMID: 34491815, PMCID: PMC8601305
490. Swami N, Hwang WL, Guo JA, Hoffman H, Abramowitz MC, Elbakouny Z, Beltran H, Chipidza F, **Choueiri T**, Pra AD, Huang F, Kaochar S, Kantoff P, Kim DW, Kishan AU, Kobetz E, Marinac C, Mucci LA, Muralidhar V, Pollack A, Sanford NN, Schaeffer EM, Spratt DE, Zhao SG, Rebbeck TR, Nguyen PL, Feng FY, Mahal BA, Alshalalfa M. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). *Cancer Genet*. 2021 Nov;258-259:61-68. PMID: 34551377
491. Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu CY, Shyr Y, Armstrong AJ, Beer TM, Bijjula RR, Bilen MA, Connell CF, Dawsey SJ, Faller B, Gao X, Gartrell BA, Gill D, Gulati S, Halabi S, Hwang C, Joshi M, Khaki AR, Menon H, Morris MJ, Puc M, Russell KB, Shah NJ, Sharifi N, Shaya J, Schweizer MT, Steinharter J, Wulff-Burchfield EM, Xu W, Zhu J, Mishra S, Grivas P, Rini BI, Warner JL, Zhang T, **Choueiri TK**, Gupta S, McKay RR. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. *JAMA Netw Open*. 2021 Nov 1;4(11):e2134330. PMID: 34767021, PMCID: PMC8590166
- Erratum in: *JAMA Netw Open*. 2021 Dec 1;4(12):e2145075. PMID: 34962566.
492. Rana HQ, Koeller DR, Schwartz A, Manning DK, Schneider KA, Krajewski KM, **Choueiri TK**, Lindeman NI, Garber JE, Ghazani AA. Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. *Eur J Med Genet*. 2021 Dec;64(12):104359. PMID: 34628056

493. Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, **Choueiri TK**. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. *JAMA Oncol*. 2021 Dec 1;7(12):1815-1823. PMID: 34673916, PMCID: PMC8532040
494. Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, **Choueiri TK**, Johnson DB, Marron TU, Wang Y, Naqash AR. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. *JAMA Oncol*. 2021 Dec 1;7(12):1856-1861. PMID: 34734989, PMCID: PMC8569601
495. Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, **Choueiri TK**, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. *Clin Cancer Res*. 2021 Dec 15;27(24):6687-6695. PMID: 34759043, PMCID: PMC9357269
496. Kehl KL, Xu W, Gusev A, Bakouny Z, **Choueiri TK**, Riaz IB, Elmarakeby H, Van Allen EM, Schrag D. Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. *Nat Commun*. 2021 Dec 15;12(1):7304. PMID: 34911934, PMCID: PMC8674229
497. Schmidinger M, Motzer RJ, Rolland F, Staehler M, Rink M, Retz M, Csozsi T, McCaffrey JA, De Giorgi U, Caserta C, Duran I, Benzaghrou F, Clary DO, Albiges L, **Choueiri TK**, Tannir NM. Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. *Acta Oncol*. 2022 Jan;61(1):52-57. PMID: 34736367, PMCID: PMC9357268
498. Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, **Choueiri TK**, Gulley JL, Carrington M. HLA-A*03 and response to immune checkpoint blockade in cancer:

an epidemiological biomarker study. *Lancet Oncol.* 2022 Jan;23(1):172-184. PMID: 34895481, PMCID: PMC8742225

499. Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilén MA, Caimi PF, **Choueiri TK**, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, Hershman DL, Khan H, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff-Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B, Hwang C, COVID-19 and Cancer Consortium (CCC19). Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. *JAMA Netw Open.* 2022 Jan 4;5(1):e2142046. PMID: 34982158, PMCID: PMC8728628
500. Bakouny Z, Sadagopan A, Ravi P, Metaferia NY, Li J, AbuHammad S, Tang S, Denize T, Garner ER, Gao X, Braun DA, Hirsch L, Steinharter JA, Bouchard G, Walton E, West D, Labaki C, Dudani S, Gan CL, Sethunath V, Carvalho FLF, Imamovic A, Ricker C, Vokes NI, Nyman J, Berchuck JE, Park J, Hirsch MS, Haq R, Mary Lee GS, McGregor BA, Chang SL, Feldman AS, Wu CJ, McDermott DF, Heng DY, Signoretti S, Van Allen EM, **Choueiri TK**, Viswanathan SR. Integrative clinical and molecular characterization of translocation renal cell carcinoma. *Cell Rep.* 2022 Jan 4;38(1):110190. PMID: 34986355, PMCID: PMC9127595
501. Bilén MA, Rini BI, Voss MH, Larkin J, Haanen JBAG, Albiges L, Pagliaro LC, Voog EG, Lam ET, Kislov N, McGregor BA, Lalani AA, Huang B, di Pietro A, Krulwicz S, Robbins PB, **Choueiri TK**. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. *Clin Cancer Res.* 2022 Feb 15;28(4):738-747. PMID: 34789480, PMCID: PMC9377757
502. Denize T, Farah S, Cimadamore A, Flaifel A, Walton E, Sticco-Ivins MA, Labaki C, Braun DA, Sun M, Wang E, Xie W, **Choueiri TK**, Signoretti S. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. *Clin Cancer Res.* 2022 Feb 15;28(4):748-755. PMID: 34921022, PMCID: PMC8866215
503. Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, Apolo AB, **Choueiri TK**. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. *Lancet Oncol.* 2022 Feb;23(2):292-303. PMID: 35032437, PMCID: PMC9479564

504. Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, McDermott DF, Stephen Hodi F, **Choueiri TK**, Freeman GJ. Soluble PD-L1 as an early marker of progressive disease on nivolumab. *J Immunother Cancer*. 2022 Feb;10(2). PMID: 35131863, PMCID: PMC8823247
505. McGregor BA, Xie W, Adib E, Stadler WM, Zakharia Y, Alva A, Michaelson MD, Gupta S, Lam ET, Farah S, Nassar AH, Wei XX, Kilbridge KL, Harshman L, Signoretti S, Sholl L, Kwiatkowski DJ, McKay RR, **Choueiri TK**. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. *JCO Precis Oncol*. 2022 Feb;6:e2100448. PMID: 35171658, PMCID: PMC8865529
506. Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, **Choueiri TK**, Leung D, Saggi SS, Lee CW, McHenry MB, Motzer RJ. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. *Eur Urol*. 2022 Mar;81(3):266-271. PMID: 34750035
507. Berchuck JE, Baca SC, McClure HM, Korthauer K, Tsai HK, Nuzzo PV, Kelleher KM, He M, Steinharter JA, Zacharia S, Spisak S, Seo JH, Conteduca V, Elemento O, Auh J, Sigouros M, Corey E, Hirsch MS, Taplin ME, **Choueiri TK**, Pomerantz MM, Beltran H, Freedman ML. Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. *Clin Cancer Res*. 2022 Mar 1;28(5):928-938. PMID: 34907080, PMCID: PMC8898270
508. Adib E, El Zarif T, Nassar AH, Akl EW, Abou Alaiwi S, Mouhieddine TH, Esplin ED, Hatchell K, Nielsen SM, Rana HQ, **Choueiri TK**, Kwiatkowski DJ, Sonpavde G. CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer. *Br J Cancer*. 2022 Mar;126(5):797-803. PMID: 34949788, PMCID: PMC8888603
509. Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, Blau S, Daher A, El Zarif T, Friese CR, Griffiths EA, Hawley JE, Hayes-Lattin B, Karivedu V, Latif T, Mavromatis BH, McKay RR, Nagaraj G, Nguyen RH, Panagiotou OA, Portuguese AJ, Puc M, Santos Dutra M, Schroeder BA, Thakkar A, Wulff-Burchfield EM, Mishra S, Farmakiotis D, Shyr Y, Warner JL, **Choueiri TK**, COVID-19 and Cancer Consortium. COVID-19 vaccination and breakthrough infections in patients with cancer. *Ann Oncol*. 2022 Mar;33(3):340-346. PMID: 34958894, PMCID: PMC8704021
510. Wang Y, Buck A, Grimaud M, Culhane AC, Kodangattil S, Razimbaud C, Bonal DM, Nguyen QD, Zhu Z, Wei K, O'Donnell ML, Huang Y, Signoretti S, **Choueiri TK**, Freeman GJ, Zhu Q, Marasco WA. Anti-CAIX BBζ CAR4/8 Tcells exhibit superior

efficacy in a ccRCC mouse model. *Mol Ther Oncolytics*. 2022 Mar 17;24:385-399. PMID: 35118195, PMCID: PMC8792103

511. Satyanarayana G, Enriquez KT, Sun T, Klein EJ, Abidi M, Advani SM, Awosika J, Bakouny Z, Bashir B, Berg S, Bernardes M, Egan PC, Elkrief A, Feldman LE, Friese CR, Goel S, Gomez CG, Grant KL, Griffiths EA, Gulati S, Gupta S, Hwang C, Jain J, Jani C, Kaltsas A, Kasi A, Khan H, Knox N, Koshkin VS, Kwon DH, Labaki C, Lyman GH, McKay RR, McNair C, Nagaraj G, Nakasone ES, Nguyen R, Nonato TK, Olszewski AJ, Panagiotou OA, Puc M, Razavi P, Robilotti EV, Santos-Dutra M, Schmidt AL, Shah DP, Shah SA, Vieira K, Weissmann LB, Wise-Draper TM, Wu U, Wu JT, **Choueiri TK**, Mishra S, Warner JL, French B, Farmakiotis D. Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. *Open Forum Infect Dis*. 2022 Mar;9(3):ofac037. PMID: 35198648, PMCID: PMC8860152
512. Adib E, El Zarif T, Jain RK, Skelton WP 4th, Freeman D, Curran C, Akl E, Nassar AH, Ravi P, Mantia C, Kwiatkowski DJ, **Choueiri TK**, Sonpavde G. FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma. *BJUI Compass*. 2022 Mar;3(2):169-172. PMID: 35224552, PMCID: PMC8880907
513. **Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry MB, Ross-Macdonald P, Wind-Rotolo M. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. *J Immunother Cancer*. 2022 Mar;10(3). PMID: 35304405, PMCID: PMC8935174**
514. Fu J, Reid SA, French B, Hennessy C, Hwang C, Gatson NT, Duma N, Mishra S, Nguyen R, Hawley JE, Singh SRK, Chism DD, Venepalli NK, Warner JL, **Choueiri TK**, Schmidt AL, Fecher LA, Girard JE, Bilen MA, Ravindranathan D, Goyal S, Wise-Draper TM, Park C, Painter CA, McGlown SM, de Lima Lopes G Jr, Serrano OK, Shah DP, COVID-19 and Cancer Consortium (CCC19). Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. *JAMA Netw Open*. 2022 Mar 1;5(3):e224304. PMID: 35344045, PMCID: PMC8961318
- Erratum in: *JAMA Netw Open*. 2022 Jun 1;5(6):e2217952. PMID: 35648408.
515. Tomita Y, Motzer RJ, **Choueiri TK**, Rini BI, Miyake H, Uemura H, Albiges L, Fujii Y, Umeyama Y, Wang J, Mariani M, Schmidinger M. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101. *ESMO Open*. 2022 Apr;7(2):100450. PMID: 35397432, PMCID: PMC9058903

516. Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, **Choueiri TK**, Culine S, Gerritsen W, Gurney H, Quinn DI, Vuky J, Vogelzang NJ, Cristescu R, Lunceford J, Saadatpour A, Loboda A, Ma J, Rajasagi M, Godwin JL, Homet Moreno B, Grivas P. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. *Clin Cancer Res.* 2022 May 13;28(10):2050-2060. PMID: 35247908
517. Park HJ, Qin L, Bakouny Z, Krajewski KM, Van Allen EM, **Choueiri TK**, Shinagare AB. Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors. *Oncologist.* 2022 May 6;27(5):389-397. PMID: 35348767, PMCID: PMC9074990
518. Rini BI, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, **Choueiri TK**, Motzer RJ, Atkins MB, Haanen J, Mariani M, Wang J, Hariharan S, Larkin J. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. *J Clin Oncol.* 2022 Jun 10;40(17):1929-1938. PMID: 35239416, PMCID: PMC9177241
519. Motzer RJ, McDermott DF, Escudier B, Burotto M, **Choueiri TK**, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Powles T, Donskov F, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, McHenry MB, Lee CW, McCarthy J, Ejzykowicz F, Tannir NM. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. *Cancer.* 2022 Jun 1;128(11):2085-2097. PMID: 35383908, PMCID: PMC9543316
520. Motzer R, Porta C, Alekseev B, Rha SY, **Choueiri TK**, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. *Lancet Oncol.* 2022 Jun;23(6):768-780. PMID: 35489363
521. Castelo-Branco L, Tsourti Z, Gennatas S, Rogado J, Sekacheva M, Viñal D, Lee R, Croitoru A, Vitorino M, Khallaf S, Šušnjar S, Soewoto W, Cardaña A, Djerouni M, Rossi M, Alonso-Gordoa T, Ngelangel C, Whisenant JG, **Choueiri TK**, Dimopoulou G, Pradervand S, Arnold D, Harrington K, Michielin O, Dafni U, Pentheroudakis G, Peters S, Romano E. COVID-19 in patients with cancer: first report of the ESMO

international, registry-based, cohort study (ESMO-CoCARE). *ESMO Open*. 2022 Jun;7(3):100499. PMID: 35644101, PMCID: PMC9080222

522. Navani V, Ernst M, Wells JC, Yuasa T, Takemura K, Donskov F, Basappa NS, Schmidt A, Pal SK, Meza L, Wood LA, Ernst DS, Szabados B, Powles T, McKay RR, Weickhardt A, Suarez C, Kapoor A, Lee JL, **Choueiri TK**, Heng DYC. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. *JAMA Netw Open*. 2022 Jun 1;5(6):e2216379. PMID: 35687336, PMCID: PMC9187954
523. Albiges L, Heng DYC, Lee JL, Walker S, Mellempgaard A, Ottesen L, Frigault MM, L'Hernault A, Wessen J, **Choueiri T**, Cancel M, Signoretti S. Impact of MET status on treatment outcomes in papillary renal cell carcinoma: Apooled analysis of historical data. *Eur J Cancer*. 2022 Jul;170:158-168. PMID: 35640484
524. Motzer RJ, Powles T, Burotto M, Escudier B, Boursolon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, **Choueiri TK**. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2022 Jul;23(7):888-898. PMID: 35688173
- Erratum in: *Lancet Oncol*. 2022 Jul;23(7):e319. PMID: 35772462.
525. Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, **Choueiri TK**, Pal S. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). *Lancet Oncol*. 2022 Jul;23(7):899-909. PMID: 35690072
526. Geynisman DM, Burotto M, Porta C, Suarez C, Boursolon MT, Huo S, Del Tejo V, Du EX, Yang X, Betts KA, **Choueiri TK**, McGregor B. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. *Clin Drug Investig*. 2022 Jul;42(7):611-622. PMID: 35696045, PMCID: PMC9250488
527. Nuzzo PV, Adib E, Weise N, Curran C, Stewart T, Freeman D, Nassar AH, Abou Alaiwi S, Bakouny Z, McGregor BA, **Choueiri TK**, Jain RK, McKay RR, Sonpavde G. Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. *Clin Genitourin Cancer*. 2022 Aug;20(4):301-306. PMID: 35614012

528. Martini A, Fallara G, Pellegrino AA, Nocera L, Larcher A, Raggi D, Campi R, Ploussard G, Malavaud B, Montorsi F, Pal SK, Spiess PE, **Choueiri TK**, Necchi A, Capitanio U. Multidisciplinary team referral at diagnosis for patients with non-metastatic renal cell carcinoma. *Urol Oncol*. 2022 Aug;40(8):384.e9-384.e384.e14. PMID: 35667983
529. Bakouny Z, Labaki C, Bhalla S, Schmidt AL, Steinharter JA, Cocco J, Tremblay DA, Awad MM, Kessler A, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, Kelleher KM, Seidman D, Huang H, Anderson-Keightly HM, El Zarif T, Alaiwi SA, Champagne C, Rosenbloom TD, Stewart PS, Johnson BE, Trinh Q, Tolaney SM, Galsky MD, **Choueiri TK**, Doroshow DB. Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study. *Ann Oncol*. 2022 Aug;33(8):836-844. PMID: 35715285, PMCID: PMC9197329
530. Graham J, Wells JC, Dudani S, Gan CL, Donskov F, Lee JL, Kollmannsberger CK, Meza L, Beuselinck B, Hansen A, North SA, Bjarnason GA, Sayegh N, Kanesvaran R, Wood LA, Hotte SJ, McKay RR, **Choueiri TK**, Heng DYC. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. *Eur J Cancer*. 2022 Aug;171:124-132. PMID: 35717820
531. Hasanov E, Yeboa DN, Tucker MD, Swanson TA, Beckham TH, Rini B, Ene CI, Hasanov M, Derks S, Smits M, Dudani S, Heng DYC, Brastianos PK, Bex A, Hanalioglu S, Weinberg JS, Hirsch L, Carlo MI, Aizer A, Brown PD, Bilen MA, Chang EL, Jaboin J, Brugarolas J, **Choueiri TK**, Atkins MB, McGregor BA, Halasz LM, Patel TR, Soltys SG, McDermott DF, Elder JB, Baskaya MK, Yu JB, Timmerman R, Kim MM, Mut M, Markert J, Beal K, Tannir NM, Samandouras G, Lang FF, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. *CA Cancer J Clin*. 2022 Sep;72(5):454-489. PMID: 35708940
532. Graff RE, Wilson KM, Sanchez A, Chang SL, McDermott DF, **Choueiri TK**, Cho E, Signoretti S, Giovannucci EL, Preston MA. Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. *Eur Urol*. 2022 Sep;82(3):247-251. PMID: 35715363
533. Denize T, Hou Y, Pignon JC, Walton E, West DJ, Freeman GJ, Braun DA, Wu CJ, Gupta S, Motzer RJ, Atkins MB, McDermott D, **Choueiri TK**, Shukla SA, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. *Clin Cancer Res*. 2022 Sep 15;28(18):4045-4055. PMID: 35802667, PMCID: PMC9481706

534. Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, **Choueiri TK**, KEYNOTE-564 Investigators. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2022 Sep;23(9):1133-1144. PMID: 36055304
535. Tomita Y, Larkin J, Venugopal B, Haanen J, Kanayama H, Eto M, Grimm MO, Fujii Y, Umeyama Y, Huang B, Mariani M, di Pietro A, **Choueiri TK**. Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. *ESMO Open*. 2022 Oct;7(5):100564. PMID: 36037566, PMCID: PMC9588905
536. Nassar AH, Adib E, Abou Alaiwi S, El Zarif T, Groha S, Akl EW, Nuzzo PV, Mouhieddine TH, Perea-Chamblee T, Taraszka K, El-Khoury H, Labban M, Fong C, Arora KS, Labaki C, Xu W, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Zaitlen N, Schoenfeld AJ, Schultz N, Berger MF, MacConaill LE, Ananda G, Kwiatkowski DJ, **Choueiri TK**, Schrag D, Carrot-Zhang J, Gusev A. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. *Cancer Cell*. 2022 Oct 10;40(10):1161-11172.e5. PMID: 36179682, PMCID: PMC9559771
537. Loo Gan C, Huang J, Pan E, Xie W, Schmidt AL, Labaki C, Meza L, Bouchard G, Li H, Jackson-Spence F, Sánchez-Ruiz C, Powles T, Kumar SA, Weise N, Hall WA, Rose BS, Beuselinck B, Suarez C, Pal SK, **Choueiri TK**, Heng DYC, McKay RR. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Eur Urol Oncol*. 2022 Oct 31. PMID: 36328934
538. Bootsma M, McKay RR, Enamekhoo H, Bade RM, Schehr JL, Mannino MC, Singh A, Wolfe SK, Schultz ZD, Sperger J, Xie W, Signoretti S, Kyriakopoulos CE, Kosoff D, Abel EJ, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Bassetti M, Floberg J, Yu M, Sethakorn N, Sharifi M, Harari PM, **Choueiri TK**, Lang JM, Zhao SG. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. *J Clin Oncol*. 2022 Nov 1;40(31):3633-3641. PMID: 35617646, PMCID: PMC9622626
539. Zhao SG, Sperger JM, Schehr JL, McKay RR, Enamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI, Wolfe SK, Mayberry RD, Krause HM, Bootsma M, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Kyriakopoulos CE, Kosoff D, Wei XX, Floberg J, Sethakorn N, Sharifi M, Harari PM, Huang W, Beltran H, **Choueiri TK**, Scher HI, Rathkopf DE, Halabi S, Armstrong AJ,

Beebe DJ, Yu M, Sundling KE, Taplin ME, Lang JM. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. *J Clin Invest*. 2022 Nov 1;132(21). PMID: 36317634, PMCID: PMC9621140

540. **Choueiri TK**, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. *J Immunother Cancer*. 2022 Nov;10(11). PMID: 36328377, PMCID: PMC9639138
541. Koelker M, Krimphove M, Alkhatib K, Nabi J, Kuo LE, Lipsitz SR, **Choueiri TK**, Chang SL, Doherty GM, Kibel AS, Trinh QD, Cole AP. Understanding Hospital-Level Patterns of Nonoperative Management for Low-risk Thyroid and Kidney Cancer. *JAMA Netw Open*. 2022 Nov 1;5(11):e2242210. PMID: 36378306, PMCID: PMC9667332
542. Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, **Choueiri TK**, Albiges L, Tannir NM, Malouf GG. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. *Oncologist*. 2022 Dec 9;27(12):1041-1047. PMID: 35979929
543. Mossanen M, Nassar AH, Stokes SM, Martinez-Chanza N, Kumar V, Nuzzo PV, Kwiatkowski DJ, Garber JE, Curran C, Freeman D, Preston M, Mouw KW, Kibel A, **Choueiri TK**, Sonpavde G, Rana HQ. Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes. *Clin Genitourin Cancer*. 2022 Dec;20(6):568-574. PMID: 36127252
544. **Choueiri TK**, Porta C, Suárez C, Hainsworth J, Voog E, Duran I, Reeves J, Czaykowski P, Castellano D, Chen J, Sedarati F, Powles T. Randomized Phase II Trial of Sapanisertib TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy. *Oncologist*. 2022 Dec 9;27(12):1048-1057. PMID: 36146944, PMCID: PMC9732228
545. Apolo AB, Powles T, Escudier B, Burotto M, Zhang J, Simsek B, Scheffold C, Motzer RJ, **Choueiri TK**. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial. *Eur J Cancer*. 2022 Dec;177:63-71. PMID: 36327527, PMCID: PMC9750497

546. Taylor CA, Watson RA, Tong O, Ye W, Nassiri I, Gilchrist JJ, de Los Aires AV, Sharma PK, Koturan S, Cooper RA, Woodcock VK, Jungkurth E, Shine B, Coupe N, Payne MJ, Church DN, Naranbhai V, Groha S, Emery P, Mankia K, Freedman ML, **Choueiri TK**, Middleton MR, Gusev A, Fairfax BP. IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma. *Nat Med*. 2022 Dec;28(12):2592-2600. PMID: 36526722, PMCID: PMC9800275
547. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, **Choueiri TK**, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. *Nat Med*. 2022 Dec;28(12):2584-2591. PMID: 36526723
548. Rini BI, Signoretti S, **Choueiri TK**, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. *J Immunother Cancer*. 2022 Dec;10(12). PMID: 36549781, PMCID: PMC9791431
549. Takemura K, Navani V, Ernst MS, Wells JC, Meza L, Pal SK, Lee JL, Li H, Agarwal N, Alva AS, Hansen AR, Basappa NS, Szabados B, Powles T, Tran B, Hocking CM, Beuselinck B, Yuasa T, **Choueiri TK**, Heng DY. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. *J Urol*. 2022 Dec 27;101097JU00000000000003132. PMID: 36573926
550. Larkin J, Oya M, Martignoni M, Thistlethwaite F, Nathan P, Ornstein MC, Powles T, Beckermann KE, Balar AV, McDermott D, Gupta S, Philips GK, Gordon MS, Uemura H, Tomita Y, Wang J, Michelon E, di Pietro A, **Choueiri TK**. Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. *Oncologist*. 2022 Dec 28. PMID: 36576173
551. Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilan MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes

- M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, **Choueiri TK**, Wise-Draper TM, COVID-19 and Cancer Consortium. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. *JAMA Oncol.* 2023 Jan 1;9(1):128-134. PMID: 36326731, PMCID: PMC9634600
552. Alhalabi O, Thouvenin J, Négrier S, Vano YA, Campedel L, Hasanov E, Bakouny Z, Hahn AW, Bilén MA, Msaouel P, **Choueiri TK**, Viswanathan SR, Sircar K, Albiges L, Malouf GG, Tannir NM. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. *Oncologist.* 2023 Jan 14. PMID: 36640141
553. Nassar AH, Abou Alaiwi S, Baca SC, Adib E, Corona RI, Seo JH, Fonseca MAS, Spisak S, El Zarif T, Tisza V, Braun DA, Du H, He M, Flaifel A, Alchoueiry M, Denize T, Matar SG, Acosta A, Shukla S, Hou Y, Steinharter J, Bouchard G, Berchuck JE, O'Connor E, Bell C, Nuzzo PV, Mary Lee GS, Signoretti S, Hirsch MS, Pomerantz M, Henske E, Gusev A, Lawrenson K, **Choueiri TK**, Kwiatkowski DJ, Freedman ML. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. *Nat Commun.* 2023 Jan 21;14(1):346. PMID: 36681680, PMCID: PMC9867739
554. Ernst MS, Navani V, Wells JC, Donskov F, Basappa N, Labaki C, Pal SK, Meza L, Wood LA, Ernst DS, Szabados B, McKay RR, Parnis F, Suarez C, Yuasa T, Lalani AK, Alva A, Bjarnason GA, **Choueiri TK**, Heng DYC. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. *Eur Urol.* 2023 Jan 25. PMID: 36707357
555. Han S, Camp SY, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker CA, Reardon B, Moore N, Kofman E, Labaki C, Braun D, **Choueiri TK**, AlDubayan SH, Van Allen EM. Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma. *medRxiv.* 2023 Jan 19. PMID: 36712083, PMCID: PMC9882438
556. Navani V, Wells JC, Boyne DJ, Cheung WY, Brenner DM, McGregor BA, Labaki C, Schmidt AL, McKay RR, Meza L, Pal SK, Donskov F, Beuselinck B, Otiato M, Ludwig L, Powles T, Szabados BE, **Choueiri TK**, Heng DYC. CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). *Clin Genitourin Cancer.* 2023 Feb;21(1):106.e1-106.e8. PMID: 35945133
557. Bakouny Z, El Zarif T, Dudani S, Connor Wells J, Gan CL, Donskov F, Shapiro J, Davis ID, Parnis F, Ravi P, Steinharter JA, Agarwal N, Alva A, Wood L, Kapoor A, Ruiz Morales JM, Kollmannsberger C, Beuselinck B, Xie W, Heng DYC, **Choueiri**

TK. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2023 Feb;83(2):145-151. PMID: 36272943

558. Shayeb AM, McManus HD, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan CL, Barata P, Bilen MA, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan MD, McGregor B, **Choueiri TK**, McKay RR. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. Clin Genitourin Cancer. 2023 Feb;21(1):55-62. PMID: 36411184
559. Tully KH, Berg S, Paciotti M, Janisch F, Reese SW, Noldus J, Shariat SF, **Choueiri T**, Müller G, McGregor B, Chang SL, Trinh QD, Mossanen M. The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. Clin Genitourin Cancer. 2023 Feb;21(1):63-68. PMID: 36517393
560. Nguyen DD, Labban M, Briggs L, Wallis CJD, Cole AP, Lipsitz SR, Iyer HS, Rebbeck TR, Weissman JS, **Choueiri TK**, Trinh QD. Access to definitive treatment and survival for intermediate-risk and high-risk prostate cancer at hospital systems serving health disparity populations. Urol Oncol. 2023 Feb 7. PMID: 36759298

Other peer-reviewed scholarship:

1. **Choueiri T**, Deitcher SR. Why shouldn't we use warfarin alone to treat acute venous thrombosis?. Cleve Clin J Med. 2002 Jul;69(7):546-548. PMID: 12109637
2. Abou-Jawde R, **Choueiri T**, Alemany C, Mekhail T. An overview of targeted treatments in cancer. Clin Ther. 2003 Aug;25(8):2121-2137. PMID: 14512124
3. **Choueiri TK**, Hutson TE, Bukowski RM. Evolving role of pegylated interferons in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2003 Dec;3(6):823-829. PMID: 14686704
4. **Choueiri TK**, Alemany CA, Abou-Jawde RM, Budd GT. Role of aromatase inhibitors in the treatment of breast cancer. Clin Ther. 2004 Aug;26(8):1199-1214. PMID: 15476902
5. Long JK, **Choueiri TK**, Hall GS, Avery RK, Sekeres MA. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc. 2005 Sep;80(9):1215-1216. PMID: 16178502
6. **Choueiri TK**, Wesolowski R, Mekhail TM. Phenoxodiol: isoflavone analog with antineoplastic activity. Curr Oncol Rep. 2006 Mar;8(2):104-107. PMID: 16507219

7. Thakkar SG, **Choueiri TK**, Garcia JA. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. *Curr Oncol Rep*. 2006 Mar;8(2):108-113. PMID: 16507220
8. **Choueiri TK**, Bukowski RM, Rini BI. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. *Semin Oncol*. 2006 Oct;33(5):596-606. PMID: 17045089
9. **Choueiri TK**, Stephenson AJ, Gilligan T, Klein EA. Management of clinical stage I nonseminomatous germ cell testicular cancer. *Urol Clin North Am*. 2007 May;34(2):137-48; abstract viii. PMID: 17484919
10. Golshayan AR, Brick AJ, **Choueiri TK**. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. *Future Oncol*. 2008 Feb;4(1):85-92. PMID: 18241003
11. **Choueiri TK**. Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents. *Clin Genitourin Cancer*. 2008 Mar;6(1):15-20. PMID: 18501077
12. **Choueiri TK**. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. *Curr Opin Investig Drugs*. 2008 Jun;9(6):658-671. PMID: 18516765
13. **Choueiri TK**, Raghavan D. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties. *Nat Clin Pract Oncol*. 2008 Aug;5(8):444-454. PMID: 18577983
14. Chowdhury S, Harper PG, **Choueiri TK**. The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy. *Nat Clin Pract Oncol*. 2008 Dec;5(12):698-699. PMID: 18852722
15. Chowdhury S, **Choueiri TK**. Recent advances in the systemic treatment of metastatic papillary renal cancer. *Expert Rev Anticancer Ther*. 2009 Mar;9(3):373-379. PMID: 19275514
16. Courtney KD, **Choueiri TK**. Optimizing recent advances in metastatic renal cell carcinoma. *Curr Oncol Rep*. 2009 May;11(3):218-226. PMID: 19336014
17. Atkins MB, **Choueiri TK**, Cho D, Regan M, Signoretti S. Treatment selection for patients with metastatic renal cell carcinoma. *Cancer*. 2009 May 15;115(10 Suppl):2327-2333. PMID: 19402069, PMCID: PMC2762357

18. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, **Choueiri TK**, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: testicular cancer. *J Natl Compr Canc Netw*. 2009 Jun;7(6):672-693. PMID: 19555582
19. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, **Choueiri TK**, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: kidney cancer. *J Natl Compr Canc Netw*. 2009 Jun;7(6):618-630. PMID: 19555584
20. Heng DY, **Choueiri TK**. Non-clear cell renal cancer: features and medical management. *J Natl Compr Canc Netw*. 2009 Jun;7(6):659-665. PMID: 19555587
21. **Choueiri TK**, Bellmunt J. Sunitinib in renal-cell carcinoma: expanded indications. *Lancet Oncol*. 2009 Aug;10(8):740. PMID: 19615941
22. Bellmunt J, Rosenberg JE, **Choueiri TK**. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. *Eur Urol*. 2009 Oct;56(4):606-608. PMID: 19635642
23. Je Y, Schutz FA, **Choueiri TK**. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. *Lancet Oncol*. 2009 Oct;10(10):967-974. PMID: 19767240
24. **Choueiri TK**, Mosquera JM, Hirsch MS. A case of adult metastatic xpl1 translocation renal cell carcinoma treated successfully with sunitinib. *Clin Genitourin Cancer*. 2009 Oct;7(3):E93-E94. PMID: 19815489
25. **Choueiri TK**, Atkins MB. Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?. *Nat Rev Clin Oncol*. 2009 Dec;6(12):679-680. PMID: 19942921
26. **Choueiri TK**. Prognostic factors in patients treated with VEGF-targeted therapies. *Clin Adv Hematol Oncol*. 2010 Feb;8(2):92-93. PMID: 20386528
27. Swinburn P, Lloyd A, Nathan P, **Choueiri TK**, Cella D, Neary MP. Elicitation of health state utilities in metastatic renal cell carcinoma. *Curr Med Res Opin*. 2010 May;26(5):1091-1096. PMID: 20225993

28. **Choueiri TK**, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. *J Clin Oncol*. 2010 May 1;28(13):2280-2285. PMID: 20351323
29. Courtney KD, **Choueiri TK**. Updates on novel therapies for metastatic renal cell carcinoma. *Ther Adv Med Oncol*. 2010 May;2(3):209-219. PMID: 21789135, PMCID: PMC3126014
30. Kelly PJ, Weiss SE, Sher DJ, Perez-Atayde AR, Dal Cin P, **Choueiri TK**. Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma. *J Clin Oncol*. 2010 Sep 1;28(25):e433-e435. PMID: 20547999
31. Katz L, **Choueiri TK**, Bellmunt J. C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy. *BJU Int*. 2010 Nov;106(9):1249-1250. PMID: 20963928
32. Bellmunt J, **Choueiri TK**, Schutz FA, Rosenberg JE. Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. *Ann Oncol*. 2011 Feb;22(2):245-247. PMID: 21278220
33. Hudes GR, Carducci MA, **Choueiri TK**, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. *J Natl Compr Canc Netw*. 2011 Feb;9 Suppl 1(0 1):S1-29. PMID: 21335444, PMCID: PMC4659363
34. Schutz FA, **Choueiri TK**, Sternberg CN. Pazopanib: Clinical development of a potent anti-angiogenic drug. *Crit Rev Oncol Hematol*. 2011 Mar;77(3):163-171. PMID: 20456972
35. Parithivel K, Ramaiya N, Jagannathan JP, O'Regan K, Krajewski K, Fisher D, **Choueiri TK**, Jacobsen E. Everolimus- and temsirolimus-associated enteritis: report of three cases. *J Clin Oncol*. 2011 May 10;29(14):e404-e406. PMID: 21357780
36. Schutz FA, Bellmunt J, Rosenberg JE, **Choueiri TK**. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. *Expert Opin Drug Saf*. 2011 Jul;10(4):645-653. PMID: 21524237
37. Sonpavde G, Agarwal N, **Choueiri TK**, Kantoff PW. Recent advances in immunotherapy for the treatment of prostate cancer. *Expert Opin Biol Ther*. 2011 Aug;11(8):997-991009. PMID: 21675925

38. Chowdhury S, Matrana MR, Tsang C, Atkinson B, **Choueiri TK**, Tannir NM. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. *Hematol Oncol Clin North Am.* 2011 Aug;25(4):853-869. PMID: 21763971, PMCID: PMC4167832
39. **Choueiri TK**. VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective. *Curr Clin Pharmacol.* 2011 Aug;6(3):164-168. PMID: 21827394
40. Williams SB, Lay AH, Lau CS, Josephson DY, Wilson TG, **Choueiri TK**, Pal SK. New therapies for castrate-resistant prostate cancer. *Expert Opin Pharmacother.* 2011 Sep;12(13):2069-2074. PMID: 21663529
41. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, **Choueiri TK**, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB, National Comprehensive Cancer Network. Kidney cancer. *J Natl Compr Canc Netw.* 2011 Sep 1;9(9):960-977. PMID: 21917622
- Erratum in: *J Natl Compr Canc Netw.* 2011 Nov 1;9(11):xlv.
42. Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, **Choueiri T**, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. *Eur Urol.* 2011 Oct;60(4):684-690. PMID: 21704448
43. Tang PA, Heng DY, **Choueiri TK**. Impact of body composition on clinical outcomes in metastatic renal cell cancer. *Oncologist.* 2011;16(11):1484-1486. PMID: 22020214, PMCID: PMC3233281
44. Heng DY, **Choueiri TK**. The evolving landscape of metastatic renal cell carcinoma. *Am Soc Clin Oncol Educ Book.* 2012;299-302. PMID: 24451753
45. Sonpavde G, **Choueiri TK**, Escudier B, Ficarra V, Hutson TE, Mulders PF, Patard JJ, Rini BI, Staehler M, Sternberg CN, Stief CG. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. *Eur Urol.* 2012 Feb;61(2):307-316. PMID: 22055147
46. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, **Choueiri TK**, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB,

National Comprehensive Cancer Network. Testicular cancer. *J Natl Compr Canc Netw*. 2012 Apr;10(4):502-535. PMID: 22491049

47. Sonpavde G, Bellmunt J, Schutz F, **Choueiri TK**. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. *Curr Oncol Rep*. 2012 Aug;14(4):295-306. PMID: 22532265
48. Klemptner SJ, **Choueiri TK**, Yee E, Doyle LA, Schuppan D, Atkins MB. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. *J Clin Oncol*. 2012 Sep 20;30(27):e264-e268. PMID: 22802316
49. Sonpavde G, **Choueiri TK**. Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. *Br J Cancer*. 2012 Sep 25;107(7):1009-1016. PMID: 22948724, PMCID: PMC3461173
50. **Choueiri TK**, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study. *Urol Oncol*. 2012 Nov-Dec;30(6):848-855. PMID: 20926319, <https://doi.org/10.1016/j.urolonc.2010.07.009>
51. Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, **Choueiri TK**, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Arterial Thromboembolism in Cancer Patients Treated with Cisplatin: A Systematic Review and Meta-analysis. *J Natl Cancer Inst*. 2012 Dec 5;104(23):1837-1840. PMID: 23093559
52. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, **Choueiri TK**, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. *J Clin Oncol*. 2012 Dec 10;30(35):4416-4426. PMID: 23150697
53. Harshman LC, **Choueiri TK**. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. *Cancer J*. 2013;19(4):316-323. PMID: 23867513
54. Bair SM, **Choueiri TK**, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. *Trends Cardiovasc Med*. 2013 May;23(4):104-113. PMID: 23290365, PMCID: PMC3621011
55. Kaymakcalan MD, Je Y, Sonpavde G, Galsky M, Nguyen PL, Heng DY, Richards CJ, **Choueiri TK**. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. *Br J Cancer*. 2013 Jun 25;108(12):2478-2484. PMID: 23736025, PMCID: PMC3694254

56. Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, Bellmunt J, **Choueiri TK**. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol*. 2013 Jul;87(1):80-89. PMID: 23317774
57. McKay RR, **Choueiri TK**, Taplin ME. Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. *Drugs*. 2013 Sep;73(13):1417-1430. PMID: 23943203, PMCID: PMC4127573
58. McKay RR, Taplin ME, **Choueiri TK**. Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. *Hematol Oncol Clin North Am*. 2013 Dec;27(6):1261-1283, ix. PMID: 24188262, PMCID: PMC4127574
59. Sonpavde G, **Choueiri TK**. Precision medicine for metastatic renal cell carcinoma. *Urol Oncol*. 2014 Jan;32(1):5-15. PMID: 24239472
60. Harshman LC, **Choueiri TK**, Drake C, Stephen Hodi F Jr. Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. *Cancer J*. 2014;20(4):272-280. PMID: 25098288, PMCID: PMC4894310
61. Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, **Choueiri TK**, Sonpavde G, Oh WK, Galsky MD. Metabolic complications with the use of mTOR inhibitors for cancer therapy. *Cancer Treat Rev*. 2014 Feb;40(1):190-196. PMID: 23684373, PMCID: PMC4744486
62. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, **Choueiri TK**, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rammers EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R, National comprehensive cancer networks. Kidney cancer, version 2.2014. *J Natl Compr Canc Netw*. 2014 Feb;12(2):175-182. PMID: 24586079
63. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, **Choueiri TK**, Bellmunt J. Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. *Eur Urol*. 2014 Jul;66(1):42-54. PMID: 24018020
64. Fay AP, Signoretti S, **Choueiri TK**. MET as a target in papillary renal cell carcinoma. *Clin Cancer Res*. 2014 Jul 1;20(13):3361-3363. PMID: 24812413

65. Gartrell BA, Ying J, Sivendran S, Boucher KM, **Choueiri TK**, Sonpavde G, Oh WK, Agarwal N, Galsky MD. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. *Target Oncol*. 2014 Sep;9(3):195-204. PMID: 23852656, PMCID: PMC4744485
66. Leow JJ, Martin-Doyle W, Fay AP, **Choueiri TK**, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. *Eur Urol*. 2014 Sep;66(3):529-541. PMID: 24680361
67. Groarke JD, **Choueiri TK**, Slosky D, Cheng S, Moslehi J. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway. *Curr Treat Options Cardiovasc Med*. 2014 Sep;16(9):335. PMID: 25099086
68. Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, Bellmunt J, **Choueiri TK**. Adrenocortical carcinoma: The management of metastatic disease. *Crit Rev Oncol Hematol*. 2014 Nov;92(2):123-132. PMID: 24958272, PMCID: PMC4578298
69. Venook AP, Arcila ME, Benson AB 3rd, Berry DA, Camidge DR, Carlson RW, **Choueiri TK**, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. *J Natl Compr Canc Netw*. 2014 Nov;12(11):1629-1649. PMID: 25361808, PMCID: PMC5241088
70. Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, **Choueiri TK**, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougerey R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. *Clin Genitourin Cancer*. 2014 Dec;12(6):395-398. PMID: 25035282
71. Harshman LC, Drake CG, **Choueiri TK**. PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond. *Cancer Immunol Res*. 2014 Dec;2(12):1132-1141. PMID: 25480555, PMCID: PMC4695990
72. Albiges L, **Choueiri T**, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R, Mulders P, Porta C, Powles T, Sternberg C, Bex A. A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. *Eur Urol*. 2015 Jan;67(1):100-110. PMID: 24841777
73. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, **Choueiri TK**, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM,

Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R, National comprehensive cancer network. Kidney cancer, version 3.2015. *J Natl Compr Canc Netw*. 2015 Feb;13(2):151-159. PMID: 25691606

74. Ghatalia P, Je Y, Mouallem NE, Nguyen PL, Trinh QD, Sonpavde G, **Choueiri TK**. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol*. 2015 Mar;93(3):257-276. PMID: 25523486
75. Ghatalia P, Morgan CJ, **Choueiri TK**, Rocha P, Naik G, Sonpavde G. Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. *Crit Rev Oncol Hematol*. 2015 Apr;94(1):136-145. PMID: 25541349
76. Sonpavde G, Jones BS, Bellmunt J, **Choueiri TK**, Sternberg CN. Future directions and targeted therapies in bladder cancer. *Hematol Oncol Clin North Am*. 2015 Apr;29(2):361-376, x. PMID: 25836940
77. Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, **Choueiri TK**, Sonpavde G. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. *Crit Rev Oncol Hematol*. 2015 May;94(2):228-237. PMID: 25577572
78. Valenca LB, Hirsch MS, **Choueiri TK**, Harshman LC. Non-clear cell renal cell carcinoma, part 1: histology. *Clin Adv Hematol Oncol*. 2015 May;13(5):308-313. PMID: 26352775
79. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, **Choueiri TK**, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. *J Natl Compr Canc Netw*. 2015 Jun;13(6):772-799. PMID: 26085393
80. Valenca LB, Hirsch MS, **Choueiri TK**, Harshman LC. Non-clear cell renal cell carcinoma, part 2: therapy. *Clin Adv Hematol Oncol*. 2015 Jun;13(6):383-391. PMID: 26352894
81. **Choueiri TK**, Motzer RJ. The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions. *J Natl Compr Canc Netw*. 2015 Oct;13(10):1168-1170. PMID: 26483056

82. de Velasco G, Hamieh L, Mickey S, **Choueiri TK**. Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. *Urol Oncol*. 2015 Dec;33(12):538-545. PMID: 26482392, PMCID: PMC4654640
83. Albiges L, Fay AP, McKay RR, Kaymakcalan MD, **Choueiri TK**. Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective. *Surg Pathol Clin*. 2015 Dec;8(4):657-662. PMID: 26612219
84. Dahal A, Bellows BK, Sonpavde G, Tantravahi SK, **Choueiri TK**, Galsky MD, Agarwal N. Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. *Am J Clin Oncol*. 2016 Oct;39(5):497-506. PMID: 24824144
85. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, **Choueiri TK**, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2017 Jun;15(6):804-834. PMID: 28596261
86. Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, **Choueiri TK**, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, CGC, Hammond LJ, Zuccarino-Catania G. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. *J Natl Compr Canc Netw*. 2019 Nov 1;17(11):1278-1285. PMID: 31693980
87. Bakouny Z, Flippot R, Braun DA, Lalani AA, **Choueiri TK**. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. *Eur Urol Focus*. 2020 Jan 15;6(1):37-40. PMID: 30827939
88. Ravi P, Bakouny Z, Schmidt A, **Choueiri TK**. Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. *Cancer J*. 2020;26(5):464-470. PMID: 32947315
89. Tenold M, Ravi P, Kumar M, Bowman A, Hammers H, **Choueiri TK**, Lara PN Jr. Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. *Am Soc Clin Oncol Educ Book*. 2020 Mar;40:1-10. PMID: 32239988

90. Bakouny Z, **Choueiri TK**. IL-8 and cancer prognosis on immunotherapy. *Nat Med*. 2020 May;26(5):650-651. PMID: 32405061
91. Nabhan C, **Choueiri TK**, Mato AR. Rethinking Clinical Trials Reform During the COVID-19 Pandemic. *JAMA Oncol*. 2020 Sep 1;6(9):1327-1329. PMID: 32761101
92. Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, **Choueiri TK**, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. *J Natl Compr Canc Netw*. 2020 Sep;18(9):1160-1170. PMID: 32886895
93. **Choueiri TK**, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. *Nat Med*. 2020 Oct;26(10):1519-1530. PMID: 33020645
94. Bakouny Z, Hawley JE, **Choueiri TK**, Peters S, Rini BI, Warner JL, Painter CA. COVID-19 and Cancer: Current Challenges and Perspectives. *Cancer Cell*. 2020 Nov 9;38(5):629-646. PMID: 33049215, PMCID: PMC7528740
95. Van Allen EM, **Choueiri TK**. Dissecting the immunogenomic biology of cancer for biomarker development. *Nat Rev Clin Oncol*. 2021 Mar;18(3):133-134. PMID: 33299070
96. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, **Choueiri TK**, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol*. 2021 May;18(5):313-319. PMID: 33723371, PMCID: PMC7957448, <https://doi.org/10.1038/s41571-021-00487-z>
- Erratum in: *Nat Rev Clin Oncol*. 2021 Mar 23:1; PMID: 33758378; PMCID: PMC7985918.
97. Schmidt AL, Tabakin AL, Singer EA, **Choueiri TK**, McKay RR. Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era. *Am Soc Clin Oncol Educ Book*. 2021 Mar;41:1-11. PMID: 33793313
98. Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, **Choueiri TK**. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal

cell carcinoma. *Nat Rev Clin Oncol*. 2021 Apr;18(4):199-214. PMID: 33437048, PMID: PMC8317018

99. Morgan G, de Azambuja E, Punie K, Ades F, Heinrich K, Personeni N, Rahme R, Ferrara R, Pels K, Garassino M, von Bergwelt-Baildon M, Lopes G, Barlesi F, **Choueiri TK***, Burris H*, Peters S*. OncoAlert Round Table Discussions: The Global COVID-19 Experience. *JCO Glob Oncol*. 2021 Apr;7:455-463. PMID: 33822643, PMID: PMC8221235
100. Paciotti M, Schmidt AL, Ravi P, McKay RR, Trinh QD, **Choueiri TK**. Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S. *Oncologist*. 2021 May;26(5):e905-e906. PMID: 33650184, PMID: PMC8100555
101. Labaki C, Peters S, **Choueiri TK**. Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic. *Cancer Discov*. 2021 Jun;11(6):1330-1335. PMID: 33811043
102. Friese CR, **Choueiri TK**, Duma N, Farmakiotis D, Grivas P, Rini BI, Shah DP, Thompson MA, Pergam SA, Mishra S, Warner JL. Care without a compass: Including patients with cancer in COVID-19 studies. *Cancer Cell*. 2021 Jul 12;39(7):895-896. PMID: 33894136, PMID: PMC8049404
103. Motzer R, **Choueiri TK**. Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply. *N Engl J Med*. 2021 Jul 15;385(3):287. PMID: 34260846
104. Chakraborty S, Balan M, Sabarwal A, **Choueiri TK**, Pal S. Metabolic reprogramming in renal cancer: Events of a metabolic disease. *Biochim Biophys Acta Rev Cancer*. 2021 Aug;1876(1):188559. PMID: 33965513, PMID: PMC8349779
105. **Choueiri TK**, Powles T. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. Reply. *N Engl J Med*. 2021 Nov 11;385(20):1920. PMID: 34758263
106. Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, **Choueiri TK**, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2022 Jan;20(1):71-90. PMID: 34991070
107. Labaki C, **Choueiri TK**. Perioperative immunotherapy for renal cell carcinoma: looking beyond the data. *Nat Rev Clin Oncol*. 2023 Feb;20(2):65-66. PMID: 36418478

Scholarship without named authorship:

1. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*. 2013 Jul 4;499(7456):43-49. PMID: 23792563, PMCID: PMC3771322
2. Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, **Choueiri TK**, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukheim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*. 2016 Jan 14;374(2):135-145. PMID: 26536169, PMCID: PMC4775252
3. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G, Panel members. Managing cancer patients during the COVID-19

pandemic: an ESMO multidisciplinary expert consensus. *Ann Oncol.* 2020 Oct;31(10):1320-1335. PMID: 32745693, PMCID: PMC7836806

4. COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org, COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. *Cancer Cell.* 2020 Dec 14;38(6):761-766. PMID: 33176160, PMCID: PMC7598547

Non-peer reviewed scholarship in print or other media:

Proceedings of meetings or other non-peer reviewed scholarship:

1. **Choueiri TK**, Atkins MB, Bakouny Z, Carlo MI, Drake CG, Jonasch E, Kapur P, Lewis B, Linehan WM, Mitchell MJ, Pal SK, Pels K, Poteat S, Rathmell WK, Rini BI, Signoretti S, Tannir N, Uzzo R, Wood CG, Hammers HJ. Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. *J Natl Cancer Inst.* 2021 Mar 1;113(3):234-243. PMID: 32359162, PMCID: PMC7936057
2. **Choueiri TK**, Albiges L, Atkins MB, Bakouny Z, Bratslavsky G, Braun DA, Haas NB, Haanen JBAG, Hakimi AA, Jewett MAS, Jonasch E, Kaelin WG, Kapur P, Labaki C, Lewis B, McDermott DF, Pal SK, Pels K, Poteat S, Powles T, Rathmell WK, Rini BI, Signoretti S, Tannir NM, Uzzo RG, Hammers HJ. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. *Clin Cancer Res.* 2022 Mar 1;28(5):831-839. PMID: 34965942, PMCID: PMC9223120

Reviews, chapters, monographs and editorials:

1. Bolwell BJ, **Choueiri TK**. Treatment approach to classical Hodgkin's disease. In: Sekeres M, Kalaycio M, Bolwell M, eds. *Clinical Malignant Hematology*, 1st ed. New York: McGraw-Hill; 2006. p. 767-81.
2. **Choueiri TK**, Olencki T. Unusual cutaneous malignancies. In: Raghavan D, Brecher M, Johnson D, Meropol N, Moots P, Thigpen J, eds. *Textbook of Uncommon Cancers*, 3rd ed. UK: John Wiley & Sons; 2006. p. 577-88.
3. **Choueiri TK**. Prognostic factors in metastatic renal cell cancer. In: Rini BI, Campbell SC, eds. *Renal Cell Carcinoma*, 1st ed. Hamilton, ON: BC Decker Inc; 2008. p. 154-66.

4. **Choueiri TK**, Thakkar SG, Raghavan D. Adjuvant and neoadjuvant treatment for genitourinary cancers. In: Silberman H, Silberman AW. Principles & Practice of Surgical Oncology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2010. p. 975-92.
5. **Choueiri TK**, Golshayan AR. VEGF inhibitors. In: Bukowski R, ed. Therapies in renal cell carcinoma. UK: Future Science Group; 2011. p. 13-25.
6. **Choueiri TK**. Renal cell carcinoma. Hematol Oncol Clin North Am. 2011 Aug;25(4):xiii-xxiv. PMID: 21763960
7. **Choueiri TK**, Pomerantz MM, Signoretti S. Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol. 2013 Feb;14(2):105-107. PMID: 23333115
8. **Choueiri TK**. Clinical treatment decisions for advanced renal cell cancer. J Natl Compr Canc Netw. 2013 May;11(5 Suppl):694-697. PMID: 23704246
9. Signoretti S, **Choueiri TK**, Kaelin WG Jr. Molecular Abnormalities in Kidney Cancer. In: Mendelsohn, Howley, Israel, Gray, Thompson, ed. The molecular basis of Cancer, 4E. Elsevier Inc.; 2014. p. 561-72.
10. Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, Bellmunt J, **Choueiri TK**. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. J Clin Oncol. 2014 Dec 20;32(36):4171-4172. PMID: 25385730
11. Pal SK, **Choueiri TK**, Karam JA, Heng DY. Metastatic renal cell carcinoma: Contending with a sea change in therapy. Urol Oncol. 2015 Dec;33(12):507-508. PMID: 26584741
12. Sun M, de Velasco G, Trinh QD, **Choueiri TK**. Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right Direction. Eur Urol. 2016 Jan;69(1):92-93. PMID: 26056068
13. Pal SK, Agarwal N, Grivas P, **Choueiri T**. Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence. J Clin Oncol. 2016 Mar 10;34(8):777-779. PMID: 26786913
14. Motzer RJ, Escudier B, **Choueiri TK**. Treatment of Advanced Renal-Cell Carcinoma. N Engl J Med. 2016 Mar 3;374(9):889-890. PMID: 26962911
15. Sun M, **Choueiri TK**. Kidney cancer: Recurrence in renal cell carcinoma: the work is not done. Nat Rev Urol. 2016 May;13(5):246-247. PMID: 27030528

16. Agarwal N, Sonpavde G, **Choueiri TK**, Pal SK. Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. *Eur Urol*. 2016 Jul;70(1):42-44. PMID: 26873842
17. **Choueiri TK**, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. *N Engl J Med*. 2017 Jan 26;376(4):354-366. PMID: 28121507
18. Albiges L, **Choueiri TK**. Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position. *Nat Rev Clin Oncol*. 2017 Feb;14(2):82-84. PMID: 28071677
19. Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Taberero J, Sweeney CJ, **Choueiri TK**, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurrpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Strategies to design clinical studies to identify predictive biomarkers in cancer research. *Cancer Treat Rev*. 2017 Feb;53:79-97. PMID: 28088073
20. Sun M, Hanna N, Trinh QD, **Choueiri TK**. Reply to C. Buttigliero et al and B. Biswas et al. *J Clin Oncol*. 2017 Apr 10;35(11):1266-1267. PMID: 28165905
21. Sun M, Vetterlein M, Harshman LC, Chang SL, **Choueiri TK**, Trinh QD. Risk Assessment in Small Renal Masses: A Review Article. *Urol Clin North Am*. 2017 May;44(2):189-202. PMID: 28411911
22. Davis ID, Pezaro C, Xie W, **Choueiri TK**, Heng DYC. Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. *Eur Urol* 2017;71:970-8. *Eur Urol*. 2017 Jun;71(6):e177-e178. PMID: 28041718
23. **Choueiri TK**, Halabi S, Morris MJ, George D. Reply to B. Rini et al and S. Buti et al. *J Clin Oncol*. 2017 Jun 1;35(16):1859-1860. PMID: 28549224
24. de Velasco G, Culhane AC, Heng DYC, Signoretti S, **Choueiri TK**. In Reply. *Oncologist*. 2017 Dec;22(12):1561. PMID: 28894018, PMCID: PMC5728026
25. Lalani AA, McGregor BA, Sonpavde GP, **Choueiri TK**. JAVELIN: Avelumab Another Spear to Fight Urothelial Carcinoma. *Lancet Oncol*. 2018 Jan;19(1):5-7. PMID: 29217289

26. Seisen T, Kamran SC, Markt SC, Preston MA, Trinh QD, Frazier LA, **Choueiri TK**, Martin NE, Nguyen PL, Beard CJ. Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. *Eur Urol* 2018;73:262-70. *Eur Urol*. 2018 Apr;73(4):e100-e101. PMID: 29108659
27. Kamran SC, Seisen T, Markt SC, Preston MA, Trinh QD, Frazier LA, **Choueiri TK**, Martin NE, Nguyen PL, Beard CJ. Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. *Eur Urol* 2018;73:262-70. *Eur Urol*. 2018 Apr;73(4):e96-e97. PMID: 29358058
28. Kanesvaran R, Le Saux O, Motzer R, **Choueiri TK**, Scotté F, Bellmunt J, Launay-Vacher V. Elderly Patients with Metastatic Renal Cell Carcinoma: position paper from the International Society of Geriatric Oncology. *Lancet Oncol*. 2018 Jun;19(6):e317-e326. PMID: 29893263
29. Albiges L, Flippot R, Rioux-Leclercq N, **Choueiri TK**. Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light. *J Clin Oncol*. 2018 Oct 29;JCO2018792531. PMID: 30372389
30. McKay RR, Bossé D, **Choueiri TK**. Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. *J Clin Oncol*. 2018 Oct 29;JCO2018790253. PMID: 30372392
31. Graham J, Abdel-Rahman O, **Choueiri TK**, Heng DY, International mRCC Database Consortium. Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. *Lancet Oncol* 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium. *Eur Urol*. 2018 Dec;74(6):e139-e140. PMID: 30031571
32. Alessandrino F, Shinagare AB, Bossé D, **Choueiri TK**, Krajewski KM. Radiogenomics in Renal Cell Carcinoma. *Abdom Radiol (NY)*. 2019 Jun;44(6):1990-1998. PMID: 29713740
33. Rubinstein SM, Steinharter JA, Warner J, Rini BI, Peters S, **Choueiri TK**. The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. *Cancer Cell*. 2020 Jun 8;37(6):738-741. PMID: 32454025, PMCID: PMC7188629

34. Green EA, Li R, Albiges L, **Choueiri TK**, Freedman M, Pal S, Dyrskjøet L, Kamat AM. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. *Eur Urol Oncol*. 2021 Dec;4(6):893-903. PMID: 33975782
35. Labaki C, Van Allen EM, **Choueiri TK**. Linking a Trio of Molecular Features in Clear-Cell Renal Cell Carcinoma. *Cancer Immunol Res*. 2022 Mar 1;10(3):274. PMID: 35131809
36. Gulati S, Labaki C, Karachaliou GS, **Choueiri TK**, Zhang T. First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape. *Oncologist*. 2022 Mar 4;27(2):125-134. PMID: 35641205, PMCID: PMC8895741
37. Morgan G, Agarwal N, **Choueiri TK**, Dizon DS, Hamilton EP, Markham MJ, Lewis M, Prowell TM, Rugo HS, Subbiah V, West HL. The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. *Cancer Discov*. 2022 Jul 6;12(7):1620-1624. PMID: 35791692
38. Labaki C, Bakouny Z, Sonpavde G, **Choueiri TK**, Van Allen EM. Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma. *Eur Urol Oncol*. 2022 Dec;5(6):719-721. PMID: 35105532

Case reports:

1. **Choueiri T**, Abou Jawde R, Pelley R. A 58-year-old female with pelvic pain. *Clinical Cases from the Cleveland Clinic Foundation*. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002. p. 148-50.
2. Tabbarah K, **Choueiri T**, Tchapoulou O, Larosa S. A 59-year-old male with a painful hand ulcer. *Clinical Cases from the Cleveland Clinic Foundation*. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002. p. 166-69.
3. **Choueiri T**, Lichtin AE. Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab. *Am J Med*. 2002 Dec 1;113(8):700-701. PMID: 12505128
4. de Velasco G, Bermas B, **Choueiri TK**. Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment. *Arthritis Rheumatol*. 2016 Feb;68(2):556-557. PMID: 26314277
5. Marmarelis ME, Davis MR, Sethi NS, Krajewski KM, McKay RR, **Choueiri TK**, Ott PA. Tumor control with PD-1 inhibition in a patient with concurrent metastatic

melanoma and renal cell carcinoma. *J Immunother Cancer*. 2016;4:26. PMID: 27099755, PMCID: PMC4837591

6. Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, **Choueiri TK**. Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: A Case Series. *J Immunother Cancer*. 2017 Aug 15;5(1):66. PMID: 28807048, PMCID: PMC5557522
7. Pal SK, Ali SM, Ross J, **Choueiri TK**, Chung JH. Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a CDKN2A Homozygous Deletion. *JCO Precis Oncol*. 2017 Nov;1:1-5. PMID: 35172492
8. Nassar AH, Lundgren K, Kim J, **Choueiri TK**, Sonpavde GP, Kwiatkowski DJ, Bellmunt J. Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma. *JCO Precis Oncol*. 2018;2. PMID: 33604497, PMCID: PMC7885951

Letters to the Editor:

1. Cella D, **Choueiri TK**, Motzer RJ. Patient-reported outcomes: what really matters to patients? - Authors' reply. *Lancet Oncol*. 2022 May;23(5):e199. PMID: 35489343
2. Goldman E, **Choueiri TK**, Mainelis G, Ramachandran G, Schaffner DW. Triethylene Glycol Can Be Predeployed as a Safe Virus-Killing Indoor Air Treatment. *J Infect Dis*. 2022 Nov 28;226(11):2040-2041. PMID: 36177834
3. Powles T, Burgents JE, Xu L, **Choueiri TK**, KEYNOTE-564 Investigators. Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma - Authors' reply. *Lancet Oncol*. 2023 Jan;24(1):e1-e2. PMID: 36603921

Professional educational materials or reports, in print or other media:

1. Atkins MB, Bakouny Z, **Choueiri TK**. Epidemiology, pathology, and pathogenesis of renal cell carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 19 November 2021.
2. Bakouny Z, **Choueiri TK**. Renal cell carcinoma with sarcomatoid features. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 19 November 2021.

3. **Choueiri TK**, Pal SK. The treatment of advanced non-clear cell renal carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 19 November 2021.
4. **Choueiri TK**, Sonpavde G. Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 19 November 2021.
5. **Choueiri TK**, Sonpavde G. Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 19 November 2021.
6. **Choueiri TK**. Hereditary kidney cancer syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 19 November 2021.
7. **Choueiri TK**. Prognostic factors in patients with renal cell carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 19 November 2021.
8. Lotan Y, **Choueiri TK**. Clinical presentation, diagnosis, and staging of bladder cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 19 November 2021.
9. Lotan Y, **Choueiri TK**. Patient education: Bladder cancer diagnosis and staging (Beyond the Basics). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 19 November 2021.
10. Richie JP, **Choueiri TK**. Role of surgery in patients with metastatic renal cell carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed 19 November 2021.

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings:

1. Agarwal N, Loriot Y, McGregor BA, Dreicer R, Dorff TB, Maughan BL, Kelly WK, Pagliaro LC, Srinivas S, Squillante CM, Vaishampayan UN, Liu Y, Curran D, **Choueiri TK**, Pal SK. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study. February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);139.
2. Agarwal N, Loriot Y, McGregor BA, Dreicer R, Dorff TB, Maughan BL, Kelly WK, Pagliaro LC, Srinivas S, Squillante CM, Vaishampayan UN, Wang EW, Curran D, **Choueiri TK**, Pal SK. Cabozantinib in combination with atezolizumab in patients with

metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5564.

3. Albiges L, Heng DY, Lee J-L, Walker S, Mellema A, Ottesen L, Frigault MM, L'Hernault A, Wessen J, **Choueiri TK**, Cancel M, Signoretti S. MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);e19321.
4. Albiges L, Tannir N, Buratto M, McDermott DF, Plimack ER, Barthelemy P, Porta CG, Powles TB, Donskov F, George S, Kollmannsberger C, Gurney H, Grimm M, Tomita Y, Castellano Gauna D, Rini BI, **Choueiri TK**, Saggi SS, McHenry MB, Motzer RJ. Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy. September 2020 ESMO Virtual Congress. Ann Oncol 2020;31(suppl_4):711P.
5. Araujo DV, Wells C, Hansen AR, Dizman N, Pal SK, Beuselinck B, Donskov F, Gan CL, Yan F, Tran B, Kollmannsberger CK, de Velasco G, Yuasa T, Reasume MN, Ernst DS, Powles T, Bjarnason GA, **Choueiri TK**, Heng DY, Dudani S. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5068.
6. Atkins MB, Puzanov I, Plimack ER, Fishman MN, McDermott DF, Cho DC, Vaishampayan UN, George S, Tarazi JC, Duggan W, Perini RF, Fernandez KC, **Choueiri TK**. Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5080.
7. Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Nassar A, Abou Alaiwi S, Flippot R, Steinharter JA, Nuzzo PV, Ishii Y, Ross-Macdonald P, Lee GSM, McDermott DF, Heng DY, Signoretti S, Van Allen Em, **Choueiri TK**. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI). February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);715.
8. Bakouny Z, Xie W, Dudani S, Wells C, Gan CL, Donskov F, Shapiro J, Davis ID, Parnis F, Ravi P, Steinharter JA, Agarwal N, Alva AS, Wood L, Kapoor A, Morales JMR, Kollmannsberger CK, Beuselinck B, Heng DY, **Choueiri TK**. Cytoreductive

nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis. February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);608.

9. Bilen MA, Rini BI, Motzer RJ, Larkin JMG, Haanen JBAG, Albiges L, Pagliaro LC, Voog E, Lam ET, Kislov N, McGregor BA, Huang B, di Pietro A, Krulewicz S, **Choueiri TK**. Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5061.
10. Chang E, Gong Y, Weinstock C, Fernandes LL, Hawley J, Gwise T, Regan MM, **Choueiri TK**, Rini BI, McDermott DF, Atkins MB, Suzman DL, Ibrahim A, Tang S, Theoret MR, Kluetz PG, Pazur R, Beaver JA. FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5081.
11. **Choueiri TK**, Albiges L, Fan L, Perini RF, Zojwalla NJ, Powles T, Rini BI. Phase III study of the hypoxia-inducible factor 2 α (HIF-2 α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC). June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);TPS5094.
12. **Choueiri TK**, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ. A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk. February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);TPS767.
13. **Choueiri TK**, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ. A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);TPS5102.
14. **Choueiri TK**, Haanen JBAG, Larkin JMG, Rini BI, Albiges L, Motzer RJ, di Pietro A, Mu XJ, Ching KA, Hariharan S, Robbins PB. Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101. February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);744.
15. **Choueiri TK**, Kluger HM, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee C-H, Hotte SJ, Miller WH, Saggi SS, Gold D, Motzer RJ, Escudier B. FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell

carcinoma (aRCC). June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5007.

16. **Choueiri TK**, Plimack ER, Bauer TM, Merchan JR, Papadopoulos KP, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Zojwalla NJ, Jonasch E. Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);611.
17. **Choueiri TK**, Powles T, Burotto M, Bourlon MT, Zurawski B, Oyervides Juarez VM, Hsieh JJ, Basso U, Shah AY, Suarez C, Hamzaj A, Barrios CH, Richardet M, Pook D, Tomita Y, Escudier B, Zhang J, Simsek B, Apolo AB, Motzer RJ. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. September 2020 ESMO Virtual Congress. Ann Oncol 2020;31(suppl_4):6960_PR.
18. **Choueiri TK**, Stwalley B, Huo S, May JR, Malcolm B, Nickel K, Szabo N, Klijn S. Comparison of long-term survival and cost-effectiveness (CE) of first-line (1L) treatment options in advanced renal cell carcinoma (aRCC) with intermediate or poor (I/P) prognostic risk. September 2020 ESMO Virtual Congress. Ann Oncol 2020;31(suppl_4):717P.
19. Doroshov D, Schmidt AL, Bakouny Z, Bhalla S, Steinharter JA, Tremblay D, Awad MM, Kessler AJ, Bouchard G, Evans M, Busser F, Zimmerman BS, Curran CR, Jun T, Haddad R, Qin Q, Nuzzo PV, Feld J, Galsky MD, **Choueiri TK**. Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS). September 2020 ESMO Virtual Congress. Ann Oncol 2020;31(suppl_4):LBA74.
20. Dudani S, Gan CL, Wells C, Bakouny Z, Dizman N, Pal SK, Kollmannsberger CK, Szabados B, Powles T, Beuselinck B, Donskov F, Hansen AR, Bjarnason GA, Canil CM, Srinivas S, Agarwal N, Liow ECH, **Choueiri TK**, Heng DYC. Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5063.
21. Dudani S, de Velasco G, Wells C, Gan CL, Donskov F, Porta C, Fracon A, Pasini F, Hansen AR, Bjarnason GA, Beuselinck B, Pal SK, Hotte SJ, Lalani AKA, Yuasa T, Kanesvaran R, Reaume MN, Canil CM, **Choueiri TK**, Heng DYC. Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);624.

22. Dudani S, de Velasco G, Wells C, Gan CL, Donskov F, Porta C, Fraccon A, Pasini F, Lee J-L, Hansen AR, Bjarnason GA, Beuselinck B, Pal SK, Yuasa T, Kroeger N, Kanesvaran R, Reaume MN, Canil CM, **Choueiri TK**, Heng DYC. Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5071.
23. Enamekhoo H, Schehr JL, Bade RM, Wei XX, McKay RR, **Choueiri TK**, Lang JM. Clinical correlation of circulating tumor cell (CTC) PD-L1 and HLA I expression in metastatic renal cell carcinoma (mRCC) using exclusion-based sample preparation technology. February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);721.
24. Ficial M, Jegede O, Sant'Angelo M, Moreno S, Braun DA, Wind-Rotolo M, Pignon J-C, Catalano PJ, Sun M, Van Allen EM, Freeman GJ, Sharpe A, Hodi FS, Motzer RJ, Wu CJ, Atkins MB, McDermott DF, Shukla SA, **Choueiri TK**, Signoretti S. Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5023.
25. Flippot R, Bakouny Z, Wei XX, Braun DA, McGregor BA, Steinharter JA, Harshman LC, Vaishampayan UN, Severgnini M, McDermott DF, Hodi FS, Lee GSM, Van Allen EM, Signoretti S, **Choueiri TK**, McKay RR. Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial. February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);740.
26. Gan CL, Dudani S, Wells C, Bakouny Z, Dizman N, Pal SK, Szabados B, Wood L, Kollmannsberger CK, Agarwal N, Donskov F, Basappa NS, Bjarnason GA, Parnis F, Porta C, Davis ID, Vaishampayan UN, Kanesvaran R, **Choueiri TK**, Heng DYC. Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5070.
27. Gan CL, Dudani S, Wells C, Donskov F, Pal SK, Dizman N, Rathi N, Beuselinck B, Yan F, Lalani AKA, Hansen AR, Szabados B, de Velasco G, Tran B, Lee JL, Vaishampayan UN, Bjarnason GA, Subasri M, **Choueiri TK**, Heng DYC. Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC

Database Consortium (IMDC). February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);639.

28. Gan CL, Stukalin I, Meyers DE, Dudani S, Grosjean HAI, Dolter S, Ewanchuk BW, Goutam S, Sander M, Wells JC, Pabani A, Cheng T, Monzon J, Morris D, Basappa NS, Pal SK, Wood LA, Donskov F, **Choueiri TK**, Heng DYC. Outcomes of patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials. September 2020 ESMO Virtual Congress. Ann Oncol 2020;31(suppl_4):1046P.
29. Grivas P, Balar AV, Vuky J, de Wit R, Vogelzang NJ, **Choueiri TK**, Bajorin D, Castellano Gauna D, Gerritsen W, Gurney H, Quinn DI, Culine S, Fradet Y, Saadatpour A, Loboda A, Ma J, Rajasagi M, Godwin JL, Moreno BH, Bellmunt J. Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC). September 2020 ESMO Virtual Congress. Ann Oncol 2020;31(suppl_4):744P.
30. Grivas P, Warner J, Shyr Y, Shah D, Rubinstein SM, Kuderer NM, **Choueiri TK**, Rivera D, Painter C, Thompson MA, Peters S, Desai A, Khaki AR, Pennell NA, Hawley J, Halmos B, Puc MM, Lyman GH, Rini BI, Lopes G. Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). September 2020 ESMO Virtual Congress. Ann Oncol 2020;31(suppl_4):LBA72.
31. Haanen JBAG, Masters JC, Huang B, **Choueiri TK**, Motzer RJ, Khandelwal A, Dai HI, di Pietro A, Brar S, Rini BI, Albiges L, Larkin JMG. Avelumab flat dose regimen: Justification for use in advanced renal cell carcinoma (aRCC). February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(5_suppl);32.
32. Haas NB, Puligandla M, Allaf ME, McDermott DF, Drake CG, Signoretti S, Cella d, Gupta RT, Shuch BM, Lara P, Kapoor A, Heng DYC, Leibovich BC, Michaelson MD, **Choueiri TK**, Jewett MAS, Maskens D, Harshman LC, Master VA, Carducci MA. PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);TPS5101.
33. Harshman LC, Puligandla M, Allaf ME, McDermott DF, Drake CG, Signoretti S, Celal D, Gupta RT, Shuch BM, Lara P, Kapoor A, Heng DYC, Leibovich B, Michaelson MD, **Choueiri TK**, Master VA, Jewett MAS, Maskens D, Haas NB, Carducci MA. PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy

(ECOG-ACRIN EA8143). February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);TPS765.

34. Jonasch E, Hasanov E, Motzer RJ, Hariharan S, **Choueiri TK**, Huang B, Haanen JBAG, Albiges L, Venugopal B, Schmidinger M, Larkin JMG, Grimm MO, Negrier S, Wang J, Mariani M, Chudnovsky A, di Pietro A, Rini BI. Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S). February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);687.
35. Mahoney KM, Ross-Macdonald PB, Shukla SA, Braun DA, Song L, Veras E, Wind-Rotolo M, Van Allen EM, McDermott DF, Hodi FS, **Choueiri TK**, Freeman GJ. Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer. February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);746.
36. McGregor BA, Agarwal N, Suarez C, Tsao C, Kelly W, Pagliaro L, Vaishampayan UM, Castellano D, Loriot Y, Werneke S, Curran D, **Choueiri TK**, Pal S. Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study. September 2020 ESMO Virtual Congress. Ann Oncol 2020;31(suppl_4):709P.
37. McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Sonpavde G, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bublely G, Siefker-Radtke AO, McKay RR, **Choueiri TK**. Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5018.
38. McKay RR, Xie W, McGregor BA, Braun DA, Wei XX, Kyriakopoulos C, Zakharia Y, Maughan BL, Rose TL, Stadler WM, McDermott DF, Harshman LC, **Choueiri TK**. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5005.
39. Motzer RJ, **Choueiri TK**, McDermott DF, Powles T, Yao J, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry BM, Ross-Macdonald P, Wind-Rotolo M. Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC). June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5009.
40. Motzer RJ, Tykodi SS, Escudier B, Oudard S, Hammers HJ, McDermott DF, George S, Castellano D, **Choueiri TK**, Alva AS, Richardet ME, Plimack ER, Srinivas S, Procopio G, Donskov F, Gurney H, Tomita Y, McHenry MB, Saggi SS, Tannir NM. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma

(aRCC). February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);617.

41. Motzer RJ, Tykodi SS, Escudier B, Oudard S, Hammers HJ, McDermott DF, George S, Castellano D, **Choueiri TK**, Alva AS, Richardet ME, Plimack ER, Srinivas S, Procopio G, Donskov F, Gurney H, Tomita Y, McHenry MB, Saggi SS, Tannir NM. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);617.
42. Nuzzo PV, Berchuck JE, Spisak S, Korthauer K, Nassar A, Abou Alaiwi S, Chakravarthy A, Shen SY, Bakouny Z, Boccardo F, Baca S, Lee GSM, Chang SL, Waikar S, Sonpavde G, Irizarry RA, Pomerantz M, De Carvalho D, Freedman ML, **Choueiri TK**. Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);728.
43. Nuzzo PV, Spisak S, Berchuck JE, Baca S, Korthauer K, Nassar A, Abou Alaiwi S, Bakouny Z, Flippot R, Steinharter JA, Curran C, Lee GSM, Waikar S, Pomerantz M, De Carvalho D, Sonpavde G, Freedman ML, **Choueiri TK**. Detection of urothelial carcinoma using plasma cell-free methylated DNA. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5046.
44. Oya M, Tamada S, Tatsugami K, Nakaigawa N, Osawa T, Kanayama H-O, Kondoh C, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kimura A, Kuroda S, Motzer RJ, **Choueiri TK**, Tomita Y. A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma. June 2020 ASCO Annual Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(suppl);5089.
45. Pal S, Tsao C, Suarez C, Kelly W, Pagliaro L, Vaishampayan UM, Loriot Y, Srinivas S, McGregor BA, Panneerselvam A, Curran D, **Choueiri TK**, Agarwal N. Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study. September 2020 ESMO Virtual Congress. Ann Oncol 2020;31(suppl_4):7020.
46. Pan W, Zhang Z, Kimball H, Qiu F, Lee GSM, **Choueiri TK**, Kantoff PW. The effect of abiraterone acetate treatment on CREB and the development of abiraterone acetate resistance in prostate cancer cells. February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl);177.
47. Stukalin I, Dudani S, Wells C, Gan CL, Pal SK, Dizman N, Powles T, Donskov F, Wood L, Bakouny Z, Kollmannsberger CK, Basappa NS, Hansen AR, de Velasco G,

- Beuselinck B, Canil CM, Vaishampayan UN, Agarwal N, **Choueiri TK**, Heng DYC. Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). February 2020 GCS Meeting. *J Clin Oncol (Meeting Abstracts)* 2020;38(6_suppl);684.
48. Tykodi SS, Bauer TM, McDermott DF, Arrowsmith E, Zojwalla NJ, **Choueiri TK**. Phase II study of the oral hypoxia-inducible factor 2 α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). February 2020 GCS Meeting. *J Clin Oncol (Meeting Abstracts)* 2020;38(6_suppl);TPS766.
49. Voss MH, Motzer RJ, Albiges L, Rini BI, Schmidinger M, Larkin JMG, Haanen JBAG, Kollmannsberger CK, Campbell MT, Grimm MO, Pal SK, Gravis G, Atkins MB, Huang B, Chudnovsky A, di Pietro A, Thomaidou D, **Choueiri TK**. Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101. February 2020 GCS Meeting. *J Clin Oncol (Meeting Abstracts)* 2020;38(6_suppl);690.
50. Wise-draper TM, Desai A, Elkrief A, Rini BI, Flora DB, Bowles DW, Shah D, Rivera D, Johnson DB, Lopes G, Grivas P, Thompson MA, Peters S, Kuderer NM, Nock NL, Grover P, Li X, Gulati S, **Choueiri TK**, Warner J. Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis. September 2020 ESMO Virtual Congress. *Ann Oncol* 2020;31(suppl_4):LBA72.
51. Zengin ZB, Weipert C, Hsu J, Salgia N, Saam J, **Choueiri TK**, Agarwal N, Pal S. Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing. September 2020 ESMO Virtual Congress. *Ann Oncol* 2020;31(suppl_4):7010.
52. Zhang T, Ballman KV, Choudhury AD, Chen RC, Watt C, Wen Y, Shergill A, Zemla TJ, Emamekhoo HE, Vaishampayan UN, Morris MJ, George DJ, **Choueiri TK**. PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). June 2020 ASCO Annual Meeting. *J Clin Oncol (Meeting Abstracts)* 2020;38(suppl);TPS5100.
53. Zhang T, Ballman KV, Choudhury AD, Chen RC, Watt C, Wen Y, Zemla T, Emamekhoo H, Vaishampayan UN, Morris MJ, George DJ, **Choueiri TK**. PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). February 2020 GCS Meeting. *J Clin Oncol (Meeting Abstracts)* 2020;38(6_suppl);TPS760.

54. Abou Alaiwi S, Nassar A, Adib E, Akl E, Groha S, Esplin ED, Nielsen S, Yang S, McGregor BA, Pomerantz M, Gusev A, Rana HQ, Sonpavde G, Garber JE, Freedman ML, **Choueiri TK**. Prevalence of pathogenic germline risk variants (PVs) in 1829 renal cell carcinoma (RCC) patients (pts). February 2020 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2020;38(6_suppl):659.
55. Adib E, Jain RK, Skelton WP, Freeman D, Curran C, Akl EW, Nassar A, Ravi P, Mantia C, Merchan JR, Tan W, Plastini TM, **Choueiri TK**, Sonpavde G. Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):472.
56. Bauer TM, **Choueiri TK**, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Park EK, Jonasch E. The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):273.
57. Cella D, **Choueiri TK**, Blum SI, Ejzykowicz F, Hamilton M, Zhang J, Ivanescu C, Motzer RJ. Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial. February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):285.
58. **Choueiri TK**, Albiges L, Fan L, Perini RF, Civkery D, Powles T, Rini BI. MK-6482, a hypoxia-inducible factor 2 α inhibitor (HIF-2 α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study. February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):TPS368.
59. **Choueiri TK**, Bauer TM, McDermott DF, Arrowsmith E, Roy A, Perini RF, Vickery D, Tykodi SS. Phase 2 study of the oral hypoxia-inducible factor 2 α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):272.
60. Gan CL, Dudani S, Wells JC, Schmidt AL, Bakouny Z, Szabados B, Parnis F, Wong S, Lee JL, de Velasco G, Pal SK, Davis ID, Kanesvaran R, Wood L, Kollmannsberger CK, McKay RR, Beuselinck B, Donskov F, **Choueiri TK**, Heng DY. Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):276.

61. Graham J, Wells C, Dudani S, Gan CL, Donskov F, Lee JL, Kollmannsberger CK, Pal SK, Beuselinck B, Hansen AR, North SA, Bjarnason GA, Agarwal N, Kansevaran R, Wood L, Hotte SJ, McKay RR, **Choueiri TK**, Heng DY. Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):316.
62. McGregor BA, Adib E, Xie W, Stadler WM, Zakharia Y, Michaelson MD, Alva AS, Farah S, Nassar A, Harshman LC, Kwiatkowski DJ, McKay RR, **Choueiri TK**. Biomarker-based phase II study of sapanisertib (TAK-228), an mTORC1/2 inhibitor in patients with refractory metastatic renal cell carcinoma (mRCC). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):306.
63. Motzer RJ, **Choueiri TK**, Powles T, Burotto M, Bourlon MT, Hsieh JJ, Maruzzo M, Shah AY, Suarez C, Barrios CH, Richardet ME, Porta C, Goh JC, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Gupta S, Apolo AB. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):308.
64. Motzer RJ, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, Alekseev B, Rha SY, Kopyltsov E, Mendez MJ, Hong SH, Kapoor A, Gordo TA, Goh JC, Merchan JR, Smoth AD, Mody K, Perini RF, Xing D, **Choueiri TK**. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):269.
65. Nassar A, Adib E, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, Sonpavde G, Haddad RI, Giannakis M, Hodi FS, **Choueiri TK**, Kwiatkowski DJ. CDKN2A alterations as markers of immune checkpoint blockade (ICB) resistance in urothelial carcinoma (UC). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):475.
66. Nuzzo PV, Curran C, Adib E, Freeman D, Nassar A, Abou Alaiwi S, Bakouny Z, McGregor BA, **Choueiri TK**, Jain RK, McKay RR, Sonpavde G. Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):354.
67. Pal SK, Albiges L, Rodrigues CS, Liu B, Doss J, Khurana S, Scheffold C, Voss MH, **Choueiri TK**. CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after

immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma. February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):TPS370.

68. Schmidt AL, Xie W, Gan CL, Wells C, Dudani S, Donskov F, Porta C, Suarez C, Szabados B, Wood L, Morales JMR, Tran B, Bjarnason GA, Yuasa T, Beuselinck B, Hansen AR, Agarwal N, Bakouny Z, Heng DYC, **Choueiri TK**. The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):339.
69. Shayeb AM, Urman D, Dizman N, Meza LA, Sivakumar A, Gan CL, Dzimitrowicz HE, Zhang T, Barata PC, Bilen MA, Gao X, Heng DYC, Pal SK, Kaymakcalan MD, McGregor BA, **Choueiri TK**, McKay RR. Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):291.
70. Tannir NM, Motzer RJ, Albiges L, Plimack ER, George S, Powles T, Donskov F, Rini BI, Grunwald V, Hammers HJ, **Choueiri TK**, Gurney H, Tykodi SS, Porta C, Burotto M, Tomita Y, Lee CW, Tang C, McDermott DF, McKay RR. Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214. February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):313.
71. Thouvenin J, Alhalabi O, Hirsch L, Hasanov E, Bathelemy P, Martini DJ, Campedel L, Amrane K, Borchiellini D, Chahoud J, Bakouny Z, Ravi P, Viswanathan SR, Bilen MA, **Choueiri TK**, Tannir NM, Malouf GG. Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC). February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):274.
72. Tomita Y, Motzer RJ, **Choueiri TK**, Rini BI, Miyake H, Oya M, Albiges L, Fujii Y, Umeyama Y, Wang J, Di Pietro A, Schmidinger M. Efficacy of avelumab plus axitinib (A + Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):302.
73. Tomita Y, Motzer RJ, **Choueiri TK**, Rini BI, Miyake H, Uemura H, Albiges L, Fujii Y, Umeyama Y, Wang J, Mariani M, Schmidinger M. Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. February 2021 GCS Meeting. J Clin Oncol 2021;39(6_suppl):301.

74. Zengin ZB, Wiepert C, Hsu J, Salgia N, Hensel C, Maughan BL, Rathi N, Goel D, Agarwal N, **Choueiri TK**, Pal SK. Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. February 2021 GCS Meeting. *J Clin Oncol* 2021;39(6_suppl):347.
75. Zhang T, Ballman KV, Choudhury AD, Chen RC, Watt C, Wen Y, Shergill A, Zemla TJ, Enamekhoo H, Vaishampayan UN, Morris MJ, George DJ, **Choueiri TK**. PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). February 2021 GCS Meeting. *J Clin Oncol* 2021;39(6_suppl):TPS366.
76. Adib E, Nassar A, Akl E, Abou Alaiwi S, El Zarif T, El-Khoury H, Ananda G, **Choueiri TK**, Gusev A. Improving tumor mutational burden calibration in non-European patients. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);1559.
77. Albiges L, Voss MH, Rini BI, Gravis G, Grimm MO, Nathan PD, Bjarnason GA, Tomita Y, Penkov K, McGregor B, Huang B, Thomaidou D, Mariani M, Di Pietro A, **Choueiri TK**. Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4514.
78. Allaf ME, Kim SE, Master VA, McDermott DF, Signoretti S, Cella D, Gupta RT, Cole S, Shuch BM, Lara Jr. PN, Kapoor A, Heng DY, Leibovich BC, Michaelson MD, **Choueiri TK**, Jewett MA, Maskens D, Harshman LC, Carducci MA, Haas NB. PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);TPS4596.
79. Apolo AB, Powles T, Burotto M, Bourlon MT, Hsieh JJ, Basso U, Shah AY, Suarez C, Porta C, Barrios CH, Gurney H, Kessler ER, Retz M, George S, Escudier B, Zhang J, Simsek B, Scheffold C, Motzer RJ, **Choueiri TK**. Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4553.
80. Bellmunt J, Necchi A, De Wit R, Lee JL, Fong L, Vogelzang NJ, Climent Durán MA, Petrylak DP, **Choueiri TK**, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, Xu JZ, Moreno BH, Godwin JL, Bajorin DF, Vaughn DJ, Fradet Y. Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or

vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4532.

81. Cella D, Motzer RJ, May J, Wallace J, Marteau F, Kwon Y, Rusibamayila N, Botteman M, Ejzykowicz F, **Choueiri TK**. Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);6567.
82. **Choueiri TK**, Donahue AC, Rini BI, Powles T, Haanen JB, Larkin J, Mu XJ, Pu J, Thomaidou D, Di Pietro A, Robbins PB, Motzer RJ. Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4547.
83. **Choueiri TK**, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Zhang EP, Willemann Rogerio J, Imai K, Quinn DI, Powles T. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. June 2021 ASCO Annual Meeting.
84. Ernst MS, Abou Alaiwi S, Dizman N, Labaki C, Nuzzo PV, Adib E, Schmidt AL, Meza LA, Gan CL, Bakouny Z, Pal SK, **Choueiri TK**, Heng DY, Dudani S. The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4552.
85. Gan CL, Schmidt AL, Powles T, Tran B, Meza LA, Labaki C, Lee JL, Wood L, Shapiro J, Ernst DS, Kapoor A, Canil CM, Yuasa T, McKay RR, Beuselinck B, Donskov F, Dudani S, **Choueiri TK**, Heng DY. Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4554.
86. Haanen JB, Larkin J, **Choueiri TK**, Albiges L, Rini BI, Atkins MB, Schmidinger M, Penkov K, Thomaidou D, Wang J, Mariani M, Di Pietro A, Motzer RJ. Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced

renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4574.

87. Hutson TE, **Choueiri TK**, Motzer RJ, Rha SY, Alyasova A, Merchan JR, Gurney H, Peer A, Takagi T, Porta C, Powles T, Grünwald V, De Giorgi U, Vaishampayan UN, Schmidinger M, Geln H, Rodriguez-Lopez K, Xing D, Dutta L, Eto M. Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4562.
88. Labaki C, Alaiwi SA, Schmidt AL, El Zarif T, Bakouny Z, Nuzzo PV, Xu W, Braun DA, McGregor BA, **Choueiri TK**. Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4583.
89. McGregor BA, Geynisman DM, Burotto M, Porta C, Suárez C, Bourlon MT, Barata PC, Gulati S, Stwalley B, Del Tejo V, Du EX, Wu A, Chin A, Betts KA, Huo S, **Choueiri TK**. Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4578.
90. McGregor BA, Xie W, Bilen MA, Braun DA, Xu W, Ravi P, Heath EI, McDermott DF, McKay RR, Hammers HJ, **Choueiri TK**. Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);TPS4592.
91. McKay RR, Jacene H, Atherton PJ, Burbano GP, Ajmera A, Baghaie S, Koball J, Zemla TJ, Chen RC, Choudhury AD, Lang JM, Cole S, Al Baghdadi T, Kwok Y, Beltran H, George DJ, Morris MJ, **Choueiri TK**. A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);TPS4593.
92. Morgan G, **Choueiri TK**, Patel R, Balaji K, Subbiah V. Impact of #ASCO Twitter impressions on the oncology community. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);11039.
93. Motzer RJ, **Choueiri TK**, May J, Kwon Y, Rusibamayila N, Botteman M, Hamilton M, Ejzykowicz F, Cella D. Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the

first-line treatment of advanced renal cell carcinoma (aRCC). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);6568.

94. Motzer RJ, Porta C, Alekseev B, Rha SY, **Choueiri TK**, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Wang J, Pan J, Asfaw AA, He CS, Mody K, Cella D. Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4502.
95. Nassar A, Adib E, Abou Alaiwi S, Akl E, El Zarif T, Nuzzo PV, Mouhieddine TH, El-Khoury H, Groha S, Sonpavde GP, Haddad RI, Mouw KW, Giannakis M, Ananda G, Freedman ML, Kwiatkowski DJ, MacConaill LE, **Choueiri TK**, Gusev A. Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);10536.
96. Patnaik A, Morgensztern D, Mantia C, Tannir NM, Harshman LC, Hill J, White K, Chung JK, Bowers B, Sciaranghella G, Lee B, **Choueiri TK**, Smith LS, Naing A. Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);2551.
97. Plimack ER, Hammers HJ, **Choueiri TK**, Rini BI, Motzer RJ, Suttner L, Perini RF, Willemann Rogerio J, Albiges L. A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);TPS4594.
98. Schmidt AL, Bakouny Z, Labaki C, Bashir B, Clement JM, Edwin NC, Flora DB, Girard J, Gulati S, Hwang C, Jani C, Lopes G, Mesa RA, Redelman-Sidi G, Mishra S, Warner JL, **Choueiri TK**. Effect of Bacillus Calmette-Guerin (BCG) exposure on severity of COVID-19 infection: A COVID-19 and Cancer Consortium (CCC19) study. June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4529.
99. Shah AY, Motzer RJ, Apolo AB, Powles T, Escudier B, Zhang J, Scheffold C, Karumanchi S, Nguyen LT, **Choueiri TK**. Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC). June 2021 ASCO Annual Meeting. *J Clin Oncol* 2021;39(15_suppl);4561.
100. Tomita Y, Larkin J, Venugopal B, Haanen JB, Kanayama HO, Eto M, Grimm MO, Fujii Y, Umeyama Y, Mariani M, Di Pietro A, **Choueiri TK**. Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell

carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101. June 2021 ASCO Annual Meeting. J Clin Oncol 2021;39(15_suppl);4548.

101. Tucker MD, Voss MH, **Choueiri TK**, Bilen MA, Grimm MO, Nathan PD, Kollmannsberger CK, Tomita Y, Huang B, Thomaidou D, Mariani M, Di Pietro A, Rini BI. Association between neutrophil-to-eosinophil ratio (NER) and efficacy outcomes in the JAVELIN Renal 101 study. June 2021 ASCO Annual Meeting. J Clin Oncol 2021;39(15_suppl);4549.
102. Xu W, Gusev A, Groha S, Rahma OE, Schrag D, **Choueiri TK**, Kehl KL. Automated identification of immune related adverse events in oncology patients using machine learning. June 2021 ASCO Annual Meeting. J Clin Oncol 2021;39(15_suppl);1551.
103. Agarwal N, McGregor BA, Maughan BL, Dorff T, Kelly W, Fang B, McKay R, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan UN, Goel S, Curran D, Panneerselvam A, Liu L, **Choueiri TK**, Pal SK. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study. September 2021 ESMO Virtual Congress. Ann Oncol 2021;32(suppl_5):S1283-S1346.
104. **Choueiri TK**, Eto M, Kopyltsov E, Rha SY, Porta CG, Motzer R, Grünwald V, Hutson TE, Méndez-Vidal MJ, Hong S, Winkvist E, Goh JCH, Maroto P, Buchler T, Takagi T, Rodriguez-Lopez K, Xing D, Smith AD, Powles T. Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update. September 2021 ESMO Virtual Congress. Ann Oncol 2021;32(suppl_5):S678-S724.
105. **Choueiri TK**, Tomczak P, Park SH, Venugopal B, Symeonides S, Hajek J, Ferguson T, Chang Y, Lee JL, Haas N, Sawrycki P, Sarwar N, Gross-Goupil M, Thiery-Vuillemin A, Mahave M, Saretsky TL, Zhang P, Willemann-Rogerio J, Quinn DI, Powles TB. Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564. September 2021 ESMO Virtual Congress. Ann Oncol 2021;32(suppl_5):S678-S724.
106. Grimm M, Oya M, **Choueiri TK**, Schmidinger M, Quinn DI, Gravis Mescam G, Verzoni E, Van den Eertwegh AJM, di Pietro A, Mariani M, Wang J, Thomaidou D, Albiges L. Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101. September 2021 ESMO Virtual Congress. Ann Oncol 2021;32(suppl_5):S678-S724.
107. McDermott DF, **Choueiri TK**, Bauer TM, Arrowsmith E, Roy A, Perini R, Vickery D, Tykodi SS. Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2 α (HIF-2 α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell

carcinoma (ccRCC). September 2021 ESMO Virtual Congress. Ann Oncol 2021;32(suppl_5):S678-S724.

108. Motzer RJ, Tannir NM, McDermott DF, Burotto M, **Choueiri TK**, Hammers HJ, Plimack ER, Porta CG, George S, Powles TB, Donskov F, Gurney H, Kollmannsberger CK, Grimm M, Tomita Y, Rini BI, McHenry MB, Lee C, Escudier B. Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). September 2021 ESMO Virtual Congress. Ann Oncol 2021;32(suppl_5):S678-S724.
109. Nuzzo PV, Adib E, Weise N, Curran C, Stewart T, Freeman D, Nassar AH, Abou Alaiwi S, Bakouny Z, McGregor BA, **Choueiri TK**, Jain RK, McKay RR, Sonpavde GP. Impact of renin-angiotensin system inhibitors (RASi) on outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI). September 2021 ESMO Virtual Congress. Ann Oncol 2021;32(suppl_5):S678-S724.
110. Porta CG, Burotto M, Suarez-Rodriguez C, Bourlon MT, Hsieh J, Shah AY, Hamzaj A, Bedke J, Pook D, Kessler ER, Tomita Y, Drakaki A, Zhang J, Simsek B, Schwab G, Escudier B, Motzer RJ, **Choueiri TK**, Apolo AB, Powles TB. First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial. September 2021 ESMO Virtual Congress. Ann Oncol 2021;32(suppl_5):S678-S724.
111. Porta CG, Motzer R, Ejzykowicz F, Blum SI, Hamilton M, May JR, Huo S, Kral P, Ivanescu C, **Choueiri TK**, Cella D. Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC). September 2021 ESMO Virtual Congress. Ann Oncol 2021;32(suppl_5):S678-S724.
112. Rini BI, Plimack ER, Powles TB, Voss MH, Gurney HP, Silverman R, Perini R, Rodriguez-Lopez K, **Choueiri TK**. Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC). September 2021 ESMO Virtual Congress. Ann Oncol 2021;32(suppl_5):S678-S724.
113. Adib E, El Zarif T, Freeman D, Labban M, Curran C, Sharma B, Song J, Felt K, Nassar A, Davidsohn M, Rodig SJ, **Choueiri TK**, Kwiatkowski DJ, Ravi P, Sonpavde GP. FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic

- urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI). February 2022 GCS Meeting. *J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);549.*
114. Alhalabi A, Thouvenin J, Negrier S, Vano YA, Campedel Jr L, Hasanov E, Bakouny Z, Hahn AW, Bilen MA, **Choueiri TK**, Viswanathan SR, Sircar K, Albiges L, Malouf GG, Tannir NM. Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study. February 2022 GCS Meeting. *J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);343.*
 115. Cella D, **Choueiri TK**, Hamilton M, Ejzykowicz F, Blum SI, Ivanescu C, Motzer RJ. Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: Five-year follow-up results. February 2022 GCS Meeting. *J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);307.*
 116. Cella D, Motzer RJ, Blum SI, Ejzykowicz F, Hamilton M, Wallace J, Zhang J, Simsek B, Ivanescu C, **Choueiri TK**. Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results. February 2022 GCS Meeting. *J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);323.*
 117. **Choueiri TK**, Albiges L, Hammers HJ, McKay RR, Heng DYC, Beckermann K, Kasturi V, Motzer RJ. TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor. February 2022 GCS Meeting. *J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);TPS405.*
 118. **Choueiri TK**, Plimack ER, Powles T, Voss MH, Gurney H, Silverman RK, Perini RF, Rodriguez-Lopez K, Rini BI. Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC). February 2022 GCS Meeting. *J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);TPS399.*
 119. **Choueiri TK**, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Xu L, Imai K, Willemann-Rogerio J, Quinn DI, Powles T. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. February 2022 GCS Meeting. *J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);290.*
 120. Enamekhoo H, Mannino MC, Bootsma ML, Bade RM, Wells M, Schehr JL, **Choueiri TK**, McKay RR, Zhao S, Lang JM. Single cell phenotyping of PDL1 and HLA1 on

circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKI). February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);381.

121. Ernst MS, Navani V, Wells JC, Donskov F, Basappa NS, Labaki C, Pal SK, Meza LA, Wood L, Ernst DS, Szabados B, McKay RR, Parnis F, Suárez C, Yuasa T, Kapoor A, Alva AS, Bjarnason GA, **Choueiri TK**, Heng DYC. Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC). February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);308.
122. Labaki C, Schmidt AL, Bakouny Z, Labban M, El Zarif T, Chang SL, McGregor BA, Kibel AS, Rebeck T, Trinh QD, **Choueiri TK**. Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic. February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);281.
123. McGregor BA, Xie W, Bilen MA, Campbell MT, Mortazabi A, Huang J, Sunkara R, Ravi P, Shah AY, Baca S, Sonpavde GP, Bellmunt J, Siefker-Radtke AO, Signoretti S, Van Allen EM, Beltran H, McKay RR, **Choueiri TK**. Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation. February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);569.
124. Motzer RJ, Albiges L, **Choueiri TK**, Plimack ER, Rini BI, Suttner L, Yin L, Willemann-Rogério J, Hammers HJ. Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC). February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);TPS404.
125. Navani V, Ernst MS, Wells C, Yuasa T, Takemura K, Donskov F, Basappa NS, Schmidt AL, Pal SK, Meza LA, Wood L, Ernst DS, Szabados B, McKay RR, Weickhardt AJ, Suárez C, Kapoor A, Lee JL, **Choueiri TK**, Heng DYC. Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC). February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);310.
126. Navani V, Wells C, Boyne DJ, Cheung WY, Brenner D, McGregor BA, Labaki C, Schmidt AL, McKay RR, Pal SK, Meza LA, Donskov F, Beuselinck B, Ernst MS, Otiato M, Ludwig L, Powles T, Szabados B, **Choueiri TK**, Heng DYC. CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients

with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);318.

127. Panian J, Saidian A, Hakimi K, Ajmera A, Barata PC, Berg SA, Chang SL, **Choueiri TK**, Dzimitrowicz HE, Enamekhoo H, Gross E, Kilari D, Lam ET, Lashgari I, Psutka SP, Thapa B, Weise N, Zhang T, Derweesh I, McKay RR. Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC). February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);334.
128. Powles T, **Choueiri TK**, Burotto M, Escudier B, Bournalon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking C, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Motzer RJ. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);350.
129. Rha SY, **Choueiri TK**, Matveev VB, Alyasova A, Hong SH, Alonso-Gordoa T, Gurney H, Bjarnason GA, Buchler T, Pedrazzoli P, Takagi T, Park SH, Lee JL, Perini RF, He C, McKenzie JA, Eto M. Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);338.
130. Roussel E, Kinget L, Beuselinck B, Albersen M, Wells C, Ernst MS, Donskov F, Schmidt AL, Szabados B, Pal SK, Meza LA, Agarwal N, Weickhardt AJ, Davis ID, Alva AS, Wood L, Porta C, **Choueiri TK**, Heng DY, Navani V. First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);317.
131. Saidian A, Hakimi K, Panian J, Ajmera A, Barata PC, Berg SA, Chang SL, **Choueiri TK**, Dzimitrowicz HE, Enamekhoo H, Gross E, Kilari D, Lam ET, Nonato T, Psutka SP, Thapa B, Weise N, Zhang T, McKay RR, Derweesh I. Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes. February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);390.
132. Tannir NM, Signoretti S, **Choueiri TK**, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, McHenry MB, Rini BI. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line

treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. February 2022 GCS Meeting. J Clin Oncol (Meeting Abstracts) 2022;40(6_suppl);352.

Narrative Report

I am currently the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School (HMS), a Senior Physician at Dana-Farber Cancer Institute (DFCI), an Associate Physician at Brigham and Women's Hospital (BWH) and Associate Member at the Broad Institute. My contributions as a clinician, researcher, and teacher have been well balanced. My teaching responsibilities extend from preceptor to Harvard medical students, teaching on rounds to house officers at BWH, mentoring medical oncology fellows at DFCI, to giving talks locally, nationally, and internationally. I provide ambulatory care in Medical Oncology 2 sessions/week at DFCI and inpatient care at BWH 1-2 weeks/year. Since April 2022, I am also serving as Medical Director - International Strategic Initiatives to provide clinical leadership for DFCI's international business and relationship development activities, including assessing new opportunities, managing key relationships with external stakeholders, and providing oversight over the implementation of international advisory services.

I trained in GU Oncology at Cleveland Clinic with a focus on clinical trials conduct, health outcomes, and prognostic classifications, as well as advanced renal cell carcinoma (RCC) genomics. I moved to DFCI in 2007 as an Instructor in Medicine and quickly became involved in pivotal studies and clinical trials that have shifted the paradigm of GU cancer care and established new drugs and targets in RCC. My earliest research accomplishments at DFCI include characterizing the side effects and risks of therapeutic agents used in GU malignancies using meta-analytical designs. Our group shed light on the risk of serious adverse events such as treatment-related mortality, arterial thromboembolism, congestive heart failure from targeted agents, and cardiovascular mortality from androgen deprivation therapy. I also collaborated with the Channing Laboratory/Harvard School of Public Health to study risk factors involved in RCC using the Nurses' Health Study, and Health Professionals Follow-Up Study, and reported on the relationship between the use of nonsteroidal anti-inflammatory drugs and the risk of RCC, and have investigated the roles of the ABO blood group and statins as well.

In 2008, I co-founded the International Metastatic RCC Database Consortium (IMDC), which currently comprises data on 11,000 patients with advanced RCC from 40+ centers and 15 countries, contributing clinical data and tissue samples for clinical and translational research questions in this disease. This database has allowed exploration of novel research questions in RCC and established novel prognostic factors in RCC patients treated with targeted therapy (IMDC risk criteria). Over the years, continued maturity of this database and its associated biospecimens allowed us to link several aspects of RCC biology to clinical outcomes on systemic therapy.

Several years into my career and building on the introduction of VEGF-targeted therapy in RCC, I led or co-led the early and late development and approval of several novel agents in RCC. The COMPARZ study comparing sunitinib to pazopanib was one of the largest trials of targeted therapy in this disease,

and established a new standard and a more tolerable agent (NEJM, 2013). I led the development and approval of the dual VEGF/MET inhibitor cabozantinib through early- to late-stage trials in refractory (NEJM 2015) and untreated RCC (JCO 2016), and most recently its combination with the PD-1 inhibitor nivolumab (NEJM 2021). I also contributed to the development of other combination therapies, including axitinib+avelumab (NEJM 2019) and lenvatinib+pembrolizumab (NEJM 2021) in untreated RCC. Since 2018, I am leading the development of first-in-class HIF2 inhibitor Belzutifan in RCC.

With interdisciplinary colleagues at DFCI, I developed an interest in deciphering the molecular basic mechanisms behind RCC tumor response and resistance to systemic therapy. In close collaborations with laboratory-based colleagues at Harvard, we assessed changes in the expression of tissue and serum biomarkers that can predict a cancer patient's response to therapy. We investigated the role of the VHL-HIF-VEGF axis and the mTOR pathway as biomarkers in response to standard targeted agents in metastatic RCC. We are now using multi-OMICS approaches such as genomics, transcriptomics, and metabolomics to understand the somatic and germline alteration landscape of RCC, including their respective contributions to recurrence in early-stage disease and more recently therapeutic response to immune checkpoint blockers in metastatic disease.

Along the same lines, our group embarked on the molecular characterization of rare kidney cancer variants. We discovered BRAF gene mutations in metanephric adenoma of the kidney; shed light on the biology of response to MET inhibitors in papillary RCC; and characterized the molecular and immune landscape of sarcomatoid RCC, a highly aggressive form of kidney cancer.

More recently, our group has pursued applying novel technologies in RCC, including the use of single cell sequencing of RCC tumors across disease stages to dissect the immune microenvironment of kidney cancer. We were also the first to characterize plasma and urine cell-free (cf) methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) as a highly sensitive assay capable of detecting GU cancers at an early stage, and compared this technology to the commonly used plasma cfDNA variant analysis.

Our research collaborations have been published in clinical and preclinical journals such as The Lancet, NEJM, Nature, Nature Medicine, Science, and others. My work has been funded by multiple sources including the National Cancer Institute and the Department of Defense.

Since joining DFCI, I have also played a role in several clinical innovations efforts, including improving clinical trials reporting and conduct; contributing to DFCI clinical pathways guidelines; leading a team at BWH to design a training conference focused on quality and cost-effectiveness/efficiency (as part of a leadership training at Harvard Business School); participating in writing NCCN clinical guidelines for kidney cancer; and helping establish best oncology practices during the COVID-19 pandemic.

For my accomplishments, I was awarded the George P. Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013. I served from 2015-2017 as Chairman of the medical and scientific steering committee of the Kidney Cancer Association (KCA), the world's first international charity dedicated specifically to the eradication of death and suffering from renal cancers, with members in more than 100 countries. In 2016, I received the Eugene P. Schonfeld award from the KCA in recognition of my significant contributions to the field of kidney cancer. In 2021, I was selected

for the Pfizer/OncLive Giants of Cancer Care recognition program for my contributions to Genitourinary Cancer.

My administrative leadership roles at DFCI began in 2013 when I became Clinical Director of the Lank Center for GU Oncology. From 2015-2018, I was the President of Medical Staff at DFCI, directing the medical-administrative aspects of our activities and representing the views, policies, needs, and grievances of the Medical Staff to the CEO and the Board of Trustees. In 2016, I transitioned into the role of the leader of the Division of GU Medical Oncology, which has grown substantially during my tenure: as of March 2021, our disease center includes 23 GU medical oncologists and counts more than 120 team members including advanced practitioners, nurses, clinical coordinators, and research staff. Likewise, our peer-reviewed research funding has quadrupled the past 5 years, and our Center remains among the most clinically and academically productive GU programs in the world.

One of most rewarding aspects of my job has been building strategic multidisciplinary collaborations within clinical and research programs in oncology, and I plan to continue to expand and refine these initiatives. Another high priority of mine is developing our next generation of leaders in GU medical oncology. I have had the chance to teach and mentor several US and international fellows in the clinical and translational field of RCC, and have seen them go on to achieve independence and academic success at DFCI or their home institutions. This has given me personal and professional satisfaction. I will continue focusing my efforts on multidisciplinary team building, growth of our junior colleagues at the local and national levels, and fostering a culture of clinical and research excellence in the field of GU oncology.